mitomycin has been researched along with Local Neoplasm Recurrence in 741 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to assess long-term follow-up after chemoresection with mitomycin (MMC), a nonsurgical treatment modality for recurrent nonmuscle invasive bladder cancer (NMIBC)." | 9.69 | DaBlaCa-13 Study: Oncological Outcome of Short-Term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial. ( Azawi, N; Dyrskjøt, L; Hansen, E; Jensen, JB; Lindgren, MS; Nielsen, AM, 2023) |
| "The purpose of the study was to compare the outcomes of high-risk non-muscle-invasive bladder cancer (HR-NMIBC) patients treated with BCG vs recirculating hyperthermic intravesical chemotherapy (HIVEC) with mitomycin C (MMC)." | 9.51 | Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial. ( de la Rosa-Kehrmann, F; González-Díaz, A; González-Padilla, DA; Guerrero-Ramos, F; Inman, BA; Rodríguez-Antolín, A; Villacampa-Aubá, F, 2022) |
| "To investigate whether the timing of an immediate instillation of mitomycin C (on the day of transurethral resection of bladder tumour [TURBT] or 1 day later) has an impact on time to recurrence of non-muscle-invasive bladder cancer (NMIBC)." | 9.27 | The effect of timing of an immediate instillation of mitomycin C after transurethral resection in 941 patients with non-muscle-invasive bladder cancer. ( Beckers, GMA; Bosschieter, J; Lissenberg-Witte, BI; Nieuwenhuijzen, JA; van Ginkel, T; van Moorselaar, RJA; Vis, AN, 2018) |
| "From those 11 studies, it is shown that intravesical chemotherapy using Epirubicin and Mitomycin-C following TURB showed significant decrease of recurrence rate of bladder cancer even to progression of the disease compared to TURB alone (p<0." | 9.22 | Comparison Between Intravesical Chemotherapy Epirubicin and Mitomycin-C after TURB vs TURB Alone With Recurrence Rate of Non-Muscle Invasive Bladder Cancer: Meta-Analysis. ( Budaya, TN; Daryanto, B; Purnomo, AF; Seputra, KP, 2022) |
| "We analyzed the outcomes of a randomized trial demonstrating that in intermediate- to high-risk non-muscle-invasive bladder cancer, mitomycin C and bacillus Calmette-Guérin (BCG) reduced disease relapse compared with BCG alone but was more toxic." | 9.20 | Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomiz ( Alonso, JM; Astobieta, A; Beardo, P; Chantada, V; Fernandez, JM; Gomez, M; Madero, R; Martinez Piñeiro, JA; Martinez-Piñeiro, L; Montesinos, M; Muntañola, P; Ojea, A; Portillo, JA; Rabadan, M; Rodriguez-Molina, J; Solsona, E; Unda, M; Zabala, JA, 2015) |
| "The purpose of this study was to determine the effectiveness of a single early instillation of mitomycin C (MMC) after transurethral resection of bladder tumor (TURBT) together with urinary alkalinization in patients with low-risk non-muscle-invasive bladder cancer (NMIBC)." | 9.17 | Single early instillation of mitomycin C and urinary alkalinization in low-risk non-muscle-invasive bladder cancer: a preliminary study. ( Ersoy, H; Karakoyunlu, AN; Ozok, HU; Sagnak, L; Topaloglu, H; Yaytokgil, M, 2013) |
| "Our aim was to assess if sequential mitomycin C (MMC) plus BCG after transurethral resection (TUR) is worthy of further study in non-muscle-invasive bladder cancer patients with CIS." | 9.15 | Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial ( ( Algaba, F; Bono, A; Busch, C; Collette, S; da Silva, FC; Kirkali, Z; Oosterlinck, W; Sylvester, R, 2011) |
| "To study the benefits of a single, early, intravesical instillation of mitomycin C(MMC) after transurethral bladder resection (TURB) in patients with low-risk non-muscle-invasive bladder cancer (NMIBC)." | 9.15 | Long-term experience with early single mitomycin C instillations in patients with low-risk non-muscle-invasive bladder cancer: prospective, single-centre randomised trial. ( Albisinni, S; Alpi, G; Cantiani, A; Carbone, A; De Nunzio, C; Iori, F; Liberti, M; Tubaro, A, 2011) |
| " Our aim was to compare TURBT alone with immediate post-TURBT intravesical passive diffusion (PD) of mitomycin and immediate pre-TURBT intravesical electromotive drug administration (EMDA) of mitomycin in non-muscle invasive bladder cancer." | 9.15 | Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. ( Di Stasi, SM; Giurioli, A; Leprini, G; Liberati, E; Masedu, F; Micali, F; Ricci, AR; Valenti, M; Verri, C; Vespasiani, G, 2011) |
| "To evaluate the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure, including mitomycin (MMC), epirubicin (EPB) and camptothecin (CPT), in the treatment of non-muscle-invasive bladder cancer (NMIBC)." | 9.15 | [Evaluation of the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure in the treatment of non-muscle-invasive bladder cancer]. ( Cao, M; Chen, HG; Ma, CK; Ma, J; Xue, W, 2011) |
| "The present study compared the therapeutic activity of intravesical BCG with intravesical mitomycin C chemotherapy in patients with non-muscle invasive bladder cancer at intermediate risk of recurrence in a prospective randomised trial." | 9.13 | A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy. ( Del Nero, A; Mangiarotti, B; Montanari, E; Trinchieri, A, 2008) |
| "It remains unclear whether people with non-muscle invasive bladder cancer (NMIBC) benefit from intravesical gemcitabine compared to other agents in the primary or recurrent setting following transurethral resection of a bladder tumor." | 9.12 | Intravesical gemcitabine for non-muscle invasive bladder cancer. ( Cleves, A; Dahm, P; Han, MA; Hwang, EC; Hwang, JE; Jung, JH; Maisch, P; Narayan, V, 2021) |
| "We analyzed the impact of a single Mitomycin C instillation in patients with low risk superficial bladder cancer with short and long-term follow-up." | 9.12 | Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term follow-up. ( El-Ganzoury, HM; El-Ghobashy, S; El-Leithy, TR; Roshdy, MM, 2007) |
| "Combining radiation with mitomycin and cisplatin in patients with locally advanced anal cancer is feasible." | 9.12 | Combining cisplatin and mitomycin with radiotherapy in anal carcinoma. ( Bosset, JF; Bosset, M; Buffet-Miny, J; Crehange, G; Dumas, JL; Lorchel, F; Mercier, M; Puyraveau, M, 2007) |
| "To report the 10-year follow-up of a study randomizing between instillations of bacillus Calmette-Guérin (BCG) and mitomycin-C (MMC) for treating high-risk and not muscle-invasive urinary bladder cancer to assess progression, the need for more aggressive treatment and survival (cancer-specific and overall), as many of the published studies comparing different treatments for disease that is not muscle-invasive have a short follow-up." | 9.12 | Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer. ( Gårdmark, T; Jahnson, S; Malmström, PU; Wahlquist, R; Wijkström, H, 2007) |
| "To observe the effect of postoperative transcatheter hepatic arterial chemoembolization (TACE) and thymosin alpha(1) (T(alpha1)) treatment on recurrence of hepatocellular carcinoma (HCC)." | 9.11 | [Transcatheter hepatic arterial chemoembolization and thymosin alpha1 in postoperative treatment of hepatocellular carcinoma]. ( Chen, H; Cheng, SQ; Cong, WM; Shen, F; Wang, PJ; Wu, MC; Yang, JH; Zhao, YX, 2004) |
| "To evaluate whether, in patients with carcinoma in situ (CIS) of the urinary bladder, alternating instillation therapy with mitomycin C (MMC) and bacillus Calmette-Guerin (BCG) was more effective and less toxic than conventional BCG monotherapy." | 9.10 | Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study. ( Duchek, M; Hellsten, S; Kaasinen, E; Malmström, PU; Mestad, O; Rintala, E; Wijkström, H, 2003) |
| "Local chemotherapy with mitomycin C is a useful option in the treatment of malignant melanomas of the conjunctiva associated with PAM if the tumor stage is pT3 or less." | 9.10 | [Management of conjunctival malignant melanoma associated with primary acquired melanosis (PAM) using 0.02% mitomycin C eyedrops]. ( Conway, RM; Groh, MJ; Holbach, LM; Kühnel, B; Naumann, GO, 2003) |
| "We analyze the impact of a single mitomycin C instillation in patients with low risk superficial bladder cancer with short and long-term followup." | 9.09 | Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. ( Casanova, J; Dumont, R; Iborra, I; Monrós, JL; Ricós, JV; Solsona, E, 1999) |
| "Chemotherapy for 5-fluorouracil (5-FU)-resistant colorectal cancer is largely ineffective with new and innovative therapeutic strategies needed to benefit patients developing progressive disease while receiving 5-FU or 5-FU-based programs." | 9.09 | A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil. ( Anderson, N; Bern, M; Coco, F; Lokich, J; Moore, C, 1999) |
| "We evaluated the prophylactic efficacy of instillations of intravesical mitomycin C in 57 patients with primary superficial bladder cancer in a multicenter clinical trial." | 9.09 | The effect of intravesical mitomycin C on the recurrence of superficial (Ta-T1) bladder cancer. A Hungarian Multicenter Study. ( Bodrogi, I; Határ, A; Kiss, A; Kiss, L; Kondás, J; Lukács, T; Szeldeli, P; Törzsök, F, 1999) |
| "To clinically evaluate topical mitomycin chemotherapy in patients with diffuse, multifocal, or recurrent primary acquired melanosis with atypia and/or conjunctival malignant melanoma and to histopathologically study ocular tissue samples obtained before and after treatment." | 9.09 | Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: clinical experience with histopathologic observations. ( Demirci, H; Finger, PT; McCormick, SA, 2000) |
| "To elucidate the most efficient topical therapy for carcinoma in situ of the bladder, the efficacy of intravesical mitomycin C plus doxorubicin therapy was compared with bacillus Calmette-Guerin (BCG) therapy." | 9.09 | Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder. ( Fukui, I; Igarashi, K; Kojima, SI; Ohya, K; Sekine, H, 2001) |
| "We determined the role, if any, of 1 and 5 instillations of intravesical mitomycin C in the treatment of newly diagnosed superficial bladder cancer." | 9.08 | The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. ( Benyon, LL; Fellows, J; Freedman, LS; Grigor, KM; Hall, RR; Hargreave, TB; Lallemand, G; Munson, K; Newling, DW; Parmar, MK; Richards, B; Robinson, MR; Rose, MB; Smith, PH; Tolley, DA; Whelan, P; Williams, JL, 1996) |
| "A randomized multicenter trial was done to compare transurethral resection only to transurethral resection plus adjuvant mitomycin C and bacillus Calmette Guerin (BCG) instillation for treatment of superficial bladder cancer (stage pTa/1 grades 1 to 3 except primary stage pTa grade 1)." | 9.08 | A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics. ( Giani, G; Krege, S; Meyer, R; Otto, T; Rübben, H, 1996) |
| "We evaluated the therapeutic activity and safety of continuously infused mitomycin C in patients with metastatic colorectal cancer who had recurred (less than 3 months) or progressed following first- or second-line 5-fluorouracil-based chemotherapy." | 9.08 | Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer. ( Bokemeyer, C; Daikeler, T; Harstrick, A; Hartmann, JT; Kanz, L; Kollmannsberger, C; Müller, C; Seeber, S, 1998) |
| "Two hundred eighty-seven patients with primary pTa G2, pT1 G1 to G2 superficial bladder cancer, following complete transurethral resection (TUR), were randomly allocated to receive intravesical treatment, either with IFN (50 x 10(6) IU) or mitomycin (MIT-C; 40 mg)." | 9.07 | Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study. ( Boccardo, F; Cannata, D; Canobbio, L; Curotto, A; Decensi, A; Guarneri, D; Martorana, G; Pegoraro, C; Rubagotti, A; Selvaggi, F, 1994) |
| "Between November 1986 and April 1989, 101 patients with superficial bladder cancer were treated with intravesical instillations of mitomycin C on day 1 and doxorubicin on day 2 of each week for 5 consecutive weeks." | 9.07 | Intravesical combination chemotherapy with mitomycin C and doxorubicin for superficial bladder cancer: a randomized trial of maintenance versus no maintenance following a complete response. ( Fukui, I; Ishiwata, D; Kawai, T; Kihara, K; Oshima, H; Sekine, H; Tachibana, Y, 1992) |
| "Intravesical chemotherapy involving the sequential instillation of mitomycin C (MMC) and Adriamycin (ADM) was performed in 40 patients with superficial bladder cancer (pathological stages Ta and T1)." | 9.07 | Sequential instillation therapy with mitomycin C and adriamycin for superficial bladder cancer. ( Abe, K; Isaka, S; Okano, T; Shimazaki, J, 1992) |
| "Both intravesical mitomycin C (MMC) and bacillus Calmette-Guérin (BCG; Pasteur strain F) were effective in the present prospective randomized multicenter study consisting of 91 patients with frequently recurrent superficial (Ta-T1) bladder cancer." | 9.07 | Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guérin) in superficial bladder cancer. ( Alfthan, O; Hansson, E; Jauhiainen, K; Juusela, H; Kanerva, K; Korhonen, H; Permi, J; Rintala, E; Sotarauta, M; Vaalasti, T, 1991) |
| "Sixty patients with Ta and T1 bladder cancer were randomized between treatment with resection only and resection and instillations with either Adriamycin or Mitomycin C." | 9.07 | Prophylactic instillation therapy of superficial bladder cancer. A randomized study comparing mitomycin C and adriamycin with special reference to DNA ploidy. ( Borgström, E; Brolin, J; Gustafson, H; Nyman, C; Tribukait, B; Wijkström, H, 1991) |
| "Intravesical instillation of adriamycin (ADM) or mitomycin C (MMC) was carried out for the purpose of preventing the recurrence of superficial bladder cancers (Ta and T1) after transurethral resection or transurethral coagulation." | 9.06 | Prophylactic intravesical instillation therapy with adriamycin and mitomycin C in patients with superficial bladder cancer. ( Matsumura, Y; Ohmori, H; Ozaki, Y; Tsushima, T; Yoshimoto, J, 1987) |
| "In a prospective, randomized, stratified study with crossover design the effect of thiotepa was compared to that of mitomycin C when each was instilled intravesically immediately at the end of complete removal of superficial bladder cancer (stages Ta and Tis) and later on tumor recurrence." | 9.05 | Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design. ( Benson, RC; Hilton, JF; Taylor, WF; Zincke, H, 1985) |
| "To evaluate the effectiveness and toxicity of intravesical gemcitabine in preventing tumour recurrence and progression in non-muscle invasive bladder cancer (NMIBC)." | 8.88 | Intravesical gemcitabine for non-muscle invasive bladder cancer. ( Cleves, A; Jones, G; Kynaston, HG; Mason, M; Shelley, M; Wilt, TJ, 2012) |
| "To assess, in a systematic review and meta-analysis, the relative effectiveness of intravesical mitomycin C and bacillus Calmette-Guérin (BCG) for tumour recurrence, disease progression and overall survival in patients with medium- to high-risk Ta and T1 bladder cancer." | 8.82 | Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. ( Coles, B; Court, J; Kynaston, H; Mason, MD; Shelley, MD; Wilt, TJ, 2004) |
| "Perioperative instillation of mitomycin-C (MMC) has shown effectiveness in reducing the recurrence of low-grade non-muscle invasive bladder cancer (NMIBC)." | 8.31 | Single-Dose Post-Office Fulguration Mitomycin C Instillation Appears to Improve Recurrence-Free Survival in Patients With Low-Grade Noninvasive Bladder Cancer. ( Baniel, J; Golan, S; Halstuch, D; Karchever, I; Kedar, D; Lotan, P; Rubinshtein, D, 2023) |
| "To compare recurrence rate and side effects with two different maintenance regimens of postoperative intravesical therapy with mitomycin and BCG in T1 bladder cancer." | 8.12 | Comparison of intravesical adjuvant therapy in bladder cancer with two different maintenance regimens of mitomycin and BCG. ( Dutta, A; Gupta, S; Pal, DK, 2022) |
| "To examine the use of Direct Visual Internal Urethrotomy with Mitomycin-C (DVIU-MMC) for bladder neck contracture and vesicourethral anastomotic stenosis in men who have undergone treatment for prostate cancer with radical prostatectomy and/or radiation therapy." | 8.12 | Outcomes of Vesicourethral Anastomotic Stenosis and Bladder Neck Contracture With Direct Visual Internal Urethrotomy With Mitomycin-C After Prostate Cancer Treatment. ( Hacker, EC; Maganty, A; Pere, MM; Rusilko, PJ, 2022) |
| "Chemoradiation (CRT) with mitomycin-C (MMC) and 5-fluorouracil (5-FU) has been shown to be superior to radiation alone in patients with muscle-invasive bladder cancer (MIBC)." | 7.96 | Radiation with concurrent radiosensitizing capecitabine tablets and single-dose mitomycin-C for muscle-invasive bladder cancer: A convenient alternative to 5-fluorouracil. ( Mertens, LS; Noordzij, A; Pos, F; Schaake, EE; Schuring, N; van de Kamp, MW; van der Heijden, MS; van Rhijn, BWG; Voskuilen, CS, 2020) |
| "Mitomycin-C (MMC) and thiotepa are intravesical agents effective in reducing the recurrence of low-grade noninvasive bladder cancer when instilled perioperatively." | 7.91 | Single-dose perioperative mitomycin-C versus thiotepa for low-grade noninvasive bladder cancer. ( Blodgett, G; Castle, EP; Chang, YH; Etzioni, DA; Faraj, K; Habermann, EB; Humphreys, MR; Rose, KM; Tyson Ii, MD, 2019) |
| " This study was performed to compare the efficacy of intravesical mitomycin C (MMC) instillation for the prophylaxis of Ta or T1 high-risk nonmuscle invasive bladder cancer (NMIBC) using different schedules." | 7.91 | Comparison of Different Treatment Schedules of Mitomycin C Intravesical Instillation in High-Risk Superficial Bladder Cancer Patients. ( Cha, TL; Chen, HR; En, M; Kao, CC; Sun, GH; Tang, SH; Tsao, CW; Wu, ST; Yu, DS, 2019) |
| "To evaluate oncological outcomes after combination intravesical therapy with gemcitabine (GC) and mitomycin C (MMC) in the setting of recurrent non-muscle-invasive bladder cancer (NMIBC) after failure of previous intravesical therapy." | 7.83 | Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer. ( Cockerill, PA; Frank, I; Karnes, RJ; Knoedler, JJ; Tarrell, R, 2016) |
| "Starting in 2009 bacillus Calmette-Guérin/electromotive drug administration of mitomycin C was introduced as the standard induction regime in patients with high risk, nonmuscle invasive bladder cancer undergoing bladder conservation." | 7.83 | Sequential bacillus Calmette-Guérin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes. ( Amery, S; Chatterton, K; Gan, C; Khan, MS; O'Brien, T; Thomas, K, 2016) |
| " A 49-year-old white male diagnosed with T3 N3 M0 Stage IIIB anal cancer was treated initially with surgical excision and adjuvant fluorouracil/cisplatin due unavailability of mitomycin." | 7.81 | Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab. ( Baxley, A; Khawandanah, M; Pant, S, 2015) |
| " The current study investigated the potential of curcumin to reduce breast cancer stem cell (BCSC) population for sensitizing breast cancer cells to mitomycin C (MMC) both in vitro and in vivo." | 7.81 | Curcumin Improves the Tumoricidal Effect of Mitomycin C by Suppressing ABCG2 Expression in Stem Cell-Like Breast Cancer Cells. ( Chen, Q; Huang, S; Lu, Y; Su, S; Ye, M; Zhang, H; Zhou, Q, 2015) |
| "To compare local control effects of superselective transcatheter arterial chemoembolization (TACE) using epirubicin (EPI) plus mitomycin C (M) and miriplatin (MPT) for hepatocellular carcinoma (HCC)." | 7.78 | Comparison of local control effects of superselective transcatheter arterial chemoembolization using epirubicin plus mitomycin C and miriplatin for hepatocellular carcinoma. ( Hashimoto, M; Matsui, O; Miyayama, S; Shibata, Y; Toshima, F; Tsuji, K; Yamashiro, M; Yoshida, M, 2012) |
| "To report the long-term complications and rate of local recurrence in a cohort of patients with histopathologically confirmed conjunctival melanoma (CM) treated with adjuvant topical mitomycin C (MMC)." | 7.77 | Outcomes in 15 patients with conjunctival melanoma treated with adjuvant topical mitomycin C: complications and recurrences. ( Ditta, LC; Shildkrot, Y; Wilson, MW, 2011) |
| " Mitomycin was a primary treatment for residual epithelial disease in ten patients (eight with PAM with atypia and two with conjunctival melanoma) and as an adjuvant to excision and cryotherapy in six with conjunctival malignant melanoma." | 7.73 | Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years' experience. ( Finger, PT; Kurli, M, 2005) |
| "Transurethral resection followed by instillation of chemotherapeutic agents such as mitomycin is considered as standard therapy in recurrent superficial bladder cancer." | 7.73 | Reducing recurrence and costs in superficial bladder cancer: preclinical evaluation of osmotic cytolysis by distilled water vs. mitomycin. ( Fechner, G; Müller, SC; Pocha, K; Schmidt, D, 2006) |
| "We studied prophylactic intravesical instillation of mitomycin C (MMC) and pirarubicin (THP) following transurethral resection of bladder tumor (TUR-Bt) for superficial bladder cancer." | 7.73 | [5 years intravesical instillation with mitomycin-C and pirarubicin as a prophylactic treatment for superficial bladder cancer]. ( Ishizaka, K; Kobayashi, S; Machida, T; Oka, K, 2006) |
| "To describe a case of recurrent, advanced conjunctival papillomatosis, treated by oral cimetidine (CIM) combined with secondary surgical intervention and an application of intraoperative mitomycin C." | 7.73 | Oral cimetidine adjuvant therapy for recalcitrant, diffuse conjunctival papillomatosis. ( Chang, SW; Huang, ZL, 2006) |
| "The aim of this analysis is to evaluate the effect of 5-fluorouracil (5-FU) rechallenge on subsequent response and survival in patients with advanced colorectal cancer (CRC)." | 7.72 | Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials. ( Chau, I; Cunningham, D; Hill, M; Norman, AR; Ross, PJ; Yeoh, C, 2003) |
| "To evaluate the efficacy and toxicity of the combination of mitomycin C, etoposide, cisplatin, and epirubicin (MEPA) as neoadjuvant therapy for patients with cervical adenocarcinoma." | 7.72 | A pilot study of neoadjuvant chemotherapy with mitomycin C, etoposide, cisplatin, and epirubicin for adenocarcinoma of the cervix. ( Nishiura, K; Obata, H; Okugawa, T; Tabata, T; Tanaka, K; Toyoda, N; Yanoh, K, 2004) |
| "To describe the use of postoperative topical mitomycin C (MMC) in the treatment of recurrent conjunctival papilloma." | 7.71 | The use of postoperative topical mitomycin C in the treatment of recurrent conjunctival papilloma. ( Chan, NR; Chi, SC; Lam, DS; Yeung, EF; Yuen, HK, 2002) |
| " In this study we aimed to evaluate the effectivity of postsurgical chemotherapy of conjunctival squamous cell carcinoma in situ (CIN) with mitomycin C eyedrops." | 7.71 | [Treatment of 9 squamous epithelial carcinoma in situ lesions of the conjunctiva (CIN) with mitomycin C eyedrops in cytological and DNA image cytometric control]. ( Böcking, A; Cartsburg, O; Kersten, A; Nadjari, B; Pomjanski, N; Sundmacher, R, 2001) |
| "To compare the tumoricidal efficacy of meglumine gamma-linolenic acid (MeGLA), mitomycin C, epirubicin and water on two urothelial cell lines, and to establish the effect of serum protein levels derived from bladder cancer resection craters on the action of these agents." | 7.70 | Bladder cancer recurrence by implantation of exfoliated cells: is gamma-linolenic acid an effective tumoricidal agent? ( Birch, BR; Cooper, AJ; Foley, SJ; Jennings, AM; Solomon, LZ, 1998) |
| "To report an effective treatment for recurrent squamous papillomas of the conjunctiva with excision and application of mitomycin C." | 7.70 | Treatment of recurrent conjunctival papillomatosis with mitomycin C. ( Hamming, NA; Hawkins, AS; Rubenstein, JB; Yu, J, 1999) |
| "From January 1984 to December 1991, 58 patients with carcinoma in situ of the bladder were treated initially with intravesical mitomycin C and doxorubicin sequential therapy." | 7.69 | Histological grading of carcinoma in situ of the bladder: its clinical significance in patients who underwent intravesical mitomycin C and doxorubicin sequential therapy. ( Fukui, I; Kojima, S; Ohshima, H; Sekine, H; Yamada, T, 1996) |
| "Mitomycin C (MMC) was given intravesically to 14 patients with transitional-cell carcinoma in situ of the bladder (CIS) between 1985 and 1989." | 7.69 | Treatment of bladder carcinoma in situ with mitomycin C: long-term follow-up. ( Cecchi, M; Felipetto, R; Minervini, R; Viganò, L, 1994) |
| "Mitomycin C (MMC) was given intravesically over a period of 36 months to 14 patients with transitional-cell carcinoma in situ of the bladder (CIS)." | 7.69 | Intravesical mitomycin C for the treatment of carcinoma in situ of the bladder: 36 months follow-up. ( Cecchi, M; Felipetto, R; Minervini, R; Pagni, G; Viganò, L, 1994) |
| "A total of 43 patients with carcinoma in situ of the bladder (primary in 26 and secondary in 17) who underwent intravesical mitomycin C and doxorubicin sequential therapy for 2 multicenter studies were followed for a median period of 45 months (range 10 to 84)." | 7.69 | Intravesical mitomycin C and doxorubicin sequential therapy for carcinoma in situ of the bladder: a longer followup result. ( Fukui, I; Ohshima, H; Ohwada, F; Sekine, H; Yamada, T; Yokokawa, M, 1994) |
| "Bladder wall calcification is a rare complication of intravesical therapy of superficial bladder cancer with Mitomycin C." | 7.68 | Incrusted cystitis after intravesical mitomycin C treatment. ( Algado, M; Botella, R; Llopis, M; Moreno, J, 1993) |
| "The effect of intravesical instillation of 200,000 IU hyaluronidase in addition to mitomycin C as chemoprophylaxis of superficial bladder cancer was evaluated." | 7.68 | Topical chemoprophylaxis of superficial bladder cancer with mitomycin C and adjuvant hyaluronidase. ( Höbarth, K; Maier, U; Marberger, M, 1992) |
| "We analyzed 29 cases of eosinophilic cystitis in a group of 80 patients with lower urothelial carcinoma who had been treated with mitomycin-C." | 7.68 | [Eosinophilic cystitis as a special form of response to mitomycin C. Analysis and comments on our cases]. ( Arango Toro, O; Bielsa Galí, O; Corominas, J; Gelabert Mas, A; Lladó Carbonell, C; Vesa Llanes, J, 1991) |
| "We studied 15 patients with histologically proved multifocal carcinoma in situ of the bladder who were in remission at a mean followup of 21 months after induction intravesical chemotherapy with mitomycin C." | 7.68 | Topical mitomycin C therapy for carcinoma in situ of the bladder: a followup. ( Grant, AB; Hosken, BM; Stricker, PD; Taylor, JS, 1990) |
| "Mitomycin C was given intravesically over periods of 2-32 months to 34 patients with carcinoma in situ of the urinary bladder." | 7.68 | Intravesical mitomycin C for carcinoma in situ of the urinary bladder. ( Hellsten, S; Henrikson, H; Idwall, I; Lindholm, K; Månsson, W; Mårtensson, S; Mikulowski, P; Oldbring, J, 1990) |
| "Since June 1984, 23 cases of progressive or recurrent breast cancers were treated with combination chemotherapy of VAM-UFT consisting of vincristine, adriamycin, mitomycin C and UFT." | 7.67 | [Vincristine, adriamycin, mitomycin-C and UFT (VAM-UFT) therapy in progressive or recurrent breast cancer]. ( Hozumi, T; Imamura, Y; Irie, K; Katou, J; Matsushita, K; Okutani, T; Oya, M; Yasutake, K; Yoshimura, Y, 1989) |
| "Both Mitomycin C (MMC) and doxorubicin (Adriamycin) (ADM) prevent the recurrence of superficial papillary (Ta-T1) urinary bladder cancers and also reduce the rate of progression." | 7.67 | Instillation of mitomycin C and doxorubicin in the prevention of recurrent superficial (Ta-T1) bladder cancer. ( Alfthan, O; Jauhiainen, K, 1987) |
| "A limited course of intravesical mitomycin C was tested in 12 patients who had at least three, and an average of six, occurrences of superficial bladder cancer, and were at high risk for subsequent recurrences." | 7.67 | Study of intravesical mitomycin C in patients with multiple prior occurrences of superficial bladder cancer. ( Brown, J; Johanson, KE; Schwarzman, MI; Surya, B, 1988) |
| "Twenty-three patients who were given intravesical Mitomycin C for treatment of superficial bladder cancer have been followed up for a further 12 and 24 months after an initial assessment 5 weeks after completing therapy." | 7.67 | Mitomycin C in superficial bladder cancer: 24-month follow-up. ( Newling, DW; Richards, B; Robinson, MR; Smith, PH; Somerville, JJ, 1985) |
| "Twenty-five patients with metastatic breast cancer who had failed with combination chemotherapies including adriamycin were treated with a combination of mitomycin C, methotrexate, and vincristine (MMV)." | 7.66 | [Combination chemotherapy with mitomycin C, methotrexate, and vincristine (MMV) for metastatic breast cancer refractory to adriamycin]. ( Hamada, Y; Kanda, K; Nomura, Y; Saeki, K; Tashiro, H, 1983) |
| "One hundred patients suffering from advanced breast cancers and resisting to one (15) or several (85) drugs previously administered have been treated by an association of mitomycin C, thiotepa and vindesine, given every 3 weeks." | 7.66 | [Chemotherapy associating mitomycin C, thiotepa and vindesine in advanced breast cancers. Study of 100 cases (author's transl)]. ( Brunet, R; Bui, BN; Chauvergne, J; Durand, M; Hoerni, B; Mauriac, L, 1981) |
| "The long-term bladder cancer-specific mortality was unexpectedly low despite the relatively ineffective instillation therapy and the poor outcome of the patients after progression." | 6.77 | Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette-Guérin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective FinnBladder 2 study with a 17- ( Group, TF; Järvinen, R; Kaasinen, E; Rintala, E, 2012) |
| "The response rate and time to disease progression were the primary endpoints, with overall survival as the secondary endpoint." | 6.71 | Hypoxic pelvic and limb perfusion with melphalan and mitomycin C for recurrent limb melanoma: a pilot study. ( Amicucci, G; Deraco, M; Di Filippo, F; Fiorentini, G; Guadagni, S; Miotto, D; Patuzzo, R; Pilati, PL; Rossi, CR; Santinami, M; Valenti, M, 2003) |
| "The mitomycin C-treated patients had 41% recurrence, 1." | 6.68 | [Prevention of superficial bladder cancer with mitomycin C or interferon: final results of a prospective study]. ( Alonso Rodrigo, A; Barros Rodríguez, M; Benavente Delgado, J; Domínguez Freire, F; Nogueira March, YJ; Ojea Calvo, A; Rodríguez Iglesias, B; Vérez Vivero, M, 1996) |
| " Haematologic toxicity is greater in the CMF group, requiring more frequent dosage reductions." | 6.67 | Randomized trial of adjuvant chemotherapy for operable breast cancer comparing i.v. CMF to an epirubicin-containing regimen [see comment]. ( Bonichon, F; Chauvergne, J; Dilhuydy, JM; Durand, M; Mauriac, L, 1992) |
| "Bladder cancer is the second most common urological malignant disease." | 6.58 | [Thermochemotherapy with Mitomycin C: an update on alternative treatment strategies in non-muscleinvasive bladder cancer]. ( Blaschke, S; Christoph, F; König, F; Lebentrau, S; Liehr, UB; Schostak, M, 2018) |
| "Bladder cancer is a heterogeneous disease: approximately 75% of its forms are non muscle invasive neoplasms." | 6.46 | Mitomycin C for the treatment of bladder cancer. ( Bassi, PF; Cappa, E; D'Agostino, D; Filianoti, A; Racioppi, M; Volpe, A, 2010) |
| "To assess the clinical and oncological outcomes of sequential treatment with Bacillus Calmette-Guerin (BCG) and Mitomycin C (MMC) administered with Electromotive Drug Administration (EMDA) in patients with high-risk NMIBC who fail BCG immunotherapy." | 5.91 | Sequential Treatment With Bacillus Calmette-Güerin (BCG) and Mitomycin C Administered With Electromotive Drug Administration (EMDA) in Patients With High-Risk Nonmuscle Invasive Bladder Cancer After BCG Failure. ( Bravo, A; Breda, A; Gaya, JM; Huguet, J; Palou, J; Robalino, J; Rodríguez Faba, Ó; Sanz Gómez, I; Territo, Á, 2023) |
| "In the rat bladder cancer model, IVI of chidamide plus mitomycin C reduced tumor burden (Ki67 index) to a greater extent than either drug alone." | 5.72 | Chidamide and mitomycin C exert synergistic cytotoxic effects against bladder cancer cells in vitro and suppress tumor growth in a rat bladder cancer model. ( Chang, YC; Chen, SL; Sung, WW; Wang, SC; Wu, YC; Yu, CY, 2022) |
| "This study aimed to assess long-term follow-up after chemoresection with mitomycin (MMC), a nonsurgical treatment modality for recurrent nonmuscle invasive bladder cancer (NMIBC)." | 5.69 | DaBlaCa-13 Study: Oncological Outcome of Short-Term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial. ( Azawi, N; Dyrskjøt, L; Hansen, E; Jensen, JB; Lindgren, MS; Nielsen, AM, 2023) |
| "To compare the therapeutic effects of locoregional deep hyperthermia combined with intravesical chemotherapy with those of intravesical chemotherapy alone in patients with intermediate-/high-risk non-muscle invasive bladder cancer (NMIBC)." | 5.62 | Loco-regional deep hyperthermia combined with intravesical Mitomycin instillation reduces the recurrence of non-muscle invasive papillary bladder cancer. ( Fan, YC; Lai, BCH; Lee, HL; Lee, LM; Lin, KH; Lin, YW; Shih, HJ; Syu, SH; Wen, YC, 2021) |
| "The purpose of the study was to compare the outcomes of high-risk non-muscle-invasive bladder cancer (HR-NMIBC) patients treated with BCG vs recirculating hyperthermic intravesical chemotherapy (HIVEC) with mitomycin C (MMC)." | 5.51 | Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial. ( de la Rosa-Kehrmann, F; González-Díaz, A; González-Padilla, DA; Guerrero-Ramos, F; Inman, BA; Rodríguez-Antolín, A; Villacampa-Aubá, F, 2022) |
| "Optima II ("OPTimized Instillation of Mitomycin for Bladder Cancer Treatment," clinicaltrials." | 5.51 | Minimal Patient-Reported Side Effects for a Chemoablative Gel (UGN-102) Used as Frontline Treatment in Adults with Nonmuscle-Invasive Bladder Cancer. ( Basak, R; Giannone, K; Hilton, A; Lipman, R; Mueller, D; Smith, AB; Stover, AM; Teal, R; Waheed, M, 2022) |
| "We observed euploid DNA-polyploidy and cytomorphological changes in all patients (19/19)." | 5.31 | Topical mitomycin C and radiation induce conjunctival DNA-polyploidy. ( Böcking, A; Cartsburg, O; Hillenkamp, J; Kallen, C; Pomjanski, N; Sundmacher, R, 2001) |
| "Patients were randomly assigned (1:1) to RITE (60min, 40mg mitomycin-C, 42±2°C) or control following stratification for carcinoma in situ (CIS) status (present/absent), therapy history (failure of previous induction/maintenance BCG), and treatment centre." | 5.30 | Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Th ( Bhatt, R; Billingham, LJ; Buckley, L; Cresswell, J; Datta, SN; Devall, AJ; Feneley, MR; Griffiths, TRL; Hodgson, D; Issa, R; Kelly, JD; Loubière, LS; Madaan, S; McGrath, J; Mostafid, H; Page, T; Panchal, A; Pope, AM; Sangar, V; Tan, WS, 2019) |
| "Celecoxib was not shown to reduce the risk of recurrence in intermediate- or high-risk non-muscle-invasive bladder cancer (NMIBC), although celecoxib was associated with delayed time to recurrence in pT1 NMIBC patients." | 5.30 | BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). ( Andrews, S; Blazeby, J; Bogle, R; Brough, R; Burnett, S; Cresswell, J; Cruickshank, C; Hall, E; Huddart, R; Johnson, M; Kelly, JD; Madaan, S; Maynard, L; Mostafid, H; Palmer, A; Porta, N; Protheroe, A; Tan, WS, 2019) |
| "To investigate whether the timing of an immediate instillation of mitomycin C (on the day of transurethral resection of bladder tumour [TURBT] or 1 day later) has an impact on time to recurrence of non-muscle-invasive bladder cancer (NMIBC)." | 5.27 | The effect of timing of an immediate instillation of mitomycin C after transurethral resection in 941 patients with non-muscle-invasive bladder cancer. ( Beckers, GMA; Bosschieter, J; Lissenberg-Witte, BI; Nieuwenhuijzen, JA; van Ginkel, T; van Moorselaar, RJA; Vis, AN, 2018) |
| "From those 11 studies, it is shown that intravesical chemotherapy using Epirubicin and Mitomycin-C following TURB showed significant decrease of recurrence rate of bladder cancer even to progression of the disease compared to TURB alone (p<0." | 5.22 | Comparison Between Intravesical Chemotherapy Epirubicin and Mitomycin-C after TURB vs TURB Alone With Recurrence Rate of Non-Muscle Invasive Bladder Cancer: Meta-Analysis. ( Budaya, TN; Daryanto, B; Purnomo, AF; Seputra, KP, 2022) |
| "Patients with SCC of anal cancer T2-4N0M0 or T (any) N1-3M0, with good performance status and normal blood and renal function, were treated with capecitabine 825 mg/m(2) bid during radiotherapy associated with a single dose of mitomycin 15 mg/m(2) on day 1." | 5.22 | Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal. ( Alex, AK; Bariani, G; Braghirolli, MI; Hoff, PM; Moniz, CM; Nahas, C; Oliveira, SC; Riechelmann, R, 2016) |
| "We analyzed the outcomes of a randomized trial demonstrating that in intermediate- to high-risk non-muscle-invasive bladder cancer, mitomycin C and bacillus Calmette-Guérin (BCG) reduced disease relapse compared with BCG alone but was more toxic." | 5.20 | Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomiz ( Alonso, JM; Astobieta, A; Beardo, P; Chantada, V; Fernandez, JM; Gomez, M; Madero, R; Martinez Piñeiro, JA; Martinez-Piñeiro, L; Montesinos, M; Muntañola, P; Ojea, A; Portillo, JA; Rabadan, M; Rodriguez-Molina, J; Solsona, E; Unda, M; Zabala, JA, 2015) |
| "We demonstrated in non-muscle-invasive bladder cancer patients with exceptionally frequent recurrences that the risk of long-term recurrence was reduced from 78-80% to 43-45% if one perioperative plus four weekly mitomycin C instillations were followed by monthly bacillus Calmette-Guérin (BCG) instillations for 1 yr instead of alternating instillations of BCG and interferon-α2b." | 5.20 | Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon ( Aaltomaa, S; Boström, PJ; Järvinen, R; Kaasinen, E; Kallio, J; Liukkonen, T; Marttila, T; Puolakka, VM; Rintala, E; Seppänen, M; Tuhkanen, K; Vaarala, M; Viitanen, J, 2015) |
| "The results of our trial--the largest in anal cancer to date--show that fluorouracil and mitomycin with 50." | 5.17 | Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. ( Begum, R; Cunningham, D; Essapen, S; Falk, S; Glynne-Jones, R; Gollins, S; James, RD; Kadalayil, L; Ledermann, J; Leslie, M; Maughan, T; McDonald, A; Meadows, HM; Myint, AS; Saunders, MP; Sebag-Montefiore, D; Wilson, C, 2013) |
| "The long-term update of US GI Intergroup RTOG 98-11 anal cancer trial found that concurrent chemoradiation (CCRT) with fluorouracil (5-FU) plus mitomycin had a significant impact on disease-free survival (DFS) and overall survival (OS) compared with induction plus concurrent 5-FU plus cisplatin." | 5.17 | Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. ( Ajani, JA; Benson, AB; Gunderson, LL; Haddock, MG; Mayer, RJ; Moughan, J; Pedersen, JE; Rich, TA; Thomas, CR; Willett, CG; Winter, KA, 2013) |
| "The purpose of this study was to determine the effectiveness of a single early instillation of mitomycin C (MMC) after transurethral resection of bladder tumor (TURBT) together with urinary alkalinization in patients with low-risk non-muscle-invasive bladder cancer (NMIBC)." | 5.17 | Single early instillation of mitomycin C and urinary alkalinization in low-risk non-muscle-invasive bladder cancer: a preliminary study. ( Ersoy, H; Karakoyunlu, AN; Ozok, HU; Sagnak, L; Topaloglu, H; Yaytokgil, M, 2013) |
| "Our aim was to assess if sequential mitomycin C (MMC) plus BCG after transurethral resection (TUR) is worthy of further study in non-muscle-invasive bladder cancer patients with CIS." | 5.15 | Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial ( ( Algaba, F; Bono, A; Busch, C; Collette, S; da Silva, FC; Kirkali, Z; Oosterlinck, W; Sylvester, R, 2011) |
| "To study the benefits of a single, early, intravesical instillation of mitomycin C(MMC) after transurethral bladder resection (TURB) in patients with low-risk non-muscle-invasive bladder cancer (NMIBC)." | 5.15 | Long-term experience with early single mitomycin C instillations in patients with low-risk non-muscle-invasive bladder cancer: prospective, single-centre randomised trial. ( Albisinni, S; Alpi, G; Cantiani, A; Carbone, A; De Nunzio, C; Iori, F; Liberti, M; Tubaro, A, 2011) |
| " Our aim was to compare TURBT alone with immediate post-TURBT intravesical passive diffusion (PD) of mitomycin and immediate pre-TURBT intravesical electromotive drug administration (EMDA) of mitomycin in non-muscle invasive bladder cancer." | 5.15 | Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. ( Di Stasi, SM; Giurioli, A; Leprini, G; Liberati, E; Masedu, F; Micali, F; Ricci, AR; Valenti, M; Verri, C; Vespasiani, G, 2011) |
| "To evaluate the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure, including mitomycin (MMC), epirubicin (EPB) and camptothecin (CPT), in the treatment of non-muscle-invasive bladder cancer (NMIBC)." | 5.15 | [Evaluation of the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure in the treatment of non-muscle-invasive bladder cancer]. ( Cao, M; Chen, HG; Ma, CK; Ma, J; Xue, W, 2011) |
| "The present study compared the therapeutic activity of intravesical BCG with intravesical mitomycin C chemotherapy in patients with non-muscle invasive bladder cancer at intermediate risk of recurrence in a prospective randomised trial." | 5.13 | A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy. ( Del Nero, A; Mangiarotti, B; Montanari, E; Trinchieri, A, 2008) |
| "It remains unclear whether people with non-muscle invasive bladder cancer (NMIBC) benefit from intravesical gemcitabine compared to other agents in the primary or recurrent setting following transurethral resection of a bladder tumor." | 5.12 | Intravesical gemcitabine for non-muscle invasive bladder cancer. ( Cleves, A; Dahm, P; Han, MA; Hwang, EC; Hwang, JE; Jung, JH; Maisch, P; Narayan, V, 2021) |
| "We analyzed the impact of a single Mitomycin C instillation in patients with low risk superficial bladder cancer with short and long-term follow-up." | 5.12 | Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term follow-up. ( El-Ganzoury, HM; El-Ghobashy, S; El-Leithy, TR; Roshdy, MM, 2007) |
| "Combining radiation with mitomycin and cisplatin in patients with locally advanced anal cancer is feasible." | 5.12 | Combining cisplatin and mitomycin with radiotherapy in anal carcinoma. ( Bosset, JF; Bosset, M; Buffet-Miny, J; Crehange, G; Dumas, JL; Lorchel, F; Mercier, M; Puyraveau, M, 2007) |
| "To report the 10-year follow-up of a study randomizing between instillations of bacillus Calmette-Guérin (BCG) and mitomycin-C (MMC) for treating high-risk and not muscle-invasive urinary bladder cancer to assess progression, the need for more aggressive treatment and survival (cancer-specific and overall), as many of the published studies comparing different treatments for disease that is not muscle-invasive have a short follow-up." | 5.12 | Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer. ( Gårdmark, T; Jahnson, S; Malmström, PU; Wahlquist, R; Wijkström, H, 2007) |
| "Of our study was to assess and compare the outcome of patients undergoing anthracycline based neoadjuvant chemotherapy in locally advanced primary breast cancers with patients receiving mitoxantrone, methotrexate and mitomycin (MMM) as neoadjuvant agents." | 5.12 | Neoadjuvant chemotherapy in locally advanced primary breast cancers: the Nottingham experience. ( Agrawal, A; Asgeirsson, KS; Chan, SY; Cheung, KL; Ellis, IO; Mathew, J; Mukherjee, A; Robertson, JF, 2007) |
| "We conducted a phase I/II study investigating synchronous chemoradiotherapy with mitomycin C and infusional 5-fluorouracil (5-FU) in muscle invasive bladder cancer." | 5.11 | Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. ( Glaholm, JG; Hussain, SA; James, ND; Peake, DR; Stocken, DD; Wallace, DM; Zarkar, A, 2004) |
| "To observe the effect of postoperative transcatheter hepatic arterial chemoembolization (TACE) and thymosin alpha(1) (T(alpha1)) treatment on recurrence of hepatocellular carcinoma (HCC)." | 5.11 | [Transcatheter hepatic arterial chemoembolization and thymosin alpha1 in postoperative treatment of hepatocellular carcinoma]. ( Chen, H; Cheng, SQ; Cong, WM; Shen, F; Wang, PJ; Wu, MC; Yang, JH; Zhao, YX, 2004) |
| "To report a phase-1 study of patients with recurrent superficial bladder cancer treated with photodynamic therapy (PDT) using sequential mitomycin C and 5-aminolaevulinic acid (ALA)." | 5.11 | A phase-1 study of sequential mitomycin C and 5-aminolaevulinic acid-mediated photodynamic therapy in recurrent superficial bladder carcinoma. ( Allman, R; Datta, SN; French, AJ; Mason, MD; Matthews, PN; Skyrme, RJ, 2005) |
| "To evaluate whether, in patients with carcinoma in situ (CIS) of the urinary bladder, alternating instillation therapy with mitomycin C (MMC) and bacillus Calmette-Guerin (BCG) was more effective and less toxic than conventional BCG monotherapy." | 5.10 | Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study. ( Duchek, M; Hellsten, S; Kaasinen, E; Malmström, PU; Mestad, O; Rintala, E; Wijkström, H, 2003) |
| "Local chemotherapy with mitomycin C is a useful option in the treatment of malignant melanomas of the conjunctiva associated with PAM if the tumor stage is pT3 or less." | 5.10 | [Management of conjunctival malignant melanoma associated with primary acquired melanosis (PAM) using 0.02% mitomycin C eyedrops]. ( Conway, RM; Groh, MJ; Holbach, LM; Kühnel, B; Naumann, GO, 2003) |
| "Ablative therapy with interferon-alpha was less effective than mitomycin-C in patients with superficial bladder cancer." | 5.10 | A randomized comparative dose-ranging study of interferon-alpha and mitomycin-C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder. ( Malmström, PU, 2002) |
| "We analyze the impact of a single mitomycin C instillation in patients with low risk superficial bladder cancer with short and long-term followup." | 5.09 | Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. ( Casanova, J; Dumont, R; Iborra, I; Monrós, JL; Ricós, JV; Solsona, E, 1999) |
| "Chemotherapy for 5-fluorouracil (5-FU)-resistant colorectal cancer is largely ineffective with new and innovative therapeutic strategies needed to benefit patients developing progressive disease while receiving 5-FU or 5-FU-based programs." | 5.09 | A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil. ( Anderson, N; Bern, M; Coco, F; Lokich, J; Moore, C, 1999) |
| "We evaluated the prophylactic efficacy of instillations of intravesical mitomycin C in 57 patients with primary superficial bladder cancer in a multicenter clinical trial." | 5.09 | The effect of intravesical mitomycin C on the recurrence of superficial (Ta-T1) bladder cancer. A Hungarian Multicenter Study. ( Bodrogi, I; Határ, A; Kiss, A; Kiss, L; Kondás, J; Lukács, T; Szeldeli, P; Törzsök, F, 1999) |
| "To clinically evaluate topical mitomycin chemotherapy in patients with diffuse, multifocal, or recurrent primary acquired melanosis with atypia and/or conjunctival malignant melanoma and to histopathologically study ocular tissue samples obtained before and after treatment." | 5.09 | Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: clinical experience with histopathologic observations. ( Demirci, H; Finger, PT; McCormick, SA, 2000) |
| "In a randomized trial, the authors evaluated the possible adjuvant activity of intraportal chemotherapy (with 5-fluorouracil 500 mg/m2/day in continuous infusion for 7 days and mitomycin C 10 mg/m2 at day 7) administered after surgery to half of the patients who underwent a full resection for Dukes B2 or C colorectal cancer." | 5.09 | Adjuvant intraportal chemotherapy for Dukes B2 and C colorectal cancer also receiving systemic treatment: results of a multicenter randomized trial. Groupe Régional d'Etude du Cancer Colo-Rectal (Belgium). ( Beauduin, M; Brohée, D; Bury, J; Focan, C; Herman, ML; Lecomte, M; Vindevoghel, A, 2000) |
| ", placement of the drug directly in the bladder) with mitomycin C is beneficial for patients with superficial bladder cancer who are at high risk of recurrence, but standard therapy is empirically based and patient response rates have been variable, in part because of inadequate drug delivery." | 5.09 | Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. ( Au, JL; Badalament, RA; Chin, JL; Harbrecht, JD; Lerner, SP; Miles, BJ; Pollifrone, DL; Venema, PL; Warner, JA; Wientjes, MG; Young, DC, 2001) |
| "To elucidate the most efficient topical therapy for carcinoma in situ of the bladder, the efficacy of intravesical mitomycin C plus doxorubicin therapy was compared with bacillus Calmette-Guerin (BCG) therapy." | 5.09 | Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder. ( Fukui, I; Igarashi, K; Kojima, SI; Ohya, K; Sekine, H, 2001) |
| "We determined the role, if any, of 1 and 5 instillations of intravesical mitomycin C in the treatment of newly diagnosed superficial bladder cancer." | 5.08 | The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. ( Benyon, LL; Fellows, J; Freedman, LS; Grigor, KM; Hall, RR; Hargreave, TB; Lallemand, G; Munson, K; Newling, DW; Parmar, MK; Richards, B; Robinson, MR; Rose, MB; Smith, PH; Tolley, DA; Whelan, P; Williams, JL, 1996) |
| "A randomized multicenter trial was done to compare transurethral resection only to transurethral resection plus adjuvant mitomycin C and bacillus Calmette Guerin (BCG) instillation for treatment of superficial bladder cancer (stage pTa/1 grades 1 to 3 except primary stage pTa grade 1)." | 5.08 | A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics. ( Giani, G; Krege, S; Meyer, R; Otto, T; Rübben, H, 1996) |
| "We evaluated the therapeutic activity and safety of continuously infused mitomycin C in patients with metastatic colorectal cancer who had recurred (less than 3 months) or progressed following first- or second-line 5-fluorouracil-based chemotherapy." | 5.08 | Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer. ( Bokemeyer, C; Daikeler, T; Harstrick, A; Hartmann, JT; Kanz, L; Kollmannsberger, C; Müller, C; Seeber, S, 1998) |
| "A randomized and placedo-controlled trial on intravesical N-CWS instillation versus mitomycin-C(MMC) therapy for recurrence prevention in postopenative bladder cancer patients was carried out." | 5.08 | [Long-term results of intravesical N-CWS instillation to prevent recurrence after surgery for bladder cancer]. ( Chen, S; Lin, Z; Xu, E, 1997) |
| "Two hundred eighty-seven patients with primary pTa G2, pT1 G1 to G2 superficial bladder cancer, following complete transurethral resection (TUR), were randomly allocated to receive intravesical treatment, either with IFN (50 x 10(6) IU) or mitomycin (MIT-C; 40 mg)." | 5.07 | Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study. ( Boccardo, F; Cannata, D; Canobbio, L; Curotto, A; Decensi, A; Guarneri, D; Martorana, G; Pegoraro, C; Rubagotti, A; Selvaggi, F, 1994) |
| "Between November 1986 and April 1989, 101 patients with superficial bladder cancer were treated with intravesical instillations of mitomycin C on day 1 and doxorubicin on day 2 of each week for 5 consecutive weeks." | 5.07 | Intravesical combination chemotherapy with mitomycin C and doxorubicin for superficial bladder cancer: a randomized trial of maintenance versus no maintenance following a complete response. ( Fukui, I; Ishiwata, D; Kawai, T; Kihara, K; Oshima, H; Sekine, H; Tachibana, Y, 1992) |
| "Intravesical chemotherapy involving the sequential instillation of mitomycin C (MMC) and Adriamycin (ADM) was performed in 40 patients with superficial bladder cancer (pathological stages Ta and T1)." | 5.07 | Sequential instillation therapy with mitomycin C and adriamycin for superficial bladder cancer. ( Abe, K; Isaka, S; Okano, T; Shimazaki, J, 1992) |
| "Both intravesical mitomycin C (MMC) and bacillus Calmette-Guérin (BCG; Pasteur strain F) were effective in the present prospective randomized multicenter study consisting of 91 patients with frequently recurrent superficial (Ta-T1) bladder cancer." | 5.07 | Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guérin) in superficial bladder cancer. ( Alfthan, O; Hansson, E; Jauhiainen, K; Juusela, H; Kanerva, K; Korhonen, H; Permi, J; Rintala, E; Sotarauta, M; Vaalasti, T, 1991) |
| "Sixty patients with Ta and T1 bladder cancer were randomized between treatment with resection only and resection and instillations with either Adriamycin or Mitomycin C." | 5.07 | Prophylactic instillation therapy of superficial bladder cancer. A randomized study comparing mitomycin C and adriamycin with special reference to DNA ploidy. ( Borgström, E; Brolin, J; Gustafson, H; Nyman, C; Tribukait, B; Wijkström, H, 1991) |
| "Intravesical instillation of adriamycin (ADM) or mitomycin C (MMC) was carried out for the purpose of preventing the recurrence of superficial bladder cancers (Ta and T1) after transurethral resection or transurethral coagulation." | 5.06 | Prophylactic intravesical instillation therapy with adriamycin and mitomycin C in patients with superficial bladder cancer. ( Matsumura, Y; Ohmori, H; Ozaki, Y; Tsushima, T; Yoshimoto, J, 1987) |
| "A randomized, controlled study was begun in 1982 on the effect of keyhole-limpet hemocyanin and mitomycin C in the prevention of recurrent superficial bladder cancer (stages pTa to pT1, grades 0 to 3) in 44 patients." | 5.06 | Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized study. ( Engelmann, U; Gasch, J; Jurincic, CD; Klippel, KF, 1988) |
| "The Georgetown University Hospital experience in the treatment of advanced breast cancer using either a combination of doxorubicin (adriamycin) and vincristine (AV) or adriamycin and mitomycin-C (AM) is presented." | 5.05 | Treatment of advanced breast cancer with two doxorubicin-containing regimens. ( Byrne, PJ; Harris, MA; Oishi, S; Schein, PS; Schlesinger, C; Smith, FP; Ueno, W, 1984) |
| "The FAM combination with the simultaneous administration of 5-fluorouracil, doxorubicin, and mitomycin C is considered standard chemotherapy for gastric adenocarcinoma." | 5.05 | Drug combinations in the treatment of gastric adenocarcinoma: a randomized Southwest Oncology Group study. ( Athens, J; Chen, TT; Costanzi, JJ; Haas, C; Heilbrun, LK; McDonald, B; Oishi, N; Panettiere, FJ; Talley, RW, 1984) |
| "In a prospective, randomized, stratified study with crossover design the effect of thiotepa was compared to that of mitomycin C when each was instilled intravesically immediately at the end of complete removal of superficial bladder cancer (stages Ta and Tis) and later on tumor recurrence." | 5.05 | Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design. ( Benson, RC; Hilton, JF; Taylor, WF; Zincke, H, 1985) |
| "Concomitant external-beam radiochemotherapy (5-fluorouracil-mitomycin C) has become the standard of care in anal cancer since the '90s." | 5.01 | Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC). ( Ajani, JA; Bosset, JF; Chakravarthy, AB; Christiaens, M; Collette, L; Glynne-Jones, R; Hannoun-Levi, JM; Haustermans, K; Konski, AA; Maingon, P; Matzinger, O; Meadows, H; Northover, J; Peiffert, D; Puyraveau, M; Rivin Del Campo, E; Winter, KA, 2019) |
| "To evaluate the effectiveness and toxicity of intravesical gemcitabine in preventing tumour recurrence and progression in non-muscle invasive bladder cancer (NMIBC)." | 4.88 | Intravesical gemcitabine for non-muscle invasive bladder cancer. ( Cleves, A; Jones, G; Kynaston, HG; Mason, M; Shelley, M; Wilt, TJ, 2012) |
| "To assess, in a systematic review and meta-analysis, the relative effectiveness of intravesical mitomycin C and bacillus Calmette-Guérin (BCG) for tumour recurrence, disease progression and overall survival in patients with medium- to high-risk Ta and T1 bladder cancer." | 4.82 | Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. ( Coles, B; Court, J; Kynaston, H; Mason, MD; Shelley, MD; Wilt, TJ, 2004) |
| "We herein compare topical interferon alpha 2b (IFN-α2b) to topical mitomycin C (MMC) in the adjuvant management after excision of primary acquired melanosis with atypia (PAM) and melanoma of the conjunctiva/cornea (CM)." | 4.31 | Real-life data of adjuvant IFN-α2b and MMC in conjunctival melanocytic lesions. ( Auw-Haedrich, C; Boehringer, D; Jiang, J; Nuessle, S; Reinhard, T, 2023) |
| "Perioperative instillation of mitomycin-C (MMC) has shown effectiveness in reducing the recurrence of low-grade non-muscle invasive bladder cancer (NMIBC)." | 4.31 | Single-Dose Post-Office Fulguration Mitomycin C Instillation Appears to Improve Recurrence-Free Survival in Patients With Low-Grade Noninvasive Bladder Cancer. ( Baniel, J; Golan, S; Halstuch, D; Karchever, I; Kedar, D; Lotan, P; Rubinshtein, D, 2023) |
| "To compare recurrence rate and side effects with two different maintenance regimens of postoperative intravesical therapy with mitomycin and BCG in T1 bladder cancer." | 4.12 | Comparison of intravesical adjuvant therapy in bladder cancer with two different maintenance regimens of mitomycin and BCG. ( Dutta, A; Gupta, S; Pal, DK, 2022) |
| "Intravesical chemotherapy instillation by mitomycin - C (MMC) immediately after transurethral resection of bladder tumor (TURBT), although effective in reducing the incidence of non- muscle invasive bladder cancer (NMIBC) recurrence, can result in non desirable effects like bladder irritation and hematuria ." | 4.12 | Continuous Saline Bladder Irrigation in Reducing Recurrence and Progression When Compared to Immediate Mitomycin- C Instillation Post- Resection of Bladder Tumor: A Short Communication. ( Abdel Majid, A; Abuhamad, M; Al Demour, S; Al Zoubi, MS; Al-Zubi, MT; Alsmadi, J; Bani-Hani, M; Elayan, B; Santarisi, A; Taysir Eldos, B, 2022) |
| "To examine the use of Direct Visual Internal Urethrotomy with Mitomycin-C (DVIU-MMC) for bladder neck contracture and vesicourethral anastomotic stenosis in men who have undergone treatment for prostate cancer with radical prostatectomy and/or radiation therapy." | 4.12 | Outcomes of Vesicourethral Anastomotic Stenosis and Bladder Neck Contracture With Direct Visual Internal Urethrotomy With Mitomycin-C After Prostate Cancer Treatment. ( Hacker, EC; Maganty, A; Pere, MM; Rusilko, PJ, 2022) |
| "Patients newly diagnosed with low-risk non-muscle invasive bladder cancer and given a postoperative single instillation of mitomycin-C were retrospectively reviewed." | 4.12 | Impact of Urinary pH on the Efficacy of a Postoperative Single Instillation of Mitomycin-C. ( Asfuroglu, A; Aslan, Y; Aykanat, IC; Balci, M; Senel, C; Tuncel, A, 2022) |
| "Consecutive patients with locally advanced (T2 ≥ 4 cm-T4 or N+) anal cancer scheduled for two cycles of concomitant 5-fluorouracil and mitomycin C chemotherapy were selected from an institutional database (n = 106)." | 4.02 | Sarcopenia and dosimetric parameters in relation to treatment-related leukopenia and survival in anal cancer. ( Johnsson, A; Nilsson, MP; Scherman, J, 2021) |
| "Chemoradiation (CRT) with mitomycin-C (MMC) and 5-fluorouracil (5-FU) has been shown to be superior to radiation alone in patients with muscle-invasive bladder cancer (MIBC)." | 3.96 | Radiation with concurrent radiosensitizing capecitabine tablets and single-dose mitomycin-C for muscle-invasive bladder cancer: A convenient alternative to 5-fluorouracil. ( Mertens, LS; Noordzij, A; Pos, F; Schaake, EE; Schuring, N; van de Kamp, MW; van der Heijden, MS; van Rhijn, BWG; Voskuilen, CS, 2020) |
| "Mitomycin-C (MMC) and thiotepa are intravesical agents effective in reducing the recurrence of low-grade noninvasive bladder cancer when instilled perioperatively." | 3.91 | Single-dose perioperative mitomycin-C versus thiotepa for low-grade noninvasive bladder cancer. ( Blodgett, G; Castle, EP; Chang, YH; Etzioni, DA; Faraj, K; Habermann, EB; Humphreys, MR; Rose, KM; Tyson Ii, MD, 2019) |
| " This study was performed to compare the efficacy of intravesical mitomycin C (MMC) instillation for the prophylaxis of Ta or T1 high-risk nonmuscle invasive bladder cancer (NMIBC) using different schedules." | 3.91 | Comparison of Different Treatment Schedules of Mitomycin C Intravesical Instillation in High-Risk Superficial Bladder Cancer Patients. ( Cha, TL; Chen, HR; En, M; Kao, CC; Sun, GH; Tang, SH; Tsao, CW; Wu, ST; Yu, DS, 2019) |
| "To evaluate oncological outcomes after combination intravesical therapy with gemcitabine (GC) and mitomycin C (MMC) in the setting of recurrent non-muscle-invasive bladder cancer (NMIBC) after failure of previous intravesical therapy." | 3.83 | Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer. ( Cockerill, PA; Frank, I; Karnes, RJ; Knoedler, JJ; Tarrell, R, 2016) |
| "SFN was compared with several commonly used chemotherapy drugs, including mitomycin (MMC) and pirarubicin (THP) for anticancer effects on the bladder cancer cell lines T24, BTT, and BIU-87 and SFN half inhibitory concentrations (IC50) were determined after 48 hours of treatment." | 3.83 | Evaluation of Su Fu'ning Lotion's Inhibitory Effects on Bladder Cancer Cells In Vitro and In Vivo by Intravesical Instillation. ( Ren, L; Wang, J; Yang, X; Zhang, H; Zhao, L, 2016) |
| "Starting in 2009 bacillus Calmette-Guérin/electromotive drug administration of mitomycin C was introduced as the standard induction regime in patients with high risk, nonmuscle invasive bladder cancer undergoing bladder conservation." | 3.83 | Sequential bacillus Calmette-Guérin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes. ( Amery, S; Chatterton, K; Gan, C; Khan, MS; O'Brien, T; Thomas, K, 2016) |
| " A 49-year-old white male diagnosed with T3 N3 M0 Stage IIIB anal cancer was treated initially with surgical excision and adjuvant fluorouracil/cisplatin due unavailability of mitomycin." | 3.81 | Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab. ( Baxley, A; Khawandanah, M; Pant, S, 2015) |
| "To prospectively evaluate the outcome of combined microwave-induced bladder wall hyperthermia and intravesical mitomycin C instillation (thermochemotherapy) in patients with recurrent non-muscle-invasive bladder cancer." | 3.81 | Is thermochemotherapy with the Synergo system a viable treatment option in patients with recurrent non-muscle-invasive bladder cancer? ( Kiss, B; Roth, B; Schneider, S; Thalmann, GN, 2015) |
| " The current study investigated the potential of curcumin to reduce breast cancer stem cell (BCSC) population for sensitizing breast cancer cells to mitomycin C (MMC) both in vitro and in vivo." | 3.81 | Curcumin Improves the Tumoricidal Effect of Mitomycin C by Suppressing ABCG2 Expression in Stem Cell-Like Breast Cancer Cells. ( Chen, Q; Huang, S; Lu, Y; Su, S; Ye, M; Zhang, H; Zhou, Q, 2015) |
| " The secondary objective was to observe recurrence-free survival differences in 1) the epirubicin group vs the mitomycin group and 2) the highly recurrent (greater than 2 recurrences in 24 months) nonmuscle invasive bladder cancer group vs the other groups." | 3.80 | Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer. ( Arends, TJ; van der Heijden, AG; Witjes, JA, 2014) |
| "To compare local control effects of superselective transcatheter arterial chemoembolization (TACE) using epirubicin (EPI) plus mitomycin C (M) and miriplatin (MPT) for hepatocellular carcinoma (HCC)." | 3.78 | Comparison of local control effects of superselective transcatheter arterial chemoembolization using epirubicin plus mitomycin C and miriplatin for hepatocellular carcinoma. ( Hashimoto, M; Matsui, O; Miyayama, S; Shibata, Y; Toshima, F; Tsuji, K; Yamashiro, M; Yoshida, M, 2012) |
| "To compare the efficacy of bacillus Calmette-Guerin (BCG) and mitomycin-C (MMC) intravesical instillation for primary T1G3 bladder cancer (BC)." | 3.78 | Adjuvant intravesical instillation for primary T1G3 bladder cancer: BCG versus MMC in Korea. ( Cho, IC; Chung, J; Joung, JY; Kim, EK; Lee, KH; Park, WS; Seo, HK, 2012) |
| "The aim of the present study was to elucidate the effectiveness of transcatheter arterial infusion chemotherapy (TAI) of the whole liver using an epirubicin-mitomycin-lipiodol emulsion, prior to radiofrequency thermal ablation (RFA), in preventing intrahepatic distant recurrence (IDR) from single hepatocellular carcinoma (HCC)." | 3.78 | Transcatheter arterial infusion chemotherapy prior to radiofrequency thermal ablation for single hepatocellular carcinoma reduces the risk of intrahepatic distant recurrence. ( Hatamaru, K; Henmi, S; Inuzuka, T; Kimura, T; Kita, R; Matsuda, F; Nakajima, J; Nasu, A; Nishikawa, H; Osaki, Y; Saito, S; Sakamoto, A; Takeda, H, 2012) |
| "5 is associated with a decreased risk of tumor recurrence in patients treated with intravesical mitomycin C for nonmuscle invasive bladder cancer." | 3.77 | Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor. ( Kikuchi, E; Maeda, T; Matsumoto, K; Miyajima, A; Oya, M, 2011) |
| "To report the long-term complications and rate of local recurrence in a cohort of patients with histopathologically confirmed conjunctival melanoma (CM) treated with adjuvant topical mitomycin C (MMC)." | 3.77 | Outcomes in 15 patients with conjunctival melanoma treated with adjuvant topical mitomycin C: complications and recurrences. ( Ditta, LC; Shildkrot, Y; Wilson, MW, 2011) |
| "To report a prospective controlled study to compare the acceptance of two different ways of administering intravesical mitomycin C, as the immediate intravesical administration of chemotherapy after surgery decreases the risk of recurrence in patients with superficial bladder cancer, but response rates are variable, partly because of inadequate drug delivery and thus an adequate administration time is important for optimum oncological efficacy." | 3.74 | Increasing patient comfort by optimized postoperative administration of intravesical mitomycin C. ( Granig, T; Mueller, T; Steiner, H; Stoehr, B; Zangerl, F, 2008) |
| " Mitomycin was a primary treatment for residual epithelial disease in ten patients (eight with PAM with atypia and two with conjunctival melanoma) and as an adjuvant to excision and cryotherapy in six with conjunctival malignant melanoma." | 3.73 | Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years' experience. ( Finger, PT; Kurli, M, 2005) |
| "Transurethral resection followed by instillation of chemotherapeutic agents such as mitomycin is considered as standard therapy in recurrent superficial bladder cancer." | 3.73 | Reducing recurrence and costs in superficial bladder cancer: preclinical evaluation of osmotic cytolysis by distilled water vs. mitomycin. ( Fechner, G; Müller, SC; Pocha, K; Schmidt, D, 2006) |
| "We studied prophylactic intravesical instillation of mitomycin C (MMC) and pirarubicin (THP) following transurethral resection of bladder tumor (TUR-Bt) for superficial bladder cancer." | 3.73 | [5 years intravesical instillation with mitomycin-C and pirarubicin as a prophylactic treatment for superficial bladder cancer]. ( Ishizaka, K; Kobayashi, S; Machida, T; Oka, K, 2006) |
| "To describe a case of recurrent, advanced conjunctival papillomatosis, treated by oral cimetidine (CIM) combined with secondary surgical intervention and an application of intraoperative mitomycin C." | 3.73 | Oral cimetidine adjuvant therapy for recalcitrant, diffuse conjunctival papillomatosis. ( Chang, SW; Huang, ZL, 2006) |
| "The aim of this analysis is to evaluate the effect of 5-fluorouracil (5-FU) rechallenge on subsequent response and survival in patients with advanced colorectal cancer (CRC)." | 3.72 | Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials. ( Chau, I; Cunningham, D; Hill, M; Norman, AR; Ross, PJ; Yeoh, C, 2003) |
| "To evaluate the efficacy and toxicity of the combination of mitomycin C, etoposide, cisplatin, and epirubicin (MEPA) as neoadjuvant therapy for patients with cervical adenocarcinoma." | 3.72 | A pilot study of neoadjuvant chemotherapy with mitomycin C, etoposide, cisplatin, and epirubicin for adenocarcinoma of the cervix. ( Nishiura, K; Obata, H; Okugawa, T; Tabata, T; Tanaka, K; Toyoda, N; Yanoh, K, 2004) |
| "To describe the use of postoperative topical mitomycin C (MMC) in the treatment of recurrent conjunctival papilloma." | 3.71 | The use of postoperative topical mitomycin C in the treatment of recurrent conjunctival papilloma. ( Chan, NR; Chi, SC; Lam, DS; Yeung, EF; Yuen, HK, 2002) |
| " In this study we aimed to evaluate the effectivity of postsurgical chemotherapy of conjunctival squamous cell carcinoma in situ (CIN) with mitomycin C eyedrops." | 3.71 | [Treatment of 9 squamous epithelial carcinoma in situ lesions of the conjunctiva (CIN) with mitomycin C eyedrops in cytological and DNA image cytometric control]. ( Böcking, A; Cartsburg, O; Kersten, A; Nadjari, B; Pomjanski, N; Sundmacher, R, 2001) |
| "To compare the tumoricidal efficacy of meglumine gamma-linolenic acid (MeGLA), mitomycin C, epirubicin and water on two urothelial cell lines, and to establish the effect of serum protein levels derived from bladder cancer resection craters on the action of these agents." | 3.70 | Bladder cancer recurrence by implantation of exfoliated cells: is gamma-linolenic acid an effective tumoricidal agent? ( Birch, BR; Cooper, AJ; Foley, SJ; Jennings, AM; Solomon, LZ, 1998) |
| "To report an effective treatment for recurrent squamous papillomas of the conjunctiva with excision and application of mitomycin C." | 3.70 | Treatment of recurrent conjunctival papillomatosis with mitomycin C. ( Hamming, NA; Hawkins, AS; Rubenstein, JB; Yu, J, 1999) |
| "(1) To determine the toxicity of an intensified postoperative adjuvant regimen for periampullary adenocarcinoma (pancreatic and nonpancreatic) utilizing concurrent 5-fluorouracil (5-FU), leucovorin (LV), dipyridamole (DPM), and mitomycin-C (MMC) combined with split-course locoregional external beam radiotherapy (EBRT) to 50 Gy." | 3.70 | Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. ( Abrams, RA; Cameron, JL; Chakravarthy, A; Donehower, RC; Grochow, LB; Hruban, RH; Hurwitz, H; Jaffee, EM; Korman, LT; Lillemoe, KD; O'Reilly, S; Yeo, CJ; Zahurek, ML, 2000) |
| "From January 1984 to December 1991, 58 patients with carcinoma in situ of the bladder were treated initially with intravesical mitomycin C and doxorubicin sequential therapy." | 3.69 | Histological grading of carcinoma in situ of the bladder: its clinical significance in patients who underwent intravesical mitomycin C and doxorubicin sequential therapy. ( Fukui, I; Kojima, S; Ohshima, H; Sekine, H; Yamada, T, 1996) |
| "Mitomycin C (MMC) was given intravesically to 14 patients with transitional-cell carcinoma in situ of the bladder (CIS) between 1985 and 1989." | 3.69 | Treatment of bladder carcinoma in situ with mitomycin C: long-term follow-up. ( Cecchi, M; Felipetto, R; Minervini, R; Viganò, L, 1994) |
| "Between 1982 and 1992, 139 patients with epidermoid carcinoma of the anal canal were treated by radiation and chemotherapy with 5-fluorouracil (5-Fu) and mitomycin C (MMC)." | 3.69 | [The prognostic factors following the simultaneous radiochemotherapy of anal canal carcinoma in a multicenter series of 139 patients]. ( Budach, V; Döker, R; Grabenbauer, GG; Huber, K; Hültenschmidt, B; Hutter, M; Kuhne-Velte, HJ; Panzer, M; Rühl, U; Wendt, T, 1994) |
| "Presentation of one study on the incidence of fibrino-necrotic ulcers in patients undergoing endovesical chemoprophylaxis with mitomycin C." | 3.69 | [Fibrino-necrotic ulcers in endovesical chemoprophylaxis in superficial bladder carcinoma: our case histories]. ( Arnáiz Esteban, F; Espuela Orgaz, R; Fernández Rosáenz, J; Guinda Sevillano, C; Martínez Pérez, E; Nogueras Gimeno, MA; Pérez Arbej, JA, 1994) |
| "Forty-two consecutive patients with anal canal cancer were treated with 15 fractions of 30-Gy photon beam radiation therapy administered anteroposterior-posteroanterior in conjunction with chemotherapy with 5-fluorouracil and mitomycin C." | 3.69 | Cancer of the anal canal: treatment with chemotherapy and low-dose radiation therapy. ( Anderson, PJ; Frost, DB; Kagan, AR; Latino, F; Peddada, AV; Rao, AR; Shah, KH; Smith, DE, 1994) |
| "Mitomycin C (MMC) was given intravesically over a period of 36 months to 14 patients with transitional-cell carcinoma in situ of the bladder (CIS)." | 3.69 | Intravesical mitomycin C for the treatment of carcinoma in situ of the bladder: 36 months follow-up. ( Cecchi, M; Felipetto, R; Minervini, R; Pagni, G; Viganò, L, 1994) |
| "A total of 43 patients with carcinoma in situ of the bladder (primary in 26 and secondary in 17) who underwent intravesical mitomycin C and doxorubicin sequential therapy for 2 multicenter studies were followed for a median period of 45 months (range 10 to 84)." | 3.69 | Intravesical mitomycin C and doxorubicin sequential therapy for carcinoma in situ of the bladder: a longer followup result. ( Fukui, I; Ohshima, H; Ohwada, F; Sekine, H; Yamada, T; Yokokawa, M, 1994) |
| " Adenocarcinoma patients receive mitomycin C and 5-fluorouracil; sarcoma patients receive cisplatin and doxorubicin." | 3.69 | Intraperitoneal chemotherapy for treatment and prevention of peritoneal carcinomatosis and sarcomatosis. ( Sugarbaker, PH, 1994) |
| "We evaluated the DNA cytophotometry in 446 bladder washing samples from 64 patients under mitomycin C after superficial bladder cancer during an observation period of up to 5 years." | 3.69 | Cytophotometry in the monitoring of bladder cancer under intravesical chemotherapy. ( Foeger, A; Maier, U; Marberger, M; Simak, R; Susani, M; Wiener, H; Zhang, ZF, 1996) |
| "Bladder wall calcification is a rare complication of intravesical therapy of superficial bladder cancer with Mitomycin C." | 3.68 | Incrusted cystitis after intravesical mitomycin C treatment. ( Algado, M; Botella, R; Llopis, M; Moreno, J, 1993) |
| "The effect of intravesical instillation of 200,000 IU hyaluronidase in addition to mitomycin C as chemoprophylaxis of superficial bladder cancer was evaluated." | 3.68 | Topical chemoprophylaxis of superficial bladder cancer with mitomycin C and adjuvant hyaluronidase. ( Höbarth, K; Maier, U; Marberger, M, 1992) |
| "We analyzed 29 cases of eosinophilic cystitis in a group of 80 patients with lower urothelial carcinoma who had been treated with mitomycin-C." | 3.68 | [Eosinophilic cystitis as a special form of response to mitomycin C. Analysis and comments on our cases]. ( Arango Toro, O; Bielsa Galí, O; Corominas, J; Gelabert Mas, A; Lladó Carbonell, C; Vesa Llanes, J, 1991) |
| "We studied 15 patients with histologically proved multifocal carcinoma in situ of the bladder who were in remission at a mean followup of 21 months after induction intravesical chemotherapy with mitomycin C." | 3.68 | Topical mitomycin C therapy for carcinoma in situ of the bladder: a followup. ( Grant, AB; Hosken, BM; Stricker, PD; Taylor, JS, 1990) |
| "Mitomycin C was given intravesically over periods of 2-32 months to 34 patients with carcinoma in situ of the urinary bladder." | 3.68 | Intravesical mitomycin C for carcinoma in situ of the urinary bladder. ( Hellsten, S; Henrikson, H; Idwall, I; Lindholm, K; Månsson, W; Mårtensson, S; Mikulowski, P; Oldbring, J, 1990) |
| "Since June 1984, 23 cases of progressive or recurrent breast cancers were treated with combination chemotherapy of VAM-UFT consisting of vincristine, adriamycin, mitomycin C and UFT." | 3.67 | [Vincristine, adriamycin, mitomycin-C and UFT (VAM-UFT) therapy in progressive or recurrent breast cancer]. ( Hozumi, T; Imamura, Y; Irie, K; Katou, J; Matsushita, K; Okutani, T; Oya, M; Yasutake, K; Yoshimura, Y, 1989) |
| "Both Mitomycin C (MMC) and doxorubicin (Adriamycin) (ADM) prevent the recurrence of superficial papillary (Ta-T1) urinary bladder cancers and also reduce the rate of progression." | 3.67 | Instillation of mitomycin C and doxorubicin in the prevention of recurrent superficial (Ta-T1) bladder cancer. ( Alfthan, O; Jauhiainen, K, 1987) |
| "A limited course of intravesical mitomycin C was tested in 12 patients who had at least three, and an average of six, occurrences of superficial bladder cancer, and were at high risk for subsequent recurrences." | 3.67 | Study of intravesical mitomycin C in patients with multiple prior occurrences of superficial bladder cancer. ( Brown, J; Johanson, KE; Schwarzman, MI; Surya, B, 1988) |
| "Twenty-three patients who were given intravesical Mitomycin C for treatment of superficial bladder cancer have been followed up for a further 12 and 24 months after an initial assessment 5 weeks after completing therapy." | 3.67 | Mitomycin C in superficial bladder cancer: 24-month follow-up. ( Newling, DW; Richards, B; Robinson, MR; Smith, PH; Somerville, JJ, 1985) |
| " A complete regression of pleural, pulmonary parenchymal, cutaneous, and bone metastases was seen following therapy with 5-fluorouracil, Adriamycin, and mitomycin C." | 3.66 | Adenoid cystic carcinoma of the salivary gland. Sustained complete response to chemotherapy. ( Budd, GT; Groppe, CW, 1983) |
| "Twenty-five patients with metastatic breast cancer who had failed with combination chemotherapies including adriamycin were treated with a combination of mitomycin C, methotrexate, and vincristine (MMV)." | 3.66 | [Combination chemotherapy with mitomycin C, methotrexate, and vincristine (MMV) for metastatic breast cancer refractory to adriamycin]. ( Hamada, Y; Kanda, K; Nomura, Y; Saeki, K; Tashiro, H, 1983) |
| "One hundred patients suffering from advanced breast cancers and resisting to one (15) or several (85) drugs previously administered have been treated by an association of mitomycin C, thiotepa and vindesine, given every 3 weeks." | 3.66 | [Chemotherapy associating mitomycin C, thiotepa and vindesine in advanced breast cancers. Study of 100 cases (author's transl)]. ( Brunet, R; Bui, BN; Chauvergne, J; Durand, M; Hoerni, B; Mauriac, L, 1981) |
| "Non-muscle invasive bladder cancer (NMIBC) is characterized by a high rate of recurrence and progression, despite surgery and adjuvant therapies." | 3.01 | A systematic review of the efficacy of intravesical electromotive drug administration therapy for non-muscle invasive bladder cancer. ( Arrabal-Polo, MÁ; Gómez-Lechuga, P; Jiménez-Moleón, JJ; Martín, MA; Melgarejo-Segura, MT; Morales-Martínez, A; Pareja-Vílchez, M; Yáñez-Castillo, Y, 2023) |
| "Locally advanced head and neck squamous cell carcinoma (LA-HNSCC) often requires postoperative chemoradiation with high risk of toxicity." | 2.94 | Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma. ( Betz, CS; Binder, M; Boettcher, A; Bokemeyer, C; Busch, CJ; Moeckelmann, N; Muenscher, A; Schafhausen, P; Vettorazzi, E; Zech, HB, 2020) |
| "Mitomycin C (MMC) was the chemotherapeutic agent." | 2.90 | Development of a high-precision bladder hyperthermic intracavitary chemotherapy device for bladder cancer and pharmacokinetic study. ( Ba, M; Cui, S; Gong, Y; Lin, K; Long, H; Tu, Y; Wu, W; Wu, Y; Zhang, B, 2019) |
| " A pharmacokinetic study was performed in 18 patients." | 2.84 | Mitomycin C hypoxic pelvic perfusion for unresectable recurrent rectal cancer: pharmacokinetic comparison of surgical and percutaneous techniques. ( Clementi, M; Fiorentini, G; Guadagni, S; Mambrini, A; Masedu, F; Palumbo, P, 2017) |
| "Non-muscle-invasive bladder cancer (NMIBC) represents a significant global therapeutic challenge, particularly in the era of Bacillus Calmette-Guérin (BCG) shortage." | 2.82 | Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage. ( Balasubramanian, A; Bolton, D; Gunjur, A; Lawrentschuk, N; Papa, N; Perera, M; Weickhardt, A, 2022) |
| "Patients with a history of bladder cancer were excluded." | 2.78 | Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasi ( Chandra, A; Chatterton, K; Khan, MS; O'Brien, T; Ray, E; Thomas, K, 2013) |
| "The long-term bladder cancer-specific mortality was unexpectedly low despite the relatively ineffective instillation therapy and the poor outcome of the patients after progression." | 2.77 | Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette-Guérin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective FinnBladder 2 study with a 17- ( Group, TF; Järvinen, R; Kaasinen, E; Rintala, E, 2012) |
| "In gemcitabine-pretreated pancreatic cancer, salvage chemotherapy has not been established, and the prognostic factors are not completely known." | 2.76 | Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting. ( Bang, YJ; Han, SW; Im, SA; Kim, TY; Lee, KH; Lim, KH; Oh, DY, 2011) |
| "Bladder cancer is a disease with a high prevalence due to its recurrence rate." | 2.73 | [Therapeutic effect of mitomycin C in the immediate postoperatory in patients with low-risk non-muscle-invasive bladder tumours]. ( Alvarez Múgica, M; Escaf Bramada, S; Fernández Gómez, JM; García Rodríguez, J; Jalón Monzón, A; Regadera Sejas, FJ, 2008) |
| "Grade 3/4 neutropenia was observed in 21 % of patients and grade 3/4 febrile neutropenia was seen in only one patient." | 2.73 | Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma. ( Ahn, JS; Ahn, MJ; Hwang, IG; Im, YH; Kang, WK; Lee, SC; Lim, HY; Park, BB; Park, K, 2008) |
| "Bladder cancer is mostly superficial at first diagnosis." | 2.72 | Intravesical adjuvant therapy using mitomycin C. ( Bhuiyan, ZH; Islam, MA; Shameem, IA, 2006) |
| "Of 148 newly diagnosed patients with T1 bladder cancer 142 were prospectively randomized in 2 groups between January 2001 and January 2005." | 2.72 | The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. ( Divrik, RT; Ozen, H; Yildirim, U; Zorlu, F, 2006) |
| "Stage III colon cancer patients were enrolled and were divided into two groups: Group W, in which the histologic type of both primary tumors and metastatic lymph nodes was well-differentiated adenocarcinoma; and Group U, in which the primary tumors and the metastatic lymph nodes were of any type other than well-differentiated." | 2.72 | Significance of histologic type of primary lesion and metastatic lymph nodes as a prognostic factor in stage III colon cancer. ( Hirota, T; Kodaira, S; Mori, T; Ohashi, Y, 2006) |
| "Twenty-nine colorectal cancer patients with non-resectable hepatic metastases were consecutively enrolled for HAI alternating with systemic chemotherapy (HA + SC group)." | 2.72 | Hepatic arterial infusion alternating with systemic chemotherapy in patients with non-resectable hepatic metastases from colorectal cancer. ( Chang, HM; Ha, HK; Kim, HC; Kim, JC; Kim, JH; Kim, TW; Lee, KH; Lee, MG; Ryu, MH; Yu, CS, 2006) |
| "The response rate and time to disease progression were the primary endpoints, with overall survival as the secondary endpoint." | 2.71 | Hypoxic pelvic and limb perfusion with melphalan and mitomycin C for recurrent limb melanoma: a pilot study. ( Amicucci, G; Deraco, M; Di Filippo, F; Fiorentini, G; Guadagni, S; Miotto, D; Patuzzo, R; Pilati, PL; Rossi, CR; Santinami, M; Valenti, M, 2003) |
| "Patients with G3 bladder tumors (Stage Ta or T1) were treated with combined intravesical chemotherapy with mitomycin-C and local radiofrequency hyperthermia of the bladder wall." | 2.71 | Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. ( Colombo, R; Gofrit, ON; Leib, Z; Naspro, R; Nativ, O; Pode, D; Shapiro, A; Sidi, A; van der Heijden, AG; Witjes, JA, 2004) |
| "CPT-11 combined with MMC can be effective against advanced or recurrent SCC of the uterine cervix." | 2.71 | Phase II study of irinotecan combined with mitomycin-C for advanced or recurrent squamous cell carcinoma of the uterine cervix: the JGOG study. ( Fujii, T; Fushiki, H; Hasegawa, K; Izumi, R; Nishida, M; Nishimura, R; Takizawa, K; Tanaka, T; Umesaki, N; Yamamoto, K, 2004) |
| "Progression-free and freedom from metastases rates were 29." | 2.71 | Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy coo ( Bamberg, M; Baumann, M; Budach, V; Budach, W; Geismar, D; Grabenbauer, G; Herrmann, T; Hinkelbein, W; Jahnke, K; Lammert, I; Stueben, G; Stuschke, M; Wernecke, KD; Wust, P, 2005) |
| "Forty-two gastric cancer patients at T(3)II-T(4)III( B) stages and 96 patients with colorectal cancer at B to D stages admitted from January 1996 to October 1998 were randomly divided into control group (group I, 65 cases) receiving intraperitoneal thermochemotherapy, and group II (73 cases) receiving both intraperitoneal thermochemotherapy and intraperitoneal IL-2 immunotherapy." | 2.70 | Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection. ( Fu, QG; Guo, RX; Meng, FD; Shen, XD, 2002) |
| " In the present study, local injection of mitomycin C bound to activated carbon (M-CH) combined with i." | 2.70 | Local injection of M-CH combined with i.p. hyperthermic hypo-osmolar infusion is an effective therapy in advanced gastric cancer. ( Fan, Y; Hagiwara, A; Huang, Y; Ma, D; Qi, X; Su, G; Wang, W, 2002) |
| "Combination chemotherapy with multiple drugs (FLMP therapy), in which the drugs were determined based on biochemical modulation and the dosing schedule was established in accordance with the circadian rhythms of the human body, was performed in cases of advanced recurrent gastric cancer." | 2.69 | [Effect of combination chemotherapy with multiple drugs (FLMP therapy) based on the circadian rhythms of the human body in advanced recurrent gastric cancer]. ( Iesato, H; Kamoshita, N; Kato, Y; Nagaoka, H; Okabe, T; Yokomori, T, 1999) |
| "Recurrence of hepatocellular carcinoma (HCC) after curative hepatic resection is frequent and is an important factor adversely influencing long-term survival." | 2.69 | Prospective case-controlled trial of adjuvant chemotherapy after resection of hepatocellular carcinoma. ( Chang, FY; Chau, GY; Chiang, JH; Huang, YH; Huo, TI; King, KL; Lee, SD; Lui, WY; Tsay, SH; Wu, JC, 2000) |
| "For the local recurrence of rectal cancer, it was observed in Dukes C and cases of relative curative resection." | 2.68 | [Cooperative study of surgical adjuvant chemotherapy for colorectal cancer. Cooperative Study Group of Surgical Adjuvant Chemotherapy for Colorectal Cancer in Japan]. ( Kikuchi, K; Kunii, Y, 1995) |
| " These results show that AO-90 in combination with MF therapy is efficacious in the treatment of patients with gastric cancer." | 2.68 | [A controlled study of AO-90, a methionine-free intravenous amino acid solution, in combination with 5-fluorouracil and mitomycin C in advanced gastric cancer patients (internal medicine group evaluation)]. ( Akazawa, S; Kitamura, S; Kosaki, G; Kurihara, M; Nakano, S; Ohtani, T; Sasaki, T; Takahashi, H; Tokunaga, K, 1995) |
| "Thirty-one patients with squamous cell carcinoma of the vulva were treated with two courses of combination chemotherapy mitomycin C, 15 mg/m2 intravenously (i." | 2.68 | Combined preoperative chemoradiotherapy followed by radical surgery in locally advanced vulvar carcinoma. A pilot study. ( di Re, F; Fontanelli, R; Kenda, R; Lupi, G; Paladini, D; Raspagliesi, F; Zucali, R, 1996) |
| "The mitomycin C-treated patients had 41% recurrence, 1." | 2.68 | [Prevention of superficial bladder cancer with mitomycin C or interferon: final results of a prospective study]. ( Alonso Rodrigo, A; Barros Rodríguez, M; Benavente Delgado, J; Domínguez Freire, F; Nogueira March, YJ; Ojea Calvo, A; Rodríguez Iglesias, B; Vérez Vivero, M, 1996) |
| "For the purpose of local control and breast conservation, intraarterial infusion chemotherapy combined with radiotherapy has been indicated in patients with locally advanced breast cancer both in primary and recurrent cases." | 2.68 | [Experience in treatment of patients with locally advanced or recurrent breast cancer: intraarterial infusion chemotherapy combined with radiotherapy]. ( Kazawa, N; Kobayashi, K; Kono, K; Kuroda, Y; Maetani, Y; Murakami, M; Okamoto, Y; Sai, H; Sano, A; Sasaki, R; Yoden, E, 1997) |
| "In an attempt to prevent local recurrence, intraoperative pelvic hyperthermochemotherapy (IOPHC) was performed in combination with curative surgery for rectal cancer." | 2.67 | [Pelvic hyperthermochemotherapy combined with surgery for rectal cancer]. ( Fujimoto, S; Ito, M; Kobayashi, K; Masaoka, H; Mutou, T; Takahashi, M, 1994) |
| "Mitomycin was used in 40 patients and dihydroxyanthracenedione (DADH) in 58 patients." | 2.67 | [The treatment of hepatocellular carcinoma by chemoembolization]. ( Bortolasi, L; Dal Dosso, I; Facci, E; Mansueto, GC; Marchiori, L; Nicoli, N; Nifosi, F; Perus, G, 1994) |
| "Vascular invasion and intrahepatic metastasis by hepatocellular carcinoma are important factors predisposing to tumor recurrence." | 2.67 | Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. ( Ii, T; Iyobe, T; Izumi, R; Matsui, O; Miyazaki, I; Nonomura, A; Shimizu, K; Yagi, M, 1994) |
| " Haematologic toxicity is greater in the CMF group, requiring more frequent dosage reductions." | 2.67 | Randomized trial of adjuvant chemotherapy for operable breast cancer comparing i.v. CMF to an epirubicin-containing regimen [see comment]. ( Bonichon, F; Chauvergne, J; Dilhuydy, JM; Durand, M; Mauriac, L, 1992) |
| "Although histology (squamous vs." | 2.67 | Postoperative adjuvant chemotherapy in non-small cell lung cancer: prognostic value of DNA ploidy and post-recurrent survival. ( Aso, H; Hara, N; Ichinose, Y; Kuda, T; Motohiro, A; Ohta, M, 1991) |
| "Twenty-five patients with cervical cancer (4 post-operative cases with FIGO stage Ib or IIb, 2 with stage IV, and 19 recurrence) were treated with a new BOMP consisting of bleomycin (5 mg/body, drip, i." | 2.67 | [Treatment of advanced or recurrent cervical cancer by a new BOMP regimen consisting of bleomycin, vincristine, mitomycin-C, and low-dose consecutive cisplatin]. ( Chen, JT; Fujimoto, I; Koi, S; Nakayama, K; Seimiya, Y; Shimizu, Y; Teshima, H; Yamakawa, Y; Yamauchi, K; Yokosuka, K, 1991) |
| "After curative resection of colorectal cancer, immediate short-term postoperative intraportal adjuvant chemotherapy reduces the relative risk of recurrence and death in the non-transfused patient significantly, when compared to transfused patients without chemotherapy." | 2.67 | [Following curative resection of colorectal cancer, portal chemotherapy especially benefits non-transfused patients]. ( Berres, M; Harder, F; Jäggi, P; Laffer, U; Metzger, U, 1990) |
| "A total of 848 patients with gastric cancer underwent curative resection were eligible." | 2.67 | [Cooperative study on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer (II). Cooperative study group on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer supp ( Ichihashi, H; Imaizumi, M; Kamei, H; Kondo, T, 1990) |
| "Patients (1,256 with colon cancer, 1,221 with rectal cancer) were divided into the treatment group (group A) and the control group (surgical resection only, group B)." | 2.66 | [Cooperative study of surgical adjuvant chemotherapy of colorectal carcinoma (second study): a preliminary report. Cooperative Study Group of Surgical Adjuvant Chemotherapy of Colorectal Cancer in Japan]. ( Abe, O; Hattori, T; Inokuchi, K; Kikuchi, K; Kodaira, S; Komi, N; Kondo, T; Ogawa, N; Taguchi, T; Uchino, J, 1989) |
| "Transperitoneal and lymph node metastases were the major causes of treatment failure." | 2.66 | Gastric cancer: overview of current therapies. ( Douglass, HO, 1985) |
| "Kondo) in Japan." | 2.65 | [Cooperative studies on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer]. ( Ichihashi, H; Imaizumi, M; Kamei, H; Kondo, T, 1984) |
| "Bladder cancer is the second most common urological malignant disease." | 2.58 | [Thermochemotherapy with Mitomycin C: an update on alternative treatment strategies in non-muscleinvasive bladder cancer]. ( Blaschke, S; Christoph, F; König, F; Lebentrau, S; Liehr, UB; Schostak, M, 2018) |
| "There was no disease progression in either treatment arm at three months' follow-up." | 2.55 | Intravesical electromotive drug administration for non-muscle invasive bladder cancer. ( Dahm, P; Gudeloglu, A; Jung, JH; Kiziloz, H; Konety, BR; Kuntz, GM; Miller, A, 2017) |
| "The majority of anal cancers are squamous cell carcinomas, and they are treated according to stage." | 2.52 | Anal cancer treatment: current status and future perspectives. ( Abdayem, P; Antoun, J; Ghosn, M; Kourie, HR; Nasr, D, 2015) |
| "Non-muscle-invasive bladder cancer is characterized by frequent recurrences requiring repeated transurethral resections and carries a risk of progression to muscle-invasive disease." | 2.49 | Adjuvant methods to improve results of local bladder irrigations by chemotherapy for NMIBC. ( Dekel, Y; Freifeld, Y; Stein, A, 2013) |
| "Bladder cancer is a heterogeneous disease: approximately 75% of its forms are non muscle invasive neoplasms." | 2.46 | Mitomycin C for the treatment of bladder cancer. ( Bassi, PF; Cappa, E; D'Agostino, D; Filianoti, A; Racioppi, M; Volpe, A, 2010) |
| "Non-muscle-invasive bladder cancers form a heterogeneous group of tumours with varying recurrence and progression rates." | 2.45 | Therapeutic options in the management of intermediate-risk nonmuscle-invasive bladder cancer. ( Horvath, A; Mostafid, H, 2009) |
| "Superficial bladder cancer can be treated surgically, but patients are at high risk for recurrence." | 2.43 | Bladder cancer: current optimal intravesical treatment. ( Hale, K; Lamm, DL; McGee, WR, 2005) |
| "Adjuvant chemotherapy for gastric cancer after potentially curative surgery has been under clinical investigation for more than four decades." | 2.43 | Postoperative chemotherapy for gastric cancer. ( Hejna, M; Raderer, M; Schmidinger, M; Wöhrer, S, 2006) |
| "Because patients with advanced gastric cancers have less than 50% chance of cure after R0 resection, the need for an adjuvant treatment to eradicate residual microscopic disease is clear." | 2.43 | A review of adjuvant therapy for resected primary gastric cancer with an update on Taegu's phase III trial with intraperitoneal chemotherapy. ( Yu, W, 2006) |
| "Adjuvant therapy of colorectal cancer with oral fluorinated pyrimidines is attractive because of its ease of administration and good tolerability." | 2.42 | Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. ( Burzykowski, T; Buyse, M; Hamada, C; Ohashi, Y; Piedbois, P; Sakamoto, J, 2004) |
| "Locally advanced cervical cancer has a poor prognosis, poor survival rate, and high local failure rate." | 2.40 | [Clinical evaluation of chemoradiotherapy for advanced cervical cancer]. ( Kaneyasu, Y; Okawa, MK; Okawa, T, 1997) |
| "Five-year survival rates were 57% for squamous cell carcinoma, 63% for adenocarcinoma, and 33% for melanoma." | 2.40 | Malignant tumors of the anal canal: the spectrum of disease, treatment, and outcomes. ( Klas, JV; Madoff, RD; Rothenberger, DA; Wong, WD, 1999) |
| "It is well-known that the patients with pancreatic cancer are vulnerable for recurrence such as local relapse and liver metastasis after surgical resection." | 2.40 | [Therapeutic strategy for the recurrence of pancreatic cancer following pancreatectomy]. ( Egawa, S; Kobari, M; Matsuno, S; Shibuya, K; Shimamura, H; Sunamura, M; Takeda, K, 1999) |
| "The management of superficial bladder cancer has advanced significantly in recent years." | 2.39 | BCG in perspective: advances in the treatment of superficial bladder cancer. ( Lamm, DL, 1995) |
| "7." | 2.38 | Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma. ( Jordan, AM; Murphy, WM; Soloway, MS, 1989) |
| "Management of the superficial bladder cancer patient consists of two complementary but separate therapeutic goals: treatment of the existing tumor(s) and prevention of tumor recurrence." | 2.37 | The biology and treatment of superficial bladder cancer. ( Lum, BL; Torti, FM, 1984) |
| "In nonmuscle invasive bladder cancer (NMIBC) patients who fail standard intravesical treatment and are unfit or unwilling to undergo a radical cystectomy, radiofrequency (RF)-induced hyperthermia combined with intravesical chemotherapy (RF-CHT) has shown promising results." | 1.91 | Evaluation of thermal dose effect in radiofrequency-induced hyperthermia with intravesical chemotherapy for nonmuscle invasive bladder cancer. ( Brummelhuis, ISG; Crezee, J; Witjes, JA, 2023) |
| "7 mM of alpha-oleate combined with Epirubicin or Mitomycin C." | 1.91 | Long-term prevention of bladder cancer progression by alpha1-oleate alone or in combination with chemotherapy. ( Ambite, I; Babjuk, M; Cavalera, M; Chaudhuri, A; Esmaeili, P; Hien, TT; Sabari, S; Svanborg, C; Wan, MLY, 2023) |
| "For females without known risk factors, bladder cancer can be regarded as a sentinel environmental cancer." | 1.91 | Complete Remission of BCG-Refractory High-grade Bladder CIS with Pharmacologic Ascorbate and Mistletoe. ( Armstrong, J; Davis, D; Kogan, M; Lowe, P; Meng, M; Morash, C; Seely, D, 2023) |
| "During the BCG drug shortage, eligible bladder cancer patients were less likely to receive gold standard intravesical BCG with a large variation in treatment patterns between US states." | 1.91 | Variation in Statewide Intravesical Treatment Rates for Non-Muscle Invasive Bladder Cancer During the Bacillus Calmette-Guerin Drug Shortage. ( Chun, B; Davies, BJ; Gabriel, N; He, M; Hernandez, I; Jacobs, BL; Jones, C; Vasan, R, 2023) |
| "To assess the clinical and oncological outcomes of sequential treatment with Bacillus Calmette-Guerin (BCG) and Mitomycin C (MMC) administered with Electromotive Drug Administration (EMDA) in patients with high-risk NMIBC who fail BCG immunotherapy." | 1.91 | Sequential Treatment With Bacillus Calmette-Güerin (BCG) and Mitomycin C Administered With Electromotive Drug Administration (EMDA) in Patients With High-Risk Nonmuscle Invasive Bladder Cancer After BCG Failure. ( Bravo, A; Breda, A; Gaya, JM; Huguet, J; Palou, J; Robalino, J; Rodríguez Faba, Ó; Sanz Gómez, I; Territo, Á, 2023) |
| "Urinary bladder cancer is a common cancer worldwide." | 1.72 | In vitro assessment of intra-operative and post-operative environment in reducing bladder cancer recurrence. ( Chan, RC; Kong, AW; Ng, CF; Teoh, JY; To, KF; Tse, RT; Wong, CY; Zhao, H, 2022) |
| "In the rat bladder cancer model, IVI of chidamide plus mitomycin C reduced tumor burden (Ki67 index) to a greater extent than either drug alone." | 1.72 | Chidamide and mitomycin C exert synergistic cytotoxic effects against bladder cancer cells in vitro and suppress tumor growth in a rat bladder cancer model. ( Chang, YC; Chen, SL; Sung, WW; Wang, SC; Wu, YC; Yu, CY, 2022) |
| "Our results suggest IMRT-based CRT with concurrent fluoropyrimidine and cisplatin is a safe and feasible option for patient with SCCA and may cause less acute toxicity." | 1.72 | Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution. ( Bednarski, BK; Chang, GJ; Das, P; Delclos, ME; Eng, C; Holliday, EB; Jennings, K; Johnson, B; Koay, EJ; Koong, AC; Ludmir, EB; Messick, CA; Minsky, BD; Morris, VK; Rodriguez-Bigas, MA; Skibber, JM; Smith, GL; Taniguchi, C; Tillman, MM; You, YN, 2022) |
| "A group of patients with urothelial bladder cancer, presenting for the first time for definitive treatment, were prospectively enrolled from 2013 to 2017." | 1.72 | Demographics, pathological characteristics and survival in urothelial bladder cancer in a cohort of Sri Lankan patients. ( Abeygunasekara, A; Dissanayake, V; Ediriweera, D; Goonewardena, S; Jayasekara, R; Lokuhetty, D; Malalasekera, AP; Perera, N; Wettasinghe, K, 2022) |
| "To compare the therapeutic effects of locoregional deep hyperthermia combined with intravesical chemotherapy with those of intravesical chemotherapy alone in patients with intermediate-/high-risk non-muscle invasive bladder cancer (NMIBC)." | 1.62 | Loco-regional deep hyperthermia combined with intravesical Mitomycin instillation reduces the recurrence of non-muscle invasive papillary bladder cancer. ( Fan, YC; Lai, BCH; Lee, HL; Lee, LM; Lin, KH; Lin, YW; Shih, HJ; Syu, SH; Wen, YC, 2021) |
| "Acute hematotoxicity (G3, 4, 5 according to Common Terminology Criteria for Adverse Events - CTCAE) was significantly associated with the concomitant chemoradiotherapy (P = 0." | 1.56 | Haematotoxicity in IMRT/VMAT curatively treated anal cancer. ( Drbohlavová, T; Jirkovská, M; Lohynská, R; Malinová, B; Mazaná, E; Nýdlová, A; Stankušová, H; Veselský, T, 2020) |
| "Thirty‑six C57BL/6J mice bearing bladder cancer were randomly divided into six treatment groups as follows: control, BCG, MMC, ADM, MMC‑BCG and ADM‑BCG." | 1.51 | Intravesical treatment of chemotherapeutic agents sensitizes bacillus Calmette‑Guerin by the modulation of the tumor immune environment. ( Fujimoto, K; Gotoh, D; Hori, S; Iida, K; Itami, Y; Miyake, M; Morizawa, Y; Nakai, Y; Onishi, K; Onishi, S; Tanaka, N; Tatsumi, Y, 2019) |
| "Patients with unresectable recurrent rectal cancer that progresses after systemic chemotherapy and radiotherapy may be candidates for palliation with hypoxic pelvic perfusion (HPP)." | 1.51 | Hypoxic pelvic perfusion with cisplatin and mitomycin C in multidisciplinary palliative treatment of patients with unresectable recurrent rectal cancer: a retrospective study. ( Bruera, G; Clementi, M; Deraco, M; Fiorentini, C; Fiorentini, G; Gailhofer, S; Guadagni, S; Kusamura, S; Masedu, F; Palumbo, P; Ricevuto, E; Sarti, D, 2019) |
| "Patients with unresectable recurrent rectal cancer that progresses after systemic chemotherapy and radiotherapy are candidates for palliation with hypoxic pelvic perfusion (HPP)." | 1.48 | Palliation with a multimodality treatment including hypoxic pelvic perfusion for unresectable recurrent rectal cancer: outcomes based on a retrospective study. ( Bencivenga, M; Clementi, M; Fiorentini, C; Guadagni, S; Kusamura, S; Masedu, F, 2018) |
| "A pathologic cervical residual tumor was observed in 16 patients (35." | 1.43 | [Stage IB2, IIA and IIB cervical carcinoma without lymph node extension treated with neoadjuvant chemoradiotherapy]. ( Ballester, M; Daraï, E; Huguet, F; Lauratet, B; Lefranc, JP; Monnier, L; Touboul, E, 2016) |
| "45 patients with anal cancer who underwent pre-treatment FDG-PET/CT were included." | 1.43 | Metabolic tumour volume of anal carcinoma on (18)FDG PET/CT before combined radiochemotherapy is the only independant determinant of recurrence free survival. ( Behrendt, FF; Eble, MJ; Heinzel, A; Mohammadkhani Shali, S; Mottaghy, FM; Schmitt, V; Verburg, FA; Winz, OH, 2016) |
| "Anal cancer was diagnosed in a 36-year-old nulliparous woman." | 1.43 | Successful Delivery in a 39-Year-Old Patient with Anal Cancer after Fertility-Preserving Surgery Followed by Primary Chemoradiation and Low Anti-Mullerian Hormone Level. ( Biel, P; Cordes, T; Köhler, C; Marnitz, S, 2016) |
| "The clinicopathological parameters and adverse effects were similar between the 2 groups (P > 0." | 1.42 | Transcatheter arterial chemoembolization combined with interferon-α is safe and effective for patients with hepatocellular carcinoma after curative resection. ( Burns, M; Hong, Y; Lei, X; Li, JL; Li, QL; Li, YG; Liu, C; Liu, HC; Liu, JS; Qiu, XX; Wang, XH; Wu, QF; Xia, M; Xiao, H; Xu, RC; Zhu, HZ; Zuo, CH, 2015) |
| "Mitomycin C (88." | 1.40 | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution. ( Hiotis, S; Jibara, G; Labow, DM; Romanoff, A; Sarpel, U; Shrager, B; Tabrizian, P; Yang, MJ, 2014) |
| "Many advanced hepatocellular carcinoma (HCC) cases can be successfully downstaged into the Milan criteria; however, immediate radical therapy cannot be applied to all such patients for various reasons." | 1.40 | Immediate radical therapy or conservative treatments when meeting the Milan criteria for advanced HCC patients after successful TACE. ( Jiang, L; Lei, JY; Li, B; Wang, WT; Wei, YG; Wen, TF; Xu, MQ; Yan, LN; Yang, JY, 2014) |
| "Inguinal lymph node metastasis is predictive of locoregional recurrence and poor overall survival in anal carcinoma." | 1.40 | Inguinal lymph node recurrence in the untreated groin of patients with anal carcinoma. ( Blinde, SE; Mens, JW; Nuyttens, JJ; Olofsen, M; Schasfoort, R; Verhoef, C, 2014) |
| "Recurrence rates of nonmuscle invasive bladder cancer were obtained from a randomized clinical trial comparing transurethral resection of bladder tumor with or without perioperative mitomycin C." | 1.40 | Commentary on "economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases." Lee CT, Barocas D, Globe DR, Oefelein MG, Colayco DC, Bruno A, O׳Day K, Bramley T, Department of Urology, University ( Hollenbeck, BK, 2014) |
| "A total of 40 patients with hepatocellular carcinoma treated with transarterial chemoembolization between January 2007 and March 2011 were included." | 1.39 | Transarterial chemoembolization for treatment of hepatocellular carcinoma: A single center experience. ( Altundağ, K; Balkancı, F; Bayraktar, Y; Cil, BE; Doğanay Erdoğan, B; Idilman, I; Kav, T; Peynircioğlu, B; Yalçın, S, 2013) |
| "In pN0 gastric cancers, prognostic factors differed significantly between early stage and advanced stage." | 1.38 | Prognostic significance of intraoperative chemotherapy and extensive lymphadenectomy in patients with node-negative gastric cancer. ( Kang, WM; Ma, ZQ; Wang, J; Yu, JC, 2012) |
| "Recurrence rates of nonmuscle invasive bladder cancer were obtained from a randomized clinical trial comparing transurethral resection of bladder tumor with or without perioperative mitomycin C." | 1.38 | Economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases. ( Barocas, D; Bramley, T; Bruno, A; Colayco, DC; Globe, DR; Lee, CT; O'Day, K; Oefelein, MG, 2012) |
| "To update our experience in treating squamous cell carcinoma of the anal margin with definitive radiotherapy (RT)." | 1.37 | Squamous cell carcinoma of the anal margin: the university of Florida experience. ( Balamucki, CJ; George, TJ; Kirwan, JM; Mendenhall, WM; Morris, CG; Newlin, HE; Rout, WR; Zlotecki, RA, 2011) |
| "The recurrence of hepatocellular carcinoma is still high even after surgery." | 1.37 | Adjuvant chemolipiodolization reduces early recurrence derived from intrahepatic metastasis of hepatocellular carcinoma after hepatectomy. ( Hayami, S; Ozawa, S; Shigekawa, Y; Tani, M; Uchiyama, K; Ueno, M; Yamaue, H, 2011) |
| "Vaginal strictures are rare entities in pediatric population, mainly due to congenital genito-urinary tract malformations and sequelae of their surgical treatment, recurrent vaginitis and multisciplinary therapy for malignant tumors." | 1.35 | Successful topical treatment with mitomycin-C in a female with post-brachytherapy vaginal stricture. ( Betalli, P; Bisogno, G; Cecchetto, G; De Corti, F; Mazzarotto, R; Meneghini, L; Minucci, D, 2008) |
| "For patients with advanced breast cancer, overall response rates were 41% for TN tumours and 31% for others (P = 0." | 1.35 | Platinum-based chemotherapy in triple-negative breast cancer. ( Arnedos, M; Ashley, S; Johnston, S; Nerurkar, A; Popat, S; Sirohi, B; Smith, IE; Walsh, G, 2008) |
| "We conclude that minimal residual disease, compared with macroscopically complete cytoreduction, correlated to failure in critical anatomical areas, suggesting the need for maximal cytoreductive surgical efforts." | 1.35 | Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). ( Baratti, D; Cabras, AD; Deraco, M; Dileo, P; Kusamura, S; Laterza, B, 2009) |
| "The charts of patients with superficial bladder cancer treated with induction or maintenance intravesical therapy (IVT) were reviewed retrospectively." | 1.35 | A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy. ( Berry, A; Carroll, P; Konety, B; Whitson, J, 2009) |
| "Previously irradiated recurrent rectal cancer is a formidable patient threat with limited treatment options." | 1.35 | Isolated chemotherapeutic perfusion of pelvis as neoadjuvant or palliative therapy for advanced cancer of the rectum. ( Begossi, G; Belliveau, J; DiSiena, M; Gustafson, E; Wanebo, HJ, 2008) |
| "Eligible patients with ovarian cancer in whom pre-operative evaluation indicated that there was a good possibility that disease could be resected to < or = 5 mm underwent surgery followed by intraperitoneal perfusion of cisplatin (100 mg/m2) or mitomycin C (30-40 mg total dose) heated to 41-43 degrees C (105." | 1.34 | Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma. ( Edwards, RP; Gordinier, ME; Helm, CW; Martin, RS; Metzinger, DS; Parker, LP; Randall-Whitis, L, 2007) |
| "7 % and adverse events were bone marrow suppression, 13; nephrotoxicity, 14; neutropenic infection, 2 and pulmonary toxicity, 1." | 1.34 | Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity. ( Baratti, D; Costanzo, P; Deraco, M; Favaro, M; Gavazzi, C; Grosso, F; Kusamura, S; Laterza, B; Oliva, GD; Younan, R, 2007) |
| " Performing splenectomy and CDDP dosage for HIPEC >240 mg were proven to be independent risk factors for both G3-4 hyperamylasemia and POPF." | 1.34 | Incidence of postoperative pancreatic fistula and hyperamylasemia after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. ( Antonucci, A; Baratti, D; Deraco, M; Gavazzi, C; Kusamura, S; Laterza, B; Oliva, GD; Younan, R, 2007) |
| "Hepatic resection for huge hepatocellular carcinoma (HCC) is challenging." | 1.32 | Multimodality management of hepatocellular carcinoma larger than 10 cm. ( Chen, IS; Chen, YC; Chou, NH; Liang, HL; Liu, SI; Lo, GH; Mok, KT; Tsai, CC; Wang, BW; Yeh, MH, 2003) |
| "In advanced gastric cancer, peritoneal recurrence is the main cause of death after curative surgical resection." | 1.32 | Application of molecular diagnosis for detection of peritoneal micrometastasis and evaluation of preoperative chemotherapy in advanced gastric carcinoma. ( Azama, T; Fujiwara, Y; Ishii, T; Monden, M; Mori, T; Sugita, Y; Takiguchi, S; Taniguchi, K; Yamazaki, K; Yano, M; Yasuda, T, 2004) |
| " As cytostatics for hyperthermic peritoneal perfusion, we have used Mitomycin in a dosage of 18 mg/m2 plus Melphalan in a dosage of 25 mg/m2." | 1.32 | Cytoreductive surgery plus intraperitoneal hyperthermic perfusion is an effective treatment for metastasized malignant mixed mesodermal tumours (MMMT)--report of six cases. ( Müller, H; Nakchbandi, V, 2004) |
| "To explore the change of T cell subsets in patients suffered from hepatocellular carcinoma (HCC) before and after hepatectomy, and study the value of Roferon-A (interferon alpha-2a) combined with hepatic artery chemoembolization (HACE) and portal vein chemotherapy (PVC) after radical resection of HCC for preventing recurrence." | 1.32 | [The value of Roferon-A combined with hepatic artery chemoembolization and portal vein chemotherapy after radical resection in hepatocellular carcinoma for preventing recurrence]. ( Chen, JS; Duan, ZH; Li, HH; Wang, J; Zhang, HW, 2004) |
| "A 73-year old man with multiple hepatocellular carcinomas underwent 4 transarterial chemoembolizations, but a tumor thrombus appeared in the left portal vein." | 1.31 | [A case report of hepatocellular carcinoma with portal thrombus responding to hepatic arterial infusion chemo-lipiodolization]. ( Esumi, K; Furukawa, H; Imamura, H; Inoue, Y; Ishida, H; Katoh, H; Kitani, K; Masuda, N; Masutani, S; Onishi, H; Shimizu, J; Tatsuta, M; Tomotsu, K; Tsuda, K; Usui, T, 2002) |
| "In phase II trials in superficial bladder cancer, marker lesions have been used to test the ablative activity of intravesical chemo- or immunotherapy." | 1.31 | Frequency of positive biopsies after visual disappearance of superficial bladder cancer marker lesions. ( Bono, AV; Brausi, M; de Balincourt, C; Hall, R; Mack, D; Oosterlinck, W; Sylvester, R, 2001) |
| "We observed euploid DNA-polyploidy and cytomorphological changes in all patients (19/19)." | 1.31 | Topical mitomycin C and radiation induce conjunctival DNA-polyploidy. ( Böcking, A; Cartsburg, O; Hillenkamp, J; Kallen, C; Pomjanski, N; Sundmacher, R, 2001) |
| " There was no significant nausea or vomiting, nephrotoxicity, or pulmonary toxicity, which was attributable to the CLD-cisplatin and the adequate dosing schedule of bleomycin." | 1.30 | Combination of consecutive low-dose cisplatin with bleomycin, vincristine, and mitomycin for recurrent cervical carcinoma. ( Akiyama, F; Hasumi, K; Ishiya, T; Shimizu, Y; Umezawa, S; Utsugi, K, 1998) |
| "We reviewed our series of stage Ta bladder cancer patients with a long-term follow-up in order to clarify the prognosis of these patients, especially those who have repeated recurrences." | 1.30 | [The results of a long-term follow-up for patients with stage Ta bladder cancer, especially regarding those with multiple recurrences]. ( Fujioka, T; Mori, Y; Nagakubo, I; Tsukamoto, T; Yamauchi, T, 1998) |
| " For this research, the pharmacokinetic advantages of mitomycin C delivery by four different methods were compared: intraaortic infusion with aortic stopflow; intraaortic infusion with inferior vena cava stopflow; intraaortic infusion with aortic and inferior caval vein stopflow (hypoxic pelvic perfusion); and hypoxic pelvic perfusion with hemofiltration." | 1.30 | Pharmacokinetics of mitomycin C in pelvic stopflow infusion and hypoxic pelvic perfusion with and without hemofiltration: a pilot study of patients with recurrent unresectable rectal cancer. ( Aigner, KR; Cantore, M; Chaudhuri, PK; Clerico, M; Deraco, M; Fiorentini, G; Guadagni, S; Palumbo, G; Pozone, T, 1998) |
| "In the survival analysis of early breast cancer patients, we have to estimate the contribution of second cancers to properly evaluate the effect of treatment." | 1.30 | Prognostic impact of second cancer on the survival of early breast cancer patients. ( Murakami, S; Nomura, Y; Takenaka, Y; Tsutsui, S, 1999) |
| "Mitomycin C (20 mg) was injected through out the induced hypertension (1." | 1.30 | [A case of liver metastases from gastric cancer responding to induced hypertensive chemotherapy with angiotensin II]. ( Arai, K; Iwasaki, Y; Kitamura, M; Nakajima, Y, 1999) |
| "The role in colorectal cancer is less clear, although there are some reports that suggest a benefit." | 1.30 | Peritonectomy and intraperitoneal chemotherapy in appendiceal and colorectal cancer. ( Clingan, P; Horsell, KW; King, DW; Merten, S; Morris, DL, 1999) |
| "Mitomycin C was administered initially and mitoxantrone was administered following the same schedule if disease recurred during followup." | 1.29 | Up-front intravesical chemotherapy for low stage, low grade recurrent bladder cancer. ( Carmignani, G; Maffezzini, M; Raber, M; Simonato, A; Zanon, M, 1996) |
| "The recurrent tumors are suggested to be sensitive to the agents as follows: locally recurrent solid tumors, 5-FU; distantly recurrent solid tumors, 5-FU and CDDP; locally recurrent effusion, CDDP; distantly recurrent effusion, ADR." | 1.29 | Anticancer chemosensitivity changes between the original and recurrent tumors after successful chemotherapy selected according to the sensitivity assay. ( Araya, S; Hayashi, H; Imamura, M; Ishigami, S; Kawabata, K; Masai, Y; Nio, Y; Tamura, K; Tsubono, M, 1995) |
| "Four hundred five patients with anal cancer were identified by computer search, and 204 (51%) were evaluable; 164 of 204 (80%) had squamous cell carcinoma, 137 of whom (84%) were treated with sphincter-preserving procedures, and 27 of whom (16%) were treated by by radical surgery." | 1.29 | Recurrent squamous cell carcinoma of the anal canal. Predictors of initial treatment failure and results of salvage therapy. ( Coplin, MA; Johnson, FE; Longo, WE; Vernava, AM; Virgo, KS; Wade, TP, 1994) |
| "All the gastric cancer lesions without liver metastases were resected 14 days after implantation of VX2 cancer cells into the stomach, and all the animals were autopsied 14 days after resection." | 1.29 | [Prophylactic effects of mitomycin C (MMC) on the liver recurrence in a rabbit gastric VX2 cancer model with high frequency of the recurrence]. ( Nakamura, T; Saitoh, Y; Tabuchi, Y; Tada, Y, 1993) |
| "We reported a case of locally advanced breast cancer who was cannulated into the right internal thoracic artery through the right femoral artery by Seldinger's method for intra-arterial chemotherapy and obtained good results." | 1.28 | [A case of complete response of locally advanced breast cancer to arterial infusion chemotherapy: cannulation through the right femoral artery and combined use of G-CSF]. ( Miura, T; Murata, M; Seki, M; Shinohara, K; Takagi, S; Tezuka, T, 1992) |
| "Twenty patients with rectal cancer underwent the preoperative regimen that consisted of 3,000 cGy delivered in 10 fractions over 12 days with concomitant 5-fluorouracil and mitomycin-C." | 1.28 | Advantages of the Papillon protocol in the preoperative treatment of rectal carcinoma. ( Broadwater, JR; Gocio, JC; Hutchins, LF; Klimberg, VS; Lang, NP; Langston, JD; Maners, A; Westbrook, KC, 1992) |
| " The success of treatment seems out of question on dosage but with the continuation of the instillation program." | 1.28 | Endovesical instillation of mitomycin-C in preventing recurrence of superficial bladder carcinoma. ( Wu, JJ; Yin, ZL; Zhu, JN, 1992) |
| "Twelve colorectal cancer patients, including 9 with local recurrent cancer and 3 with remnant cancer after surgery, were treated with intraarterial chemotherapy." | 1.28 | [Intra-arterial chemotherapy of local recurrence and non-curative case of colorectal cancer]. ( Hashimoto, M; Hosoda, Y; Katai, H; Koh, J; Maeda, K; Murayama, Y; Sakai, S; Sano, M; Suzuki, K; Yamamoto, O, 1992) |
| "Mitomycin C was given on Day 1 (dose: 15 mg/m2 i." | 1.28 | Mitomycin C, 5-fluorouracil and radiation in advanced, locally recurrent rectal cancer. ( Dobrowsky, W, 1992) |
| "Fourteen patients with relapsing ovarian cancer were treated with Mitomycin C (Mit C) and 5 Fluorouracil (5-FU)." | 1.28 | Phase II study of mitomycin C and 5 fluorouracil in platinum resistant ovarian cancer. ( Covens, A; Mazurka, J; O'Connell, G; Rusthoven, J, 1992) |
| "Superficial bladder cancer has a good prognosis compared with invasive bladder cancer." | 1.28 | [Superficial bladder cancer: prophylaxis of recurrence and progression]. ( Akaza, H; Koiso, K; Miyanaga, N, 1991) |
| "In order to prevent local recurrence, intra-operative pelvic hyperthermochemotherapy (IOPHC) combined with surgery for rectal cancer has been performed." | 1.28 | [Clinical evaluation of intra-operative pelvic hyperthermochemotherapy combined with operation for rectal cancer]. ( Endoh, F; Fujimoto, S; Kobayashi, K; Kokubun, M; Masuda, Y; Obata, G; Ohno, K; Takahashi, M; Takai, M, 1991) |
| "Seventeen patients with colorectal cancer metastatic to the liver underwent hepatic resection." | 1.28 | Hepatic recurrence not prevented with low-dosage long-term intraportal 5-FU infusion after resection of colorectal liver metastasis. ( Furusawa, M; Kakeji, Y; Maehara, Y; Sugimachi, K; Tomoda, H; Tsujitani, S; Watanabe, A, 1991) |
| "In order to prevent local recurrence after curative surgery for rectal cancer, intra-operative pelvic hyperthermochemotherapy (IOPHC) was performed, combined with surgery." | 1.28 | [Intra-operative pelvic hyperthermochemotherapy combined with surgery in rectal cancer]. ( Endoh, F; Fujimoto, S; Kobayashi, N; Masuda, Y; Obata, G; Oohno, K; Takahashi, M; Takai, M; Tanaka, H, 1990) |
| "These two cases showed no recurrent liver cancers." | 1.28 | [Results of prophylactic intra-arterial infusion chemotherapy after hepatic resection in colorectal metastases]. ( Houjo, K; Kawano, N; Moriya, Y; Sugihara, K, 1990) |
| "A 62-year-old female with anal cancer underwent Miles operation in November, 1987." | 1.28 | [Effects of intra-arterial infusion chemotherapy in local recurrence of anal cancer]. ( Amino, K; Mieno, K; Miura, S; Satoi, Y; Shikata, J; Takeda, Y, 1989) |
| "This regimen is active in advanced ovarian cancer that has not responded to prior treatment and warrants further study combination with other active drugs as a first-line regimen for ovarian cancer." | 1.28 | Phase II study of combination 4'-epidoxorubicin and mitomycin C in recurrent epithelial ovarian cancer. ( Buxton, J; Chetiyawardana, A; Crawford, M; Lawton, F; Mould, J; O'Brien, M; Patterson, M; Redman, C; Stuart, N; Sykes, V, 1989) |
| "Excisions of metastatic liver cancer were performed in 36 patients and 23 had nonresectable metastatic liver cancer." | 1.28 | [Results of intra-arterial infusion chemotherapy of colorectal cancer in patients with metastatic liver cancer]. ( Hojo, K; Moriya, Y; Sawada, T, 1989) |
| "5-fluorouracil (5-FU) was administered by arterial continuous infusion, and adriamycin (ADM) and mitomycin C (MMC) by bolus infusion." | 1.28 | [Clinical effectiveness of arterial infusion chemotherapy in advanced and recurrent gastric cancer]. ( Odaka, Y; Oikawa, K; Saito, K; Sato, M; Takagane, A; Terashima, M, 1989) |
| "The principle treatment of cervical cancer now consists of surgery and radiotherapy, which have produced excellent treatment results." | 1.27 | [Problems in the treatment of cervical carcinoma]. ( Kohno, I; Sekiba, K, 1983) |
| " The toxicities in the case of intra-arterial infusion were less prominent than in the case of intravenous administration of the same dosage of the oncostatics." | 1.27 | [Intra-arterial infusion of oncostatics in recurrent cervical carcinoma]. ( Iijima, S; Inaba, J; Kawagoe, K; Sasaki, J; Tsunoda, H, 1983) |
| "Of 55 patients with esophageal squamous cell carcinoma, 30 with localized disease were treated with a combined modality for curative intent." | 1.27 | Combined modality therapy for esophageal squamous cell carcinoma. ( Asfaw, I; Franklin, R; Hoschner, J; Loh, J; Miller, P; Rosenberg, J; Steiger, Z; Vaishampayan, G, 1983) |
| "Mitomycin C has proved to be useful as prophylaxis against superficial bladder tumor recurrences." | 1.27 | Prostatic recurrences in the management of superficial bladder tumors. ( Bondhus, MJ; Chaikin, L; Lockhart, JL; Politano, VA, 1983) |
| "Mitomycin C was administered in one course of 10 daily doses of 40 mg, starting 24 to 48 hours after TUR." | 1.27 | Intravesical instillation of mitomycin C in the prophylactic treatment of recurring superficial transitional cell carcinoma of the bladder. ( Bendimerad, O; Bouvier, R; Devonec, M; Dubernard, JM; Gelet, A; Sarkissian, J, 1983) |
| "In case of recurrent colorectal cancer, 17 cases of 27 patients has multiple liver metastasis." | 1.27 | [Treatment of recurrent gastrointestinal cancer]. ( Taguchi, T, 1983) |
| "The rate of recurring bladder tumors decreased after instillation therapy." | 1.27 | [Experimental and clinical studies on intravesical instillation therapy for bladder cancer]. ( Imai, K; Kaburagi, Y; Miki, M; Yamanaka, H, 1983) |
| "The anti-tumor effect of twice a week instillation of 30 mg mitomycin C combined with 200 mg cytosine arabinoside dissolved in 30 ml saline was studied in 37 bladder tumor patients." | 1.27 | [Anti-tumor effect of intravesical instillation of mitomycin C combined with cytosine arabinoside]. ( Fujioka, H; Matsuda, M; Matsumiya, K; Nakano, E; Osafune, M; Sonoda, T; Tada, Y; Takaha, M, 1984) |
| "Twenty women with recurrent squamous cell carcinoma of the cervix were treated with bleomycin followed by adriamycin and mitomycin-C." | 1.27 | Assessment of bleomycin, adriamycin and mitomycin-C in the treatment of recurrent cervical cancer. ( Blackledge, G; Chan, KK; Lawton, FG; Luesley, DM; Meanwell, CA; Mould, JJ; Perren, TJ, 1985) |
| "Fifteen consenting patients with brain metastases recurrent after cranial irradiation were treated with intraarterial mitomycin-C, 15 mg/m2, administered in a total final volume of 100 ml 0." | 1.27 | Intraarterial mitomycin-C for recurrent brain metastases. ( Benoit, BG; Danjoux, C; Grahovac, Z; Hugenholtz, H; Maroun, JA; Richard, MT; Riding, MD; Russell, NA; Stewart, DJ, 1987) |
| "Seventeen patients with recurrent uterine cervical cancer were treated with combination chemotherapy consisting of consecutive intravenous drip infusion of PEP 5 mg for 6 days and intravenous infusion of MMC 10 mg on the 6th day." | 1.27 | [Clinical effect of combination chemotherapy with peplomycin and mitomycin C (PM therapy) in recurrent uterine cervical cancer]. ( Chiba, T; Hiura, M; Kaneko, H; Tanaka, M; Yokoyama, T; Yorishima, M, 1988) |
| "As for the treatment of recurrent breast cancer, it is important to consider hormone receptor, lesion and age and to choose the effective mode of treatment for the first (recurrence of the) disease." | 1.27 | [An analysis of treatments of recurrent breast cancer in relation to the lesion]. ( Hirai, T; Iino, Y; Ishida, T; Izuo, M; Kawai, T; Ogawa, T; Suzuki, H; Yokoe, T, 1985) |
| "A 56-year-old woman with recurrent gastric cancer treated with PMU therapy, combined CDDP 75 mg/m2 i." | 1.27 | [PMU therapy of recurrent gastric cancer. A case report]. ( Matsuki, N; Miyata, R; Miyazaka, I; Noto, H; Ogino, S; Ohyama, S; Sakuma, H; Sawa, T; Yagi, M; Yonemura, Y, 1986) |
| "Two percent had congestive heart failure associated with doxorubicin." | 1.27 | Early and delayed clinical cardiotoxicity of doxorubicin. ( Blumenschein, GR; Buzdar, AU; Marcus, C; Smith, TL, 1985) |
| "Metastatic colorectal cancer occurring in the pelvis was basically a vascular-deficient tumor." | 1.27 | Pelvic intra-arterial mitomycin C infusion in previously treated patients with metastatic, unresectable, pelvic colorectal cancer and angiographic determination of tumor vascularity. ( Park, HC; Tseng, MH, 1985) |
| "Nine patients with advanced cervical cancer were treated with a combination chemotherapy (MVP) consisting of mitomycin C 8 mg/m2 i." | 1.27 | [A combination chemotherapy using mitomycin C, vincristine and cisplatin (MVP) for advanced cervical cancer]. ( Adachi, K; Horikoshi, N; Ikeda, K; Inagaki, J; Inoue, K; Nakada, H; Ogawa, M; Tada, A; Usui, N; Yamazaki, H, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 137 (18.49) | 18.7374 |
| 1990's | 201 (27.13) | 18.2507 |
| 2000's | 185 (24.97) | 29.6817 |
| 2010's | 161 (21.73) | 24.3611 |
| 2020's | 57 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Gordon, NS | 1 |
| Baxter, LA | 1 |
| Goel, A | 2 |
| Arnold, R | 1 |
| Kaur, B | 1 |
| Liu, W | 1 |
| Pirrie, SJ | 1 |
| Hussain, S | 1 |
| Viney, R | 1 |
| Ford, D | 1 |
| Zarkar, A | 2 |
| Wood, MA | 1 |
| Mitin, T | 1 |
| Thompson, RF | 1 |
| James, ND | 3 |
| Ward, DG | 1 |
| Bryan, RT | 2 |
| Gupta, S | 1 |
| Dutta, A | 1 |
| Pal, DK | 1 |
| Carrión, DM | 1 |
| Gómez Rivas, J | 1 |
| Aguilera Bazán, A | 1 |
| Ballesteros Ruiz, C | 1 |
| Álvarez-Maestro, M | 1 |
| Ríos González, E | 1 |
| Martínez-Piñeiro, L | 3 |
| Wen, YC | 1 |
| Lee, LM | 1 |
| Lin, YW | 1 |
| Syu, SH | 1 |
| Lin, KH | 1 |
| Fan, YC | 1 |
| Lee, HL | 1 |
| Lai, BCH | 1 |
| Shih, HJ | 1 |
| Zazzara, M | 1 |
| Nazaraj, A | 1 |
| Scarcia, M | 1 |
| Cardo, G | 1 |
| Carando, R | 1 |
| Ludovico, GM | 1 |
| Tse, RT | 1 |
| Zhao, H | 1 |
| Wong, CY | 1 |
| Kong, AW | 1 |
| Chan, RC | 1 |
| To, KF | 1 |
| Ng, CF | 1 |
| Teoh, JY | 2 |
| Wang, SC | 1 |
| Yu, CY | 1 |
| Wu, YC | 1 |
| Chang, YC | 1 |
| Chen, SL | 2 |
| Sung, WW | 2 |
| Guerrero-Ramos, F | 1 |
| González-Padilla, DA | 1 |
| González-Díaz, A | 1 |
| de la Rosa-Kehrmann, F | 1 |
| Rodríguez-Antolín, A | 1 |
| Inman, BA | 2 |
| Villacampa-Aubá, F | 1 |
| Witsberger, EM | 1 |
| Dalvin, LA | 1 |
| Patel, SV | 1 |
| Balasubramanian, A | 1 |
| Gunjur, A | 1 |
| Weickhardt, A | 1 |
| Papa, N | 1 |
| Bolton, D | 1 |
| Lawrentschuk, N | 1 |
| Perera, M | 1 |
| Bani-Hani, M | 1 |
| Abdel Majid, A | 1 |
| Al-Zubi, MT | 1 |
| Al Demour, S | 1 |
| Al Zoubi, MS | 1 |
| Abuhamad, M | 1 |
| Santarisi, A | 1 |
| Taysir Eldos, B | 1 |
| Alsmadi, J | 1 |
| Elayan, B | 1 |
| Hacker, EC | 1 |
| Maganty, A | 1 |
| Pere, MM | 1 |
| Rusilko, PJ | 1 |
| Holliday, EB | 1 |
| Morris, VK | 1 |
| Johnson, B | 1 |
| Eng, C | 1 |
| Ludmir, EB | 1 |
| Das, P | 1 |
| Minsky, BD | 2 |
| Taniguchi, C | 1 |
| Smith, GL | 1 |
| Koay, EJ | 1 |
| Koong, AC | 1 |
| Delclos, ME | 1 |
| Skibber, JM | 1 |
| Rodriguez-Bigas, MA | 1 |
| You, YN | 1 |
| Bednarski, BK | 1 |
| Tillman, MM | 1 |
| Chang, GJ | 1 |
| Jennings, K | 1 |
| Messick, CA | 1 |
| Stover, AM | 1 |
| Basak, R | 1 |
| Mueller, D | 1 |
| Lipman, R | 1 |
| Teal, R | 1 |
| Hilton, A | 1 |
| Giannone, K | 1 |
| Waheed, M | 1 |
| Smith, AB | 1 |
| Senel, C | 1 |
| Asfuroglu, A | 1 |
| Aykanat, IC | 1 |
| Balci, M | 1 |
| Aslan, Y | 1 |
| Tuncel, A | 1 |
| Kim, SH | 1 |
| Lerner, SP | 2 |
| Daryanto, B | 1 |
| Purnomo, AF | 1 |
| Seputra, KP | 1 |
| Budaya, TN | 1 |
| Lindgren, MS | 1 |
| Hansen, E | 1 |
| Azawi, N | 1 |
| Nielsen, AM | 1 |
| Dyrskjøt, L | 1 |
| Jensen, JB | 1 |
| Nuessle, S | 1 |
| Auw-Haedrich, C | 1 |
| Jiang, J | 1 |
| Boehringer, D | 1 |
| Reinhard, T | 1 |
| Melgarejo-Segura, MT | 1 |
| Morales-Martínez, A | 1 |
| Yáñez-Castillo, Y | 1 |
| Arrabal-Polo, MÁ | 1 |
| Gómez-Lechuga, P | 1 |
| Pareja-Vílchez, M | 1 |
| Jiménez-Moleón, JJ | 1 |
| Martín, MA | 1 |
| Melgarejo Segura, MT | 4 |
| Morales Martínez, A | 4 |
| Yáñez Castillo, Y | 4 |
| Arrabal Polo, MÁ | 4 |
| Gómez Lechuga, P | 3 |
| Pareja Vílchez, M | 4 |
| Arrabal Martín, M | 4 |
| Kumar, V | 2 |
| Bansal, S | 2 |
| Badola, A | 2 |
| Nautiyal, V | 2 |
| Gupta, M | 2 |
| Ahmad, M | 2 |
| Saini, S | 2 |
| Brummelhuis, ISG | 1 |
| Crezee, J | 1 |
| Witjes, JA | 7 |
| Nevo, N | 1 |
| Lee Goldstein, A | 1 |
| Bar-David, S | 1 |
| Abu-Abeid, A | 1 |
| Dayan, D | 1 |
| Lahat, G | 1 |
| Nizri, E | 1 |
| van Wijngaarden, C | 1 |
| Bus, MTJ | 1 |
| Ruiter, AEC | 1 |
| Lagerveld, BW | 1 |
| Hien, TT | 1 |
| Ambite, I | 1 |
| Wan, MLY | 1 |
| Cavalera, M | 1 |
| Esmaeili, P | 1 |
| Chaudhuri, A | 1 |
| Sabari, S | 1 |
| Babjuk, M | 3 |
| Svanborg, C | 1 |
| Peng, CK | 1 |
| Davis, D | 1 |
| Seely, D | 1 |
| Morash, C | 1 |
| Armstrong, J | 1 |
| Meng, M | 1 |
| Lowe, P | 1 |
| Kogan, M | 1 |
| Moschini, M | 1 |
| Salonia, A | 4 |
| Briganti, A | 3 |
| Montorsi, F | 3 |
| Busetto, GM | 1 |
| Finati, M | 1 |
| Chirico, M | 1 |
| Cinelli, F | 1 |
| D'Altilia, N | 1 |
| Falagario, UG | 1 |
| Sanguedolce, F | 1 |
| Del Giudice, F | 1 |
| De Berardinis, E | 2 |
| Ferro, M | 1 |
| Crocetto, F | 1 |
| Porreca, A | 1 |
| Di Gianfrancesco, L | 2 |
| Calo', B | 1 |
| Mancini, V | 1 |
| Bettocchi, C | 1 |
| Carrieri, G | 1 |
| Cormio, L | 1 |
| Chun, B | 1 |
| He, M | 1 |
| Jones, C | 1 |
| Vasan, R | 1 |
| Gabriel, N | 1 |
| Jacobs, BL | 1 |
| Hernandez, I | 1 |
| Davies, BJ | 1 |
| Rose, KM | 2 |
| Murray, KS | 1 |
| Labbate, C | 1 |
| Woldu, S | 2 |
| Linehan, J | 1 |
| Jacob, J | 1 |
| Kaimakliotis, H | 1 |
| Dickstein, R | 1 |
| Feldman, A | 1 |
| Matin, SF | 2 |
| Lotan, Y | 5 |
| Humphreys, MR | 2 |
| Sexton, WJ | 1 |
| Sanz Gómez, I | 1 |
| Huguet, J | 2 |
| Bravo, A | 1 |
| Robalino, J | 1 |
| Rodríguez Faba, Ó | 1 |
| Territo, Á | 1 |
| Gaya, JM | 1 |
| Palou, J | 5 |
| Breda, A | 2 |
| Halstuch, D | 1 |
| Lotan, P | 1 |
| Karchever, I | 1 |
| Rubinshtein, D | 1 |
| Kedar, D | 2 |
| Baniel, J | 2 |
| Golan, S | 1 |
| Seiler, R | 1 |
| Egger, M | 1 |
| De Menna, M | 1 |
| Wehrli, S | 1 |
| Minoli, M | 1 |
| Radić, M | 1 |
| Lyatoshinsky, P | 1 |
| Hösli, R | 1 |
| Blarer, J | 1 |
| Abt, D | 1 |
| Kruithof-de Julio, M | 1 |
| Laukhtina, E | 1 |
| Shariat, SF | 4 |
| Fan, M | 1 |
| Shi, Y | 2 |
| Zhao, J | 2 |
| Li, L | 1 |
| Akbulut, F | 1 |
| Pazir, Y | 1 |
| Esmeray, A | 1 |
| Erbin, A | 1 |
| Ozgor, F | 1 |
| Sarilar, O | 1 |
| Prasad, SM | 1 |
| Huang, WC | 1 |
| Shore, ND | 1 |
| Hu, B | 1 |
| Bjurlin, M | 1 |
| Brown, G | 1 |
| Genov, P | 1 |
| Shishkov, D | 1 |
| Khuskivadze, A | 1 |
| Ganev, T | 1 |
| Marchev, D | 1 |
| Orlov, I | 1 |
| Kopyltsov, E | 1 |
| Zubarev, V | 1 |
| Nosov, A | 1 |
| Komlev, D | 1 |
| Burger, B | 1 |
| Raju, S | 1 |
| Meads, A | 1 |
| Schoenberg, M | 1 |
| Malalasekera, AP | 1 |
| Ediriweera, D | 1 |
| Goonewardena, S | 1 |
| Perera, N | 1 |
| Abeygunasekara, A | 1 |
| Jayasekara, R | 1 |
| Wettasinghe, K | 1 |
| Dissanayake, V | 1 |
| Lokuhetty, D | 1 |
| Racioppi, M | 2 |
| Ragonese, M | 1 |
| Palermo, G | 1 |
| Sacco, E | 1 |
| Bassi, P | 1 |
| Rivin Del Campo, E | 1 |
| Matzinger, O | 1 |
| Haustermans, K | 1 |
| Peiffert, D | 2 |
| Glynne-Jones, R | 5 |
| Winter, KA | 2 |
| Konski, AA | 1 |
| Ajani, JA | 2 |
| Bosset, JF | 3 |
| Hannoun-Levi, JM | 1 |
| Puyraveau, M | 3 |
| Chakravarthy, AB | 1 |
| Meadows, H | 2 |
| Northover, J | 1 |
| Collette, L | 1 |
| Christiaens, M | 1 |
| Maingon, P | 3 |
| Faraj, K | 1 |
| Chang, YH | 1 |
| Habermann, EB | 1 |
| Etzioni, DA | 1 |
| Blodgett, G | 1 |
| Castle, EP | 1 |
| Tyson Ii, MD | 1 |
| Baratti, D | 6 |
| Kusamura, S | 8 |
| Azmi, N | 1 |
| Guaglio, M | 1 |
| Montenovo, M | 1 |
| Deraco, M | 10 |
| Ba, M | 2 |
| Cui, S | 2 |
| Long, H | 2 |
| Gong, Y | 2 |
| Wu, Y | 2 |
| Lin, K | 1 |
| Tu, Y | 1 |
| Zhang, B | 1 |
| Wu, W | 1 |
| Suman, S | 1 |
| Kumar, A | 1 |
| Fankhauser, CD | 1 |
| Mostafid, H | 5 |
| Costales, AB | 1 |
| Chambers, L | 1 |
| Chichura, A | 1 |
| Rose, PG | 1 |
| Mahdi, H | 1 |
| Michener, CM | 1 |
| Yao, M | 1 |
| Debernardo, R | 1 |
| Freifeld, Y | 2 |
| Ghandour, R | 1 |
| Singla, N | 1 |
| Bagrodia, A | 1 |
| Rapoport, LM | 1 |
| Gazimiev, M | 1 |
| Delafuente, K | 1 |
| Kulangara, R | 1 |
| Robyak, H | 1 |
| Petros, FG | 1 |
| Raman, JD | 2 |
| Margulis, V | 1 |
| Voskuilen, CS | 1 |
| van de Kamp, MW | 1 |
| Schuring, N | 1 |
| Mertens, LS | 1 |
| Noordzij, A | 1 |
| Pos, F | 1 |
| van Rhijn, BWG | 1 |
| van der Heijden, MS | 1 |
| Schaake, EE | 1 |
| Westekemper, H | 2 |
| Manthey, A | 1 |
| Bechrakis, N | 1 |
| Porta, C | 1 |
| Giannatempo, P | 1 |
| Rizzo, M | 1 |
| Lucarelli, G | 1 |
| Ditonno, P | 1 |
| Battaglia, M | 1 |
| Lohynská, R | 1 |
| Nýdlová, A | 1 |
| Drbohlavová, T | 1 |
| Mazaná, E | 1 |
| Jirkovská, M | 1 |
| Veselský, T | 1 |
| Malinová, B | 1 |
| Stankušová, H | 1 |
| Zech, HB | 1 |
| Moeckelmann, N | 1 |
| Boettcher, A | 1 |
| Muenscher, A | 1 |
| Binder, M | 1 |
| Vettorazzi, E | 1 |
| Bokemeyer, C | 3 |
| Schafhausen, P | 1 |
| Betz, CS | 1 |
| Busch, CJ | 1 |
| Pyrgidis, N | 1 |
| Lackner, J | 1 |
| Schneidewind, L | 1 |
| Sokolakis, I | 1 |
| Zahid, A | 1 |
| Clarke, L | 1 |
| Carr, N | 1 |
| Chandrakumaran, K | 3 |
| Tzivanakis, A | 1 |
| Dayal, S | 1 |
| Mohamed, F | 5 |
| Cecil, T | 1 |
| Moran, BJ | 2 |
| Han, MA | 1 |
| Maisch, P | 1 |
| Jung, JH | 2 |
| Hwang, JE | 1 |
| Narayan, V | 1 |
| Cleves, A | 2 |
| Hwang, EC | 1 |
| Dahm, P | 2 |
| Ourfali, S | 1 |
| Matillon, X | 1 |
| Ricci, E | 1 |
| Fassi-Fehri, H | 1 |
| Benoit-Janin, M | 1 |
| Badet, L | 1 |
| Colombel, M | 1 |
| Taylor, CA | 1 |
| Tobert, CM | 1 |
| Kahnoski, RJ | 1 |
| Humphrey, JE | 1 |
| Lane, BR | 1 |
| Nilsson, MP | 1 |
| Johnsson, A | 2 |
| Scherman, J | 1 |
| Wang, B | 1 |
| Yan, Z | 1 |
| Wang, S | 1 |
| Gözen, AS | 1 |
| Umari, P | 1 |
| Scheitlin, W | 1 |
| Su, FE | 1 |
| Akin, Y | 1 |
| Rassweiler, J | 1 |
| Guadagni, S | 7 |
| Fiorentini, G | 5 |
| Clementi, M | 3 |
| Palumbo, P | 2 |
| Mambrini, A | 1 |
| Masedu, F | 4 |
| Gudeloglu, A | 1 |
| Kiziloz, H | 1 |
| Kuntz, GM | 1 |
| Miller, A | 1 |
| Konety, BR | 1 |
| Scholz, SL | 1 |
| Eckstein, A | 1 |
| Dekowski, D | 1 |
| Esser, J | 1 |
| Steuhl, KP | 1 |
| Kaimbo Wa Kaimbo, D | 1 |
| Christoph, F | 1 |
| König, F | 1 |
| Lebentrau, S | 1 |
| Blaschke, S | 1 |
| Liehr, UB | 1 |
| Schostak, M | 2 |
| Blasi, MA | 1 |
| Maceroni, M | 1 |
| Sammarco, MG | 1 |
| Pagliara, MM | 1 |
| Wilson, SS | 1 |
| Crawford, ED | 1 |
| Unda-Urzaiz, M | 1 |
| Fernandez-Gomez, JM | 1 |
| Cozar-Olmo, JM | 1 |
| Juárez, A | 1 |
| Xylinas, E | 1 |
| Kent, M | 1 |
| Dabi, Y | 1 |
| Rieken, M | 1 |
| Kluth, LA | 1 |
| Al Hussein Al Awamlh, B | 1 |
| Ouzaid, I | 1 |
| Pycha, A | 1 |
| Comploj, E | 1 |
| Svatek, RS | 2 |
| Karakiewicz, PI | 1 |
| Holmang, S | 2 |
| Bosschieter, J | 1 |
| van Moorselaar, RJA | 1 |
| Vis, AN | 1 |
| van Ginkel, T | 1 |
| Lissenberg-Witte, BI | 1 |
| Beckers, GMA | 1 |
| Nieuwenhuijzen, JA | 1 |
| Faba, OR | 1 |
| Crijnen, J | 1 |
| De Reijke, TM | 1 |
| Aigner, KR | 2 |
| Gailhofer, S | 2 |
| Aigner, K | 1 |
| Ubrig, B | 1 |
| Roth, S | 1 |
| Boy, A | 1 |
| Bencivenga, M | 1 |
| Fiorentini, C | 2 |
| Soloway, MS | 6 |
| Sotgia, F | 1 |
| Ozsvari, B | 1 |
| Fiorillo, M | 1 |
| De Francesco, EM | 1 |
| Bonuccelli, G | 1 |
| Lisanti, MP | 1 |
| Ma, IH | 1 |
| Hu, FR | 1 |
| Wang, IJ | 1 |
| Chen, WL | 1 |
| Hsu, YJ | 1 |
| Chu, HS | 1 |
| Yuan, CT | 1 |
| Hou, YC | 1 |
| Tan, WS | 2 |
| Panchal, A | 1 |
| Buckley, L | 1 |
| Devall, AJ | 1 |
| Loubière, LS | 1 |
| Pope, AM | 1 |
| Feneley, MR | 1 |
| Cresswell, J | 2 |
| Issa, R | 1 |
| Madaan, S | 2 |
| Bhatt, R | 1 |
| McGrath, J | 1 |
| Sangar, V | 1 |
| Griffiths, TRL | 1 |
| Page, T | 1 |
| Hodgson, D | 1 |
| Datta, SN | 2 |
| Billingham, LJ | 1 |
| Kelly, JD | 2 |
| Porta, N | 1 |
| Huddart, R | 1 |
| Protheroe, A | 1 |
| Bogle, R | 1 |
| Blazeby, J | 1 |
| Palmer, A | 1 |
| Johnson, M | 1 |
| Brough, R | 1 |
| Andrews, S | 1 |
| Cruickshank, C | 1 |
| Burnett, S | 1 |
| Maynard, L | 1 |
| Hall, E | 2 |
| Chen, HR | 1 |
| Kao, CC | 1 |
| Tsao, CW | 1 |
| Tang, SH | 1 |
| En, M | 1 |
| Cha, TL | 1 |
| Sun, GH | 1 |
| Wu, ST | 1 |
| Yu, DS | 1 |
| Lenis, AT | 1 |
| Asanad, K | 1 |
| Blaibel, M | 1 |
| Donin, NM | 1 |
| Chamie, K | 1 |
| Santoni, A | 1 |
| Thariat, J | 2 |
| Maschi, C | 1 |
| Herault, J | 1 |
| Baillif, S | 1 |
| Lassalle, S | 1 |
| Peyrichon, ML | 1 |
| Salleron, J | 1 |
| Caujolle, JP | 1 |
| Hori, S | 1 |
| Miyake, M | 1 |
| Tatsumi, Y | 1 |
| Morizawa, Y | 1 |
| Nakai, Y | 1 |
| Onishi, S | 1 |
| Onishi, K | 1 |
| Iida, K | 1 |
| Gotoh, D | 1 |
| Itami, Y | 1 |
| Tanaka, N | 1 |
| Fujimoto, K | 1 |
| Huang, Y | 2 |
| Cen, J | 1 |
| Liu, Z | 1 |
| Wei, J | 1 |
| Chen, Z | 1 |
| Feng, Z | 1 |
| Lu, J | 1 |
| Fang, Y | 1 |
| Zhou, F | 1 |
| Luo, J | 1 |
| Mo, C | 1 |
| Chen, W | 1 |
| Ricevuto, E | 1 |
| Bruera, G | 1 |
| Sarti, D | 1 |
| Kang, YK | 3 |
| Chang, HM | 4 |
| Yook, JH | 3 |
| Ryu, MH | 4 |
| Park, I | 1 |
| Min, YJ | 1 |
| Zang, DY | 2 |
| Kim, GY | 1 |
| Yang, DH | 2 |
| Jang, SJ | 2 |
| Park, YS | 2 |
| Lee, JL | 3 |
| Kim, TW | 4 |
| Oh, ST | 2 |
| Park, BK | 1 |
| Jung, HY | 2 |
| Kim, BS | 3 |
| James, RD | 1 |
| Meadows, HM | 2 |
| Cunningham, D | 3 |
| Myint, AS | 1 |
| Saunders, MP | 1 |
| Maughan, T | 1 |
| McDonald, A | 1 |
| Essapen, S | 1 |
| Leslie, M | 2 |
| Falk, S | 1 |
| Wilson, C | 1 |
| Gollins, S | 2 |
| Begum, R | 2 |
| Ledermann, J | 1 |
| Kadalayil, L | 2 |
| Sebag-Montefiore, D | 3 |
| Chua, TC | 3 |
| Quinn, LE | 1 |
| Morris, DL | 4 |
| Idilman, I | 1 |
| Peynircioğlu, B | 1 |
| Cil, BE | 1 |
| Doğanay Erdoğan, B | 1 |
| Yalçın, S | 1 |
| Bayraktar, Y | 1 |
| Kav, T | 1 |
| Altundağ, K | 1 |
| Balkancı, F | 1 |
| Huddart, RA | 1 |
| Hussain, SA | 2 |
| Jenkins, P | 1 |
| Rawlings, C | 1 |
| Tremlett, J | 1 |
| Crundwell, M | 1 |
| Adab, FA | 1 |
| Sheehan, D | 1 |
| Syndikus, I | 1 |
| Hendron, C | 1 |
| Lewis, R | 1 |
| Waters, R | 1 |
| Lee, JH | 2 |
| Kim, YH | 3 |
| Kim, MS | 1 |
| Kim, EC | 1 |
| Kim, BH | 1 |
| Kim, MK | 1 |
| Wee, WR | 1 |
| Oh, JY | 1 |
| Gunderson, LL | 1 |
| Moughan, J | 1 |
| Pedersen, JE | 1 |
| Benson, AB | 1 |
| Thomas, CR | 1 |
| Mayer, RJ | 1 |
| Haddock, MG | 1 |
| Rich, TA | 1 |
| Willett, CG | 1 |
| O'Brien, T | 2 |
| Ray, E | 1 |
| Chatterton, K | 2 |
| Khan, MS | 2 |
| Chandra, A | 1 |
| Thomas, K | 2 |
| Ozdemir, O | 1 |
| Ozdemir, P | 1 |
| Veral, A | 1 |
| Uluer, H | 1 |
| Ozhan, MH | 1 |
| Yoo, C | 1 |
| Lee, YJ | 1 |
| Kim, JH | 2 |
| Besley, J | 1 |
| Pappalardo, J | 1 |
| Lee, GA | 1 |
| Hirst, LW | 1 |
| Vincent, SJ | 1 |
| Milla, P | 1 |
| Fiorito, C | 1 |
| Soria, F | 1 |
| Arpicco, S | 1 |
| Cattel, L | 1 |
| Gontero, P | 1 |
| Tabrizian, P | 1 |
| Shrager, B | 1 |
| Jibara, G | 1 |
| Yang, MJ | 1 |
| Romanoff, A | 1 |
| Hiotis, S | 1 |
| Sarpel, U | 1 |
| Labow, DM | 1 |
| Maffezzini, M | 2 |
| Campodonico, F | 1 |
| Canepa, G | 1 |
| Manuputty, EE | 1 |
| Tamagno, S | 1 |
| Puntoni, M | 1 |
| Khawandanah, M | 1 |
| Baxley, A | 1 |
| Pant, S | 1 |
| Jiang, L | 1 |
| Lei, JY | 1 |
| Wang, WT | 1 |
| Yan, LN | 1 |
| Li, B | 1 |
| Wen, TF | 1 |
| Xu, MQ | 1 |
| Yang, JY | 1 |
| Wei, YG | 1 |
| Arends, TJ | 1 |
| van der Heijden, AG | 3 |
| Twu, CW | 1 |
| Wang, WY | 1 |
| Chen, CC | 1 |
| Liang, KL | 1 |
| Jiang, RS | 1 |
| Wu, CT | 1 |
| Shih, YT | 1 |
| Lin, PJ | 1 |
| Liu, YC | 1 |
| Lin, JC | 1 |
| Kim, K | 2 |
| Chie, EK | 2 |
| Jang, JY | 2 |
| Kim, SW | 2 |
| Han, SW | 3 |
| Oh, DY | 3 |
| Im, SA | 3 |
| Kim, TY | 4 |
| Bang, YJ | 3 |
| Ha, SW | 2 |
| Blinde, SE | 1 |
| Schasfoort, R | 1 |
| Mens, JW | 2 |
| Verhoef, C | 1 |
| Olofsen, M | 1 |
| Nuyttens, JJ | 1 |
| Samuel, L | 2 |
| Geh, JI | 1 |
| Lowdell, C | 1 |
| James, R | 1 |
| Beare, S | 1 |
| Ledermann, JA | 1 |
| Thind, G | 1 |
| Johal, B | 1 |
| Follwell, M | 1 |
| Kennecke, HF | 1 |
| Molina Escudero, R | 1 |
| Alvarez Ardura, M | 1 |
| Ripalda Ferretti, E | 1 |
| Crespo Martínez, L | 1 |
| González Avila, N | 1 |
| Dorado Valentín, M | 1 |
| Páez Borda, A | 1 |
| Lord, AC | 1 |
| Shihab, O | 1 |
| Cecil, TD | 1 |
| Solsona, E | 4 |
| Madero, R | 1 |
| Chantada, V | 1 |
| Fernandez, JM | 1 |
| Zabala, JA | 1 |
| Portillo, JA | 1 |
| Alonso, JM | 1 |
| Astobieta, A | 1 |
| Unda, M | 1 |
| Rabadan, M | 1 |
| Ojea, A | 1 |
| Rodriguez-Molina, J | 1 |
| Beardo, P | 1 |
| Muntañola, P | 1 |
| Gomez, M | 1 |
| Montesinos, M | 1 |
| Martinez Piñeiro, JA | 1 |
| Kiss, B | 1 |
| Schneider, S | 1 |
| Thalmann, GN | 1 |
| Roth, B | 1 |
| Patkowski, W | 1 |
| Stankiewicz, R | 1 |
| Grąt, M | 1 |
| Krasnodębski, M | 1 |
| Kornasiewicz, O | 1 |
| Krawczyk, M | 1 |
| Vaira, M | 1 |
| Robella, M | 1 |
| Mellano, A | 1 |
| Sottile, A | 1 |
| De Simone, M | 1 |
| Hollenbeck, BK | 1 |
| Leon, O | 1 |
| Guren, M | 1 |
| Hagberg, O | 1 |
| Glimelius, B | 1 |
| Dahl, O | 2 |
| Havsteen, H | 1 |
| Naucler, G | 1 |
| Svensson, C | 1 |
| Tveit, KM | 3 |
| Jakobsen, A | 1 |
| Pfeiffer, P | 1 |
| Wanderås, E | 1 |
| Ekman, T | 1 |
| Lindh, B | 1 |
| Balteskard, L | 2 |
| Frykholm, G | 2 |
| Zuo, CH | 1 |
| Xia, M | 1 |
| Liu, JS | 1 |
| Qiu, XX | 1 |
| Lei, X | 1 |
| Xu, RC | 1 |
| Liu, HC | 1 |
| Li, JL | 1 |
| Li, YG | 1 |
| Li, QL | 1 |
| Xiao, H | 1 |
| Hong, Y | 1 |
| Wang, XH | 1 |
| Zhu, HZ | 1 |
| Wu, QF | 1 |
| Burns, M | 1 |
| Liu, C | 2 |
| Delhorme, JB | 1 |
| Triki, E | 1 |
| Romain, B | 1 |
| Meyer, N | 1 |
| Rohr, S | 1 |
| Brigand, C | 1 |
| Rivière, A | 1 |
| Ploussard, G | 1 |
| Desgranchamps, F | 1 |
| Cockerill, PA | 1 |
| Knoedler, JJ | 1 |
| Frank, I | 1 |
| Tarrell, R | 1 |
| Karnes, RJ | 1 |
| Lykke, MR | 1 |
| Nielsen, TK | 1 |
| Ebbensgaard, NA | 1 |
| Zieger, K | 1 |
| Ghosn, M | 1 |
| Kourie, HR | 1 |
| Abdayem, P | 1 |
| Antoun, J | 1 |
| Nasr, D | 1 |
| Järvinen, R | 4 |
| Marttila, T | 2 |
| Kaasinen, E | 10 |
| Rintala, E | 10 |
| Aaltomaa, S | 1 |
| Kallio, J | 2 |
| Liukkonen, T | 3 |
| Puolakka, VM | 2 |
| Seppänen, M | 1 |
| Tuhkanen, K | 2 |
| Vaarala, M | 1 |
| Viitanen, J | 2 |
| Boström, PJ | 1 |
| Troussier, I | 1 |
| Huguet, F | 2 |
| Servagi-Vernat, S | 1 |
| Benahim, C | 1 |
| Khalifa, J | 1 |
| Darmon, I | 1 |
| Ortholan, C | 1 |
| Krebs, L | 1 |
| Dejean, C | 1 |
| Fenoglietto, P | 1 |
| Vieillot, S | 1 |
| Bensadoun, RJ | 1 |
| Decaestecker, K | 1 |
| Lumen, N | 1 |
| Ringoir, A | 1 |
| Oosterlinck, W | 7 |
| Boström, P | 1 |
| Sylvester, RJ | 2 |
| Sydes, MR | 1 |
| Birtle, A | 1 |
| Gudjonsson, S | 1 |
| De Nunzio, C | 2 |
| Okamura, K | 1 |
| Ali-El-Dein, B | 1 |
| Tatar, CA | 1 |
| N'Dow, J | 1 |
| Oddens, JR | 1 |
| Sabourin, JC | 1 |
| Rouprêt, M | 2 |
| Compérat, E | 1 |
| Zigeuner, R | 1 |
| Burger, M | 1 |
| Cowan, NC | 1 |
| Böhle, A | 3 |
| Van Rhijn, BW | 1 |
| Lépinoy, A | 1 |
| Lescut, N | 1 |
| Caubet, M | 1 |
| Boustani, J | 1 |
| Lakkis, Z | 1 |
| Fantoli, M | 1 |
| Buffet-Miny, J | 2 |
| Kim, S | 1 |
| Bednarek, C | 1 |
| Créhange, G | 3 |
| Zhou, Q | 1 |
| Ye, M | 1 |
| Lu, Y | 1 |
| Zhang, H | 3 |
| Chen, Q | 1 |
| Huang, S | 2 |
| Su, S | 1 |
| Ren, L | 1 |
| Yang, X | 1 |
| Zhao, L | 1 |
| Wang, J | 4 |
| Shibing, Y | 1 |
| Qiang, W | 1 |
| Motamedinia, P | 1 |
| Keheila, M | 1 |
| Leavitt, DA | 1 |
| Rastinehad, AR | 1 |
| Okeke, Z | 1 |
| Smith, AD | 1 |
| Shah, KJ | 1 |
| Mogilishetty, G | 1 |
| Holland, EJ | 2 |
| Oliveira, SC | 1 |
| Moniz, CM | 1 |
| Riechelmann, R | 1 |
| Alex, AK | 1 |
| Braghirolli, MI | 1 |
| Bariani, G | 1 |
| Nahas, C | 1 |
| Hoff, PM | 1 |
| Horinouchi, H | 1 |
| Goto, Y | 1 |
| Kanda, S | 1 |
| Fujiwara, Y | 2 |
| Nokihara, H | 1 |
| Yamamoto, N | 2 |
| Sumi, M | 1 |
| Tamura, T | 1 |
| Ohe, Y | 1 |
| Monnier, L | 1 |
| Touboul, E | 2 |
| Daraï, E | 1 |
| Lefranc, JP | 1 |
| Lauratet, B | 1 |
| Ballester, M | 1 |
| Gan, C | 1 |
| Amery, S | 1 |
| Hassan, M | 1 |
| Qureshi, A | 1 |
| Nasir, H | 1 |
| Mohammadkhani Shali, S | 1 |
| Schmitt, V | 1 |
| Behrendt, FF | 1 |
| Winz, OH | 1 |
| Heinzel, A | 1 |
| Mottaghy, FM | 1 |
| Eble, MJ | 1 |
| Verburg, FA | 1 |
| Esuvaranathan, K | 1 |
| Köhler, C | 1 |
| Marnitz, S | 1 |
| Biel, P | 1 |
| Cordes, T | 1 |
| Zhuo, C | 1 |
| Li, X | 2 |
| Zhuang, H | 1 |
| Tian, S | 1 |
| Cui, H | 1 |
| Jiang, R | 1 |
| Tao, R | 1 |
| Lin, X | 1 |
| Lu, DD | 1 |
| Boorjian, SA | 1 |
| Chang, SS | 1 |
| Prasad, NN | 1 |
| Muddukrishna, SN | 1 |
| Betalli, P | 1 |
| De Corti, F | 1 |
| Minucci, D | 1 |
| Mazzarotto, R | 1 |
| Meneghini, L | 1 |
| Bisogno, G | 1 |
| Cecchetto, G | 1 |
| Damato, B | 1 |
| Coupland, SE | 1 |
| Sirohi, B | 1 |
| Arnedos, M | 1 |
| Popat, S | 1 |
| Ashley, S | 2 |
| Nerurkar, A | 1 |
| Walsh, G | 2 |
| Johnston, S | 1 |
| Smith, IE | 1 |
| Saint, F | 1 |
| Chen, H | 2 |
| Liang, C | 1 |
| Zhang, L | 1 |
| Wu, X | 1 |
| Stoehr, B | 1 |
| Mueller, T | 1 |
| Granig, T | 1 |
| Zangerl, F | 1 |
| Steiner, H | 1 |
| Horvath, A | 1 |
| Jalón Monzón, A | 2 |
| Fernández Gómez, JM | 2 |
| Escaf Bramada, S | 1 |
| Alvarez Múgica, M | 2 |
| García Rodríguez, J | 1 |
| Regadera Sejas, FJ | 2 |
| El-Ghobashy, S | 1 |
| El-Leithy, TR | 1 |
| Roshdy, MM | 1 |
| El-Ganzoury, HM | 1 |
| Escaf Barmadah, S | 1 |
| Martín Benito, JL | 1 |
| Cabras, AD | 1 |
| Dileo, P | 1 |
| Laterza, B | 3 |
| Whitson, J | 1 |
| Berry, A | 1 |
| Carroll, P | 1 |
| Konety, B | 1 |
| Terai, Y | 1 |
| Kanemura, M | 1 |
| Sasaki, H | 1 |
| Tsunetoh, S | 1 |
| Tanaka, Y | 1 |
| Yamashita, Y | 1 |
| Yamamoto, K | 2 |
| Narabayashi, I | 1 |
| Ohmichi, M | 1 |
| Mangiarotti, B | 1 |
| Trinchieri, A | 2 |
| Del Nero, A | 1 |
| Montanari, E | 1 |
| Myerson, RJ | 1 |
| Outlaw, ED | 1 |
| Chang, A | 1 |
| Birnbaum, EH | 1 |
| Fleshman, JW | 1 |
| Grigsby, PW | 1 |
| Kodner, IJ | 1 |
| Malayapa, RS | 1 |
| Mutch, MG | 1 |
| Parikh, P | 1 |
| Picus, J | 1 |
| Tan, BR | 1 |
| Echternach, M | 1 |
| Arndt, S | 1 |
| Mattern, D | 1 |
| Maier, W | 1 |
| Richter, B | 1 |
| Sankila, A | 1 |
| Donaldson, AM | 1 |
| Gonzalez, JG | 1 |
| Parmar, MK | 5 |
| Donaldson, N | 1 |
| Hogg, ME | 1 |
| Popowich, DA | 1 |
| Wang, EC | 1 |
| Kiel, KD | 1 |
| Stryker, SJ | 1 |
| Halverson, AL | 1 |
| Klug, C | 2 |
| Berzaczy, D | 1 |
| Voracek, M | 2 |
| Nell, C | 1 |
| Ploder, O | 1 |
| Millesi, W | 2 |
| Ewers, R | 3 |
| Lingnau, A | 1 |
| Miller, K | 1 |
| Steiner, U | 1 |
| Jentzmik, F | 1 |
| Weikert, S | 1 |
| Nativ, O | 3 |
| Hendricksen, K | 1 |
| Cohen, M | 1 |
| Sidi, A | 2 |
| Colombo, R | 6 |
| Leibovitch, I | 1 |
| Stenzl, A | 1 |
| Miyamoto, H | 1 |
| Yoshida, M | 3 |
| Yamanouchi, T | 1 |
| Kanda, K | 2 |
| Zinnouchi, K | 1 |
| Kiyozumi, T | 1 |
| Koba, I | 1 |
| Akashi, R | 1 |
| Sagara, K | 1 |
| Rudkin, AK | 1 |
| Muecke, JS | 1 |
| Addeo, R | 1 |
| Caraglia, M | 1 |
| Bellini, S | 1 |
| Abbruzzese, A | 1 |
| Vincenzi, B | 1 |
| Montella, L | 1 |
| Miragliuolo, A | 1 |
| Guarrasi, R | 1 |
| Lanna, M | 1 |
| Cennamo, G | 1 |
| Faiola, V | 1 |
| Del Prete, S | 1 |
| Wu, WJ | 1 |
| Ke, HL | 1 |
| Yang, YH | 1 |
| Li, CC | 1 |
| Chou, YH | 1 |
| Huang, CH | 1 |
| Nieder, AM | 1 |
| Nagano, T | 1 |
| Goto, K | 1 |
| Kubota, K | 1 |
| Ohmatsu, H | 1 |
| Niho, S | 1 |
| Yoh, K | 1 |
| Naito, Y | 1 |
| Saijo, N | 1 |
| Nishiwaki, Y | 1 |
| Watanabe, K | 1 |
| Otake, T | 1 |
| Yasuda, M | 1 |
| Takenoshita, S | 1 |
| Tans, L | 1 |
| Ansink, AC | 1 |
| van Rooij, PH | 1 |
| Kleijnen, C | 1 |
| Wright, JL | 1 |
| Patil, SM | 1 |
| Temple, LK | 1 |
| Saltz, LB | 1 |
| Goodman, KA | 1 |
| Gupta, A | 1 |
| Muecke, J | 2 |
| Russell, HC | 1 |
| Chadha, V | 1 |
| Lockington, D | 1 |
| Kemp, EG | 2 |
| Shildkrot, Y | 2 |
| Wilson, MW | 2 |
| Volpe, A | 1 |
| D'Agostino, D | 1 |
| Cappa, E | 1 |
| Filianoti, A | 1 |
| Bassi, PF | 1 |
| Wolff, HA | 1 |
| Raus, I | 1 |
| Jung, K | 1 |
| Schüler, P | 1 |
| Herrmann, MK | 1 |
| Hennies, S | 1 |
| Vorwerk, H | 1 |
| Hille, A | 1 |
| Hess, CF | 1 |
| Christiansen, H | 1 |
| Noura, S | 1 |
| Ohue, M | 1 |
| Shingai, T | 1 |
| Kano, S | 1 |
| Ohigashi, H | 2 |
| Yano, M | 2 |
| Ishikawa, O | 2 |
| Takenaka, A | 1 |
| Murata, K | 1 |
| Kameyama, M | 2 |
| Birkholz, ES | 1 |
| Goins, KM | 1 |
| Sutphin, JE | 2 |
| Kitzmann, AS | 1 |
| Wagoner, MD | 1 |
| Balamucki, CJ | 1 |
| Zlotecki, RA | 1 |
| Rout, WR | 1 |
| Newlin, HE | 1 |
| Morris, CG | 1 |
| Kirwan, JM | 1 |
| George, TJ | 1 |
| Mendenhall, WM | 1 |
| Carretero, R | 1 |
| Cabrera, T | 1 |
| Gil, H | 1 |
| Saenz-Lopez, P | 1 |
| Maleno, I | 1 |
| Aptsiauri, N | 1 |
| Cozar, JM | 1 |
| Garrido, F | 1 |
| Bakrin, N | 1 |
| Cotte, E | 1 |
| Sayag-Beaujard, A | 1 |
| Raudrant, D | 1 |
| Isaac, S | 1 |
| Gilly, FN | 1 |
| Glehen, O | 1 |
| Glockzin, G | 1 |
| Renner, P | 1 |
| Popp, FC | 1 |
| Dahlke, MH | 1 |
| von Breitenbuch, P | 1 |
| Schlitt, HJ | 1 |
| Piso, P | 1 |
| Kirkali, Z | 1 |
| Sylvester, R | 6 |
| da Silva, FC | 2 |
| Busch, C | 2 |
| Algaba, F | 1 |
| Collette, S | 1 |
| Bono, A | 2 |
| Maeda, T | 1 |
| Kikuchi, E | 1 |
| Matsumoto, K | 1 |
| Miyajima, A | 1 |
| Oya, M | 4 |
| Lim, KH | 1 |
| Lee, KH | 3 |
| Mansoor, M | 1 |
| Ali, S | 1 |
| Fasihuddin, Q | 1 |
| Baloch, MU | 1 |
| Hamaguchi, T | 1 |
| Shirao, K | 1 |
| Ohtsu, A | 1 |
| Hyodo, I | 1 |
| Arai, Y | 1 |
| Takiuchi, H | 1 |
| Fujii, H | 2 |
| Saito, H | 1 |
| Denda, T | 1 |
| Koizumi, W | 1 |
| Iwase, H | 1 |
| Boku, N | 1 |
| Onishi, T | 1 |
| Sasaki, T | 2 |
| Hoshina, A | 1 |
| Yabana, T | 1 |
| Carbone, A | 1 |
| Albisinni, S | 1 |
| Alpi, G | 1 |
| Cantiani, A | 1 |
| Liberti, M | 2 |
| Tubaro, A | 1 |
| Iori, F | 1 |
| Ueno, M | 1 |
| Uchiyama, K | 1 |
| Ozawa, S | 1 |
| Hayami, S | 1 |
| Shigekawa, Y | 1 |
| Tani, M | 1 |
| Yamaue, H | 2 |
| Ditta, LC | 1 |
| Shields, CL | 2 |
| Ramasubramanian, A | 1 |
| Mellen, PL | 1 |
| Shields, JA | 2 |
| Di Stasi, SM | 1 |
| Valenti, M | 3 |
| Verri, C | 1 |
| Liberati, E | 1 |
| Giurioli, A | 1 |
| Leprini, G | 1 |
| Ricci, AR | 1 |
| Micali, F | 1 |
| Vespasiani, G | 1 |
| Liauw, W | 1 |
| Serretta, V | 1 |
| Cao, M | 1 |
| Ma, CK | 1 |
| Ma, J | 1 |
| Chen, HG | 1 |
| Xue, W | 1 |
| Zhuchenko, AP | 2 |
| Kalganov, ID | 2 |
| Filon, AF | 2 |
| Khan, MA | 1 |
| Lanitis, S | 1 |
| Desai, AP | 1 |
| Rosin, RD | 1 |
| Miyayama, S | 1 |
| Yamashiro, M | 1 |
| Shibata, Y | 1 |
| Hashimoto, M | 3 |
| Tsuji, K | 1 |
| Toshima, F | 1 |
| Matsui, O | 3 |
| Jones, G | 1 |
| Wilt, TJ | 2 |
| Mason, M | 1 |
| Kynaston, HG | 1 |
| Shelley, M | 1 |
| Krane, LS | 1 |
| Kader, AK | 1 |
| Levine, EA | 1 |
| Austin, F | 1 |
| Mavanur, A | 1 |
| Sathaiah, M | 1 |
| Steel, J | 1 |
| Lenzner, D | 1 |
| Ramalingam, L | 2 |
| Holtzman, M | 1 |
| Ahrendt, S | 1 |
| Pingpank, J | 1 |
| Zeh, HJ | 2 |
| Bartlett, DL | 2 |
| Choudry, HA | 2 |
| Yu, JC | 1 |
| Kang, WM | 1 |
| Ma, ZQ | 1 |
| Likhter, MS | 1 |
| Fradet, Y | 1 |
| Bentzen, AG | 1 |
| Guren, MG | 1 |
| Wanderås, EH | 1 |
| Wilsgaard, T | 1 |
| Cutress, ML | 1 |
| Stewart, GD | 1 |
| Zakikhani, P | 1 |
| Phipps, S | 1 |
| Thomas, BG | 1 |
| Tolley, DA | 4 |
| Cho, IC | 1 |
| Kim, EK | 1 |
| Joung, JY | 1 |
| Seo, HK | 1 |
| Chung, J | 1 |
| Park, WS | 1 |
| Virzì, S | 1 |
| Iusco, DR | 1 |
| Puccio, F | 1 |
| Macrì, A | 1 |
| Famulari, C | 1 |
| Solazzo, M | 1 |
| Bonomi, S | 1 |
| Grassi, A | 1 |
| Rocchini, L | 2 |
| Suardi, N | 2 |
| Benigni, F | 2 |
| Colciago, G | 2 |
| Bettiga, A | 2 |
| Pellucchi, F | 2 |
| Maccagnano, C | 2 |
| Rigatti, P | 4 |
| Nishikawa, H | 1 |
| Osaki, Y | 1 |
| Kita, R | 1 |
| Kimura, T | 1 |
| Inuzuka, T | 1 |
| Takeda, H | 1 |
| Nakajima, J | 1 |
| Matsuda, F | 1 |
| Sakamoto, A | 1 |
| Henmi, S | 1 |
| Hatamaru, K | 1 |
| Saito, S | 1 |
| Nasu, A | 1 |
| Galor, A | 1 |
| Karp, CL | 1 |
| Oellers, P | 1 |
| Kao, AA | 1 |
| Abdelaziz, A | 1 |
| Feuer, W | 1 |
| Dubovy, SR | 1 |
| Castillo, OA | 1 |
| Landerer, E | 1 |
| Feria-Flores, M | 1 |
| Vidal-Mora, I | 1 |
| Franco, C | 1 |
| Group, TF | 1 |
| Hompes, D | 1 |
| Tiek, J | 1 |
| Wolthuis, A | 1 |
| Fieuws, S | 1 |
| Penninckx, F | 1 |
| Van Cutsem, E | 1 |
| D'Hoore, A | 1 |
| Perisanidis, C | 1 |
| Sulzbacher, I | 1 |
| Mittlböck, M | 1 |
| Mitchell, D | 1 |
| Czembirek, C | 1 |
| Seemann, R | 1 |
| Schopper, C | 1 |
| Selzer, E | 2 |
| Garg, M | 1 |
| Prakash, J | 1 |
| Lee, CT | 2 |
| Barocas, D | 1 |
| Globe, DR | 1 |
| Oefelein, MG | 1 |
| Colayco, DC | 1 |
| Bruno, A | 1 |
| O'Day, K | 1 |
| Bramley, T | 1 |
| Dewas, CV | 1 |
| Dalban, C | 1 |
| Petitfils, A | 1 |
| Peignaux, K | 1 |
| Truc, G | 1 |
| Martin, E | 1 |
| Khoury, C | 1 |
| Dewas, S | 1 |
| Klaver, YL | 1 |
| Verwaal, VJ | 1 |
| de Hingh, IH | 1 |
| Ersoy, H | 1 |
| Yaytokgil, M | 1 |
| Karakoyunlu, AN | 1 |
| Topaloglu, H | 1 |
| Sagnak, L | 1 |
| Ozok, HU | 1 |
| Dekel, Y | 1 |
| Stein, A | 1 |
| Pacelli, F | 1 |
| Sanchez, AM | 1 |
| Covino, M | 2 |
| Tortorelli, AP | 1 |
| Bossola, M | 1 |
| Valentini, V | 4 |
| Gambacorta, MA | 3 |
| Doglietto, GB | 2 |
| Baumgartner, JM | 1 |
| Ahrendt, SA | 1 |
| Pingpank, JF | 1 |
| Holtzman, MP | 1 |
| Jones, HL | 1 |
| Zureikat, AH | 1 |
| Hofheinz, RD | 2 |
| Hartung, G | 1 |
| Samel, S | 1 |
| Hochhaus, A | 2 |
| Pichlmeier, U | 4 |
| Post, S | 1 |
| Hehlmann, R | 2 |
| Queisser, W | 2 |
| Hsu, CH | 1 |
| Chen, CL | 1 |
| Hong, RL | 2 |
| Chen, KL | 1 |
| Lin, JF | 1 |
| Cheng, AL | 1 |
| Hellström, P | 1 |
| Juusela, H | 2 |
| Rajala, P | 1 |
| Korhonen, H | 2 |
| Yuen, HK | 1 |
| Yeung, EF | 1 |
| Chan, NR | 1 |
| Chi, SC | 1 |
| Lam, DS | 1 |
| Panda, A | 1 |
| Sudan, R | 2 |
| Brown, TA | 1 |
| Ridge, JA | 1 |
| Goldberg, M | 1 |
| Fu, QG | 1 |
| Meng, FD | 1 |
| Shen, XD | 1 |
| Guo, RX | 1 |
| Crinò, L | 1 |
| Rodríguez-Pérez, C | 1 |
| Del Campo, Z | 1 |
| Wolley-Dod, C | 1 |
| Gris, O | 1 |
| Jocham, D | 2 |
| Bock, PR | 1 |
| Masutani, S | 1 |
| Shimizu, J | 1 |
| Tatsuta, M | 1 |
| Katoh, H | 1 |
| Kitani, K | 1 |
| Esumi, K | 1 |
| Masuda, N | 1 |
| Imamura, H | 1 |
| Ishida, H | 1 |
| Furukawa, H | 2 |
| Onishi, H | 1 |
| Tsuda, K | 1 |
| Inoue, Y | 2 |
| Tomotsu, K | 1 |
| Usui, T | 2 |
| Hara, I | 1 |
| Miyake, H | 1 |
| Takechi, Y | 1 |
| Eto, H | 1 |
| Gotoh, A | 1 |
| Fujisawa, M | 1 |
| Okada, H | 1 |
| Arakawa, S | 1 |
| Kamidono, S | 1 |
| Santinami, M | 1 |
| Patuzzo, R | 1 |
| Pilati, PL | 1 |
| Miotto, D | 1 |
| Rossi, CR | 1 |
| Di Filippo, F | 1 |
| Amicucci, G | 2 |
| Grau, JJ | 1 |
| Martín, M | 1 |
| Fuster, J | 1 |
| Pera, M | 1 |
| García-Valdecasas, JC | 1 |
| Bombí, JA | 1 |
| Bordas, JM | 1 |
| Alcobendas, F | 2 |
| Grande, L | 1 |
| Estapé, J | 2 |
| Chang, D | 1 |
| Sugarbaker, PH | 8 |
| Vogl, TJ | 3 |
| Heller, M | 2 |
| Zangos, S | 3 |
| Schwarz, W | 1 |
| Eichler, K | 2 |
| Mack, MG | 1 |
| Berger, D | 1 |
| Balzer, JO | 2 |
| Wijkström, H | 5 |
| Malmström, PU | 5 |
| Hellsten, S | 2 |
| Duchek, M | 1 |
| Mestad, O | 1 |
| Weisser, A | 1 |
| Willer, A | 1 |
| Hausladen, DA | 1 |
| Wheeler, MA | 1 |
| Altieri, DC | 1 |
| Colberg, JW | 1 |
| Weiss, RM | 1 |
| Nashimoto, A | 1 |
| Nakajima, T | 3 |
| Kitamura, M | 2 |
| Kinoshita, T | 1 |
| Yamamura, Y | 1 |
| Sasako, M | 1 |
| Kunii, Y | 3 |
| Motohashi, H | 1 |
| Yamamoto, S | 1 |
| Tong, M | 1 |
| Yu, LZ | 1 |
| Ding, Y | 1 |
| Liu, LB | 1 |
| Pan, BN | 1 |
| Na, YQ | 1 |
| Graf, R | 1 |
| Wust, P | 2 |
| Hildebrandt, B | 1 |
| Gögler, H | 1 |
| Ullrich, R | 1 |
| Herrmann, R | 2 |
| Riess, H | 1 |
| Felix, R | 1 |
| Snyder, ME | 1 |
| Liang, H | 1 |
| Wang, P | 1 |
| Wang, XN | 1 |
| Liu, N | 1 |
| Yue, X | 1 |
| Wang, DC | 1 |
| Wang, JC | 1 |
| Hao, XS | 1 |
| Wang, H | 2 |
| Li, H | 1 |
| Zang, M | 1 |
| Xu, F | 1 |
| Deniaud-Alexandre, E | 1 |
| Tiret, E | 1 |
| Sezeur, A | 1 |
| Houry, S | 1 |
| Gallot, D | 1 |
| Parc, R | 1 |
| Huang, R | 1 |
| Qu, SH | 1 |
| Pène, F | 1 |
| Schlienger, M | 1 |
| Server Pastor, G | 1 |
| Rigabert Montiel, M | 1 |
| Bañón Pérez, V | 1 |
| Valdelvira Nadal, P | 1 |
| Cao Avellaneda, E | 1 |
| García Hernández, JA | 1 |
| Pérez Albacete, M | 1 |
| Nakamori, M | 1 |
| Iwahashi, M | 1 |
| Nakamura, M | 1 |
| Yeoh, C | 1 |
| Chau, I | 1 |
| Norman, AR | 1 |
| Hill, M | 1 |
| Ross, PJ | 1 |
| IMANAGA, H | 1 |
| IZUO, M | 2 |
| Groh, MJ | 1 |
| Holbach, LM | 1 |
| Kühnel, B | 1 |
| Conway, RM | 1 |
| Naumann, GO | 1 |
| Miyazaki, S | 1 |
| Izukura, M | 1 |
| Nisijima, J | 1 |
| Darnton, SJ | 2 |
| Archer, VR | 2 |
| Stocken, DD | 3 |
| Mulholland, PJ | 2 |
| Casson, AG | 1 |
| Ferry, DR | 2 |
| Da Pozzo, LF | 1 |
| Leib, Z | 2 |
| Caldarera, E | 1 |
| Pavone-Macaluso, M | 1 |
| Lamm, DL | 3 |
| Mok, KT | 1 |
| Wang, BW | 1 |
| Lo, GH | 1 |
| Liang, HL | 1 |
| Liu, SI | 1 |
| Chou, NH | 1 |
| Tsai, CC | 1 |
| Chen, IS | 1 |
| Yeh, MH | 1 |
| Chen, YC | 1 |
| Peyromaure, M | 1 |
| Zerbib, M | 1 |
| Chen, C | 1 |
| Louis, D | 1 |
| Dodd, T | 1 |
| Mori, T | 2 |
| Sugita, Y | 1 |
| Azama, T | 1 |
| Ishii, T | 1 |
| Taniguchi, K | 1 |
| Yamazaki, K | 1 |
| Takiguchi, S | 1 |
| Yasuda, T | 2 |
| Monden, M | 1 |
| Sakamoto, J | 2 |
| Ohashi, Y | 4 |
| Hamada, C | 2 |
| Buyse, M | 1 |
| Burzykowski, T | 1 |
| Piedbois, P | 1 |
| Shelley, MD | 1 |
| Court, J | 1 |
| Coles, B | 1 |
| Kynaston, H | 1 |
| Mason, MD | 2 |
| Gofrit, ON | 1 |
| Shapiro, A | 1 |
| Pode, D | 1 |
| Naspro, R | 1 |
| Gething, S | 1 |
| Haiba, M | 1 |
| Brun, EA | 1 |
| Müller, H | 2 |
| Nakchbandi, V | 1 |
| Peake, DR | 1 |
| Glaholm, JG | 1 |
| Wallace, DM | 1 |
| Tabata, T | 1 |
| Nishiura, K | 1 |
| Yanoh, K | 1 |
| Okugawa, T | 1 |
| Obata, H | 1 |
| Tanaka, K | 1 |
| Toyoda, N | 1 |
| Piovesan, LF | 1 |
| Salvador, J | 1 |
| Vicente, J | 1 |
| Villavicencio, H | 1 |
| Strocchi, E | 1 |
| Iaffaioli, RV | 1 |
| Facchini, G | 1 |
| Mantovani, G | 1 |
| Ricci, S | 1 |
| Cavallo, G | 1 |
| Tortoriello, A | 1 |
| D'Angelo, R | 1 |
| Formato, R | 1 |
| Rosato, G | 1 |
| Fiore, F | 1 |
| Iaccarino, V | 1 |
| Petrella, G | 1 |
| Memoli, B | 1 |
| Santangelo, M | 1 |
| Camaggi, CM | 1 |
| Cheng, SQ | 1 |
| Wu, MC | 1 |
| Shen, F | 1 |
| Yang, JH | 1 |
| Cong, WM | 1 |
| Zhao, YX | 1 |
| Wang, PJ | 1 |
| Umesaki, N | 1 |
| Fujii, T | 1 |
| Nishimura, R | 1 |
| Tanaka, T | 2 |
| Nishida, M | 1 |
| Fushiki, H | 1 |
| Takizawa, K | 2 |
| Hasegawa, K | 1 |
| Izumi, R | 3 |
| Huang, X | 1 |
| Cai, SM | 2 |
| Tang, J | 1 |
| Li, ZT | 2 |
| Zang, RY | 2 |
| Terauchi, F | 1 |
| Katayama, H | 1 |
| Yamashita, T | 1 |
| Sengoku, K | 1 |
| Ishikawa, M | 2 |
| Li, HH | 1 |
| Duan, ZH | 1 |
| Zhang, HW | 1 |
| Chen, JS | 1 |
| de Bree, E | 2 |
| Romanos, J | 1 |
| Relakis, K | 1 |
| Tsiftsis, DD | 1 |
| Wutzl, A | 1 |
| Kermer, C | 1 |
| Kornek, G | 1 |
| Glaser, C | 1 |
| Poeschl, PW | 1 |
| Chan, AK | 1 |
| Wong, A | 1 |
| Jenken, D | 1 |
| Heine, J | 1 |
| Buie, D | 1 |
| Johnson, D | 1 |
| Gibson, MK | 1 |
| Holcroft, CA | 1 |
| Kvols, LK | 1 |
| Haller, D | 1 |
| Budach, V | 2 |
| Stuschke, M | 1 |
| Budach, W | 1 |
| Baumann, M | 1 |
| Geismar, D | 1 |
| Grabenbauer, G | 1 |
| Lammert, I | 1 |
| Jahnke, K | 1 |
| Stueben, G | 1 |
| Herrmann, T | 1 |
| Bamberg, M | 1 |
| Hinkelbein, W | 1 |
| Wernecke, KD | 1 |
| Moskovitz, B | 2 |
| Meyer, G | 1 |
| Kravtzov, A | 1 |
| Gross, M | 1 |
| Kastin, A | 1 |
| Biton, K | 1 |
| Ferrigno, R | 1 |
| Nakamura, RA | 1 |
| Dos Santos Novaes, PE | 1 |
| Pellizzon, AC | 1 |
| Maia, MA | 1 |
| Fogarolli, RC | 1 |
| Salvajoli, JV | 1 |
| Filho, WJ | 1 |
| Lopes, A | 1 |
| Stewart, AB | 2 |
| Skyrme, RJ | 1 |
| French, AJ | 1 |
| Allman, R | 1 |
| Matthews, PN | 1 |
| Park, JH | 1 |
| Lee, HW | 1 |
| Baek, HJ | 1 |
| Zo, JI | 1 |
| Shim, YM | 1 |
| Alexander-Sefre, F | 1 |
| Banerjee, S | 1 |
| Sexton, R | 1 |
| Thomas, JM | 1 |
| Moran, B | 1 |
| Kurli, M | 1 |
| Finger, PT | 2 |
| Grabenbauer, GG | 4 |
| Kessler, H | 1 |
| Matzel, KE | 1 |
| Sauer, R | 6 |
| Hohenberger, W | 1 |
| Schneider, IH | 2 |
| Windschall, A | 1 |
| Ott, OJ | 1 |
| Strnad, V | 1 |
| Senior, K | 1 |
| Ge, NL | 1 |
| Ren, ZG | 1 |
| Ye, SL | 1 |
| Lin, ZY | 1 |
| Xia, JL | 1 |
| Gan, YH | 1 |
| Li, LX | 1 |
| Shen, YF | 1 |
| Tang, ZY | 1 |
| Mawdsley, S | 1 |
| Grainger, J | 1 |
| Richman, P | 1 |
| Makris, A | 1 |
| Harrison, M | 1 |
| Ashford, R | 1 |
| Harrison, RA | 1 |
| Osborne, M | 1 |
| Livingstone, JI | 1 |
| MacDonald, P | 1 |
| Mitchell, IC | 1 |
| Meyrick-Thomas, J | 1 |
| Northover, JM | 1 |
| Windsor, A | 1 |
| Novell, R | 1 |
| Wallace, M | 1 |
| McGee, WR | 1 |
| Hale, K | 1 |
| Bonacina, P | 1 |
| Butti, A | 1 |
| Cappoli, S | 1 |
| Esposito, N | 1 |
| Invernizzi, S | 1 |
| Librizzi, A | 1 |
| Locatelli, G | 1 |
| Coco, C | 2 |
| Manno, A | 1 |
| Mattana, C | 1 |
| Verbo, A | 1 |
| Cellini, N | 3 |
| Mantini, G | 1 |
| Miccichè, F | 1 |
| Pedretti, G | 1 |
| Petito, L | 1 |
| Rizzo, G | 1 |
| Cosimelli, M | 1 |
| Impiombato, FA | 1 |
| Picciocchi, A | 2 |
| Younan, R | 3 |
| Costanzo, P | 2 |
| Favaro, M | 2 |
| Gavazzi, C | 3 |
| Islam, MA | 1 |
| Bhuiyan, ZH | 1 |
| Shameem, IA | 1 |
| Mostafid, AH | 1 |
| Rajkumar, RG | 1 |
| Singh, R | 1 |
| Hejna, M | 1 |
| Wöhrer, S | 1 |
| Schmidinger, M | 1 |
| Raderer, M | 1 |
| Shintani, S | 1 |
| Hino, S | 1 |
| Nakashiro, K | 1 |
| Hamakawa, H | 1 |
| Clarke, NS | 1 |
| Basu, S | 1 |
| Prescott, S | 1 |
| Puri, R | 1 |
| Divrik, RT | 1 |
| Yildirim, U | 1 |
| Zorlu, F | 1 |
| Ozen, H | 1 |
| Yu, W | 1 |
| Hirota, T | 1 |
| Kodaira, S | 4 |
| Fechner, G | 1 |
| Pocha, K | 1 |
| Schmidt, D | 1 |
| Müller, SC | 1 |
| Kim, JC | 1 |
| Kim, HC | 1 |
| Yu, CS | 1 |
| Ha, HK | 1 |
| Lee, MG | 1 |
| Kobayashi, S | 3 |
| Oka, K | 1 |
| Machida, T | 3 |
| Ishizaka, K | 1 |
| Besarani, D | 1 |
| Al-Akraa, M | 1 |
| Ratto, C | 2 |
| Ricci, R | 1 |
| Castri, F | 1 |
| Parello, A | 1 |
| Vecchio, FM | 1 |
| van Luijk, IF | 1 |
| Coens, C | 1 |
| van der Burg, ME | 1 |
| Kobierska, A | 1 |
| Namer, M | 1 |
| Lhomme, C | 1 |
| Zola, P | 1 |
| Zanetta, G | 1 |
| Vermorken, JB | 1 |
| Chang, SW | 1 |
| Huang, ZL | 1 |
| Bosset, M | 1 |
| Lorchel, F | 1 |
| Dumas, JL | 1 |
| Mercier, M | 1 |
| Helm, CW | 1 |
| Randall-Whitis, L | 1 |
| Martin, RS | 1 |
| Metzinger, DS | 1 |
| Gordinier, ME | 1 |
| Parker, LP | 1 |
| Edwards, RP | 1 |
| Koo, DH | 1 |
| Lee, JS | 1 |
| Gårdmark, T | 1 |
| Jahnson, S | 2 |
| Wahlquist, R | 1 |
| Sugiura, M | 1 |
| Colby, KA | 1 |
| Mihm, MC | 1 |
| Zembowicz, A | 1 |
| Friedrich, MG | 2 |
| Schwaibold, H | 4 |
| Conrad, S | 2 |
| Huland, H | 9 |
| Evans, CP | 1 |
| Mathew, J | 1 |
| Asgeirsson, KS | 1 |
| Agrawal, A | 1 |
| Mukherjee, A | 1 |
| Ellis, IO | 1 |
| Cheung, KL | 2 |
| Chan, SY | 2 |
| Robertson, JF | 2 |
| Chen, YW | 1 |
| Yen, SH | 1 |
| Chen, SY | 1 |
| Huang, PI | 1 |
| Shiau, CY | 1 |
| Liu, YM | 1 |
| Lin, JK | 1 |
| Wang, LW | 1 |
| Bijelic, L | 2 |
| Yan, TD | 2 |
| Oliva, GD | 2 |
| Grosso, F | 1 |
| Hulsbergen-Van de Kaa, CA | 1 |
| Fennell, DA | 1 |
| Steele, JP | 1 |
| Shamash, J | 1 |
| Slater, SE | 1 |
| Sheaff, MT | 1 |
| Wells, P | 1 |
| Rudd, RM | 1 |
| Stebbing, J | 1 |
| Jacob, U | 2 |
| Keilhauer, R | 1 |
| Bauer, RW | 2 |
| Karam, JA | 1 |
| Ashfaq, R | 1 |
| Sagalowsky, AI | 1 |
| Antonucci, A | 1 |
| Soler-Martínez, J | 1 |
| Vozmediano-Chicharro, R | 1 |
| Morales-Jiménez, P | 1 |
| Hernández-Alcaraz, D | 1 |
| Vivas-Vargas, E | 1 |
| Santos García-Vaquero, I | 1 |
| Baena-González, V | 1 |
| Hammerstingl, RM | 1 |
| Böcher, E | 1 |
| Wanebo, HJ | 2 |
| DiSiena, M | 1 |
| Begossi, G | 1 |
| Belliveau, J | 1 |
| Gustafson, E | 1 |
| Char, DH | 1 |
| Crawford, JB | 1 |
| Isbarn, H | 1 |
| Budäus, L | 1 |
| Park, BB | 1 |
| Im, YH | 1 |
| Hwang, IG | 1 |
| Lee, SC | 1 |
| Ahn, JS | 1 |
| Ahn, MJ | 1 |
| Lim, HY | 1 |
| Kang, WK | 1 |
| Park, K | 1 |
| Strojan, P | 1 |
| Karner, K | 1 |
| Smid, L | 1 |
| Soba, E | 1 |
| Fajdiga, I | 1 |
| Jancar, B | 1 |
| Anicin, A | 1 |
| Budihna, M | 1 |
| Zakotnik, B | 1 |
| Gericke, A | 1 |
| Pitz, S | 1 |
| Strempel, I | 1 |
| Sekundo, W | 1 |
| Wan, S | 1 |
| Levine, E | 1 |
| McDonald, AC | 1 |
| Myint, S | 1 |
| Boice, CR | 1 |
| Freedman, RS | 1 |
| Herson, J | 1 |
| Wharton, JT | 2 |
| Rutledge, FN | 1 |
| Tropé, C | 1 |
| Simonsen, E | 1 |
| Johnsson, JE | 1 |
| Sigurdsson, K | 1 |
| Sekiba, K | 1 |
| Kohno, I | 1 |
| Kawagoe, K | 1 |
| Iijima, S | 1 |
| Tsunoda, H | 1 |
| Sasaki, J | 1 |
| Inaba, J | 1 |
| Veronesi, A | 1 |
| Magri, MD | 1 |
| Tirelli, U | 1 |
| Galligioni, E | 1 |
| Frustaci, S | 1 |
| Crivellari, D | 1 |
| Tumolo, S | 1 |
| Grigoletto, E | 1 |
| Budd, GT | 1 |
| Groppe, CW | 1 |
| Michaelson, RA | 1 |
| Magill, GB | 1 |
| Quan, SH | 1 |
| Leaming, RH | 1 |
| Nikrui, M | 1 |
| Stearns, MW | 1 |
| Franklin, R | 1 |
| Steiger, Z | 2 |
| Vaishampayan, G | 1 |
| Asfaw, I | 2 |
| Rosenberg, J | 1 |
| Loh, J | 1 |
| Hoschner, J | 1 |
| Miller, P | 1 |
| Flam, MS | 1 |
| John, M | 1 |
| Lovalvo, LJ | 1 |
| Mills, RJ | 1 |
| Ramalho, LD | 1 |
| Prather, C | 1 |
| Mowry, PA | 1 |
| Morgan, DR | 1 |
| Lau, BP | 1 |
| Milla, A | 1 |
| Curto, J | 1 |
| Pera, C | 1 |
| Lum, BL | 2 |
| Lockhart, JL | 1 |
| Chaikin, L | 1 |
| Bondhus, MJ | 1 |
| Politano, VA | 1 |
| Nomura, Y | 2 |
| Tashiro, H | 1 |
| Hamada, Y | 1 |
| Saeki, K | 1 |
| Devonec, M | 1 |
| Bouvier, R | 1 |
| Sarkissian, J | 1 |
| Bendimerad, O | 1 |
| Gelet, A | 1 |
| Dubernard, JM | 1 |
| Taguchi, T | 6 |
| Friedell, GH | 1 |
| Niijima, T | 2 |
| Koiso, K | 4 |
| Akaza, H | 4 |
| Harris, MA | 1 |
| Byrne, PJ | 1 |
| Smith, FP | 1 |
| Ueno, W | 1 |
| Schlesinger, C | 1 |
| Oishi, S | 1 |
| Schein, PS | 1 |
| Imaizumi, M | 2 |
| Kondo, T | 3 |
| Kamei, H | 2 |
| Ichihashi, H | 2 |
| Tenaglia, R | 1 |
| Gentile, V | 1 |
| Ikeuchi, T | 1 |
| Onodera, Y | 1 |
| Kai, Y | 1 |
| Panettiere, FJ | 1 |
| Haas, C | 1 |
| McDonald, B | 1 |
| Costanzi, JJ | 1 |
| Talley, RW | 1 |
| Athens, J | 1 |
| Oishi, N | 1 |
| Heilbrun, LK | 1 |
| Chen, TT | 1 |
| Torti, FM | 1 |
| Otto, U | 3 |
| Droese, M | 1 |
| Klöppel, G | 3 |
| Yamanaka, H | 1 |
| Kaburagi, Y | 1 |
| Imai, K | 1 |
| Miki, M | 1 |
| Tiver, KW | 1 |
| Langlands, AO | 1 |
| Duprat, G | 1 |
| Chalaoui, J | 1 |
| Sylvestre, J | 1 |
| Simard, P | 1 |
| Roy, P | 1 |
| Potvin, C | 1 |
| Cantin, J | 1 |
| Robidoux, A | 1 |
| Erdmann, WD | 1 |
| Harzmann, R | 2 |
| Flüchter, SH | 2 |
| Bichler, KH | 2 |
| Denis, L | 2 |
| Prout, GR | 2 |
| Kopp, J | 1 |
| Jakse, G | 1 |
| Matsuda, M | 2 |
| Matsumiya, K | 1 |
| Tada, Y | 2 |
| Nakano, E | 1 |
| Fujioka, H | 1 |
| Osafune, M | 1 |
| Takaha, M | 1 |
| Sonoda, T | 1 |
| Rainer, H | 1 |
| Kovats, E | 1 |
| Lehmann, HG | 1 |
| Micksche, M | 1 |
| Rauhs, R | 1 |
| Sedlacek, HH | 1 |
| Seidl, W | 1 |
| Schemper, M | 1 |
| Schiessel, R | 1 |
| Schweiger, B | 1 |
| Wunderlich, M | 1 |
| Chauvergne, J | 2 |
| Durand, M | 3 |
| Brunet, R | 1 |
| Bui, BN | 1 |
| Hoerni, B | 1 |
| Mauriac, L | 3 |
| Jacobi, GH | 1 |
| Engelmann, U | 2 |
| Frohneberg, D | 1 |
| Thüroff, JW | 1 |
| Erdmann, D | 1 |
| Rübben, H | 2 |
| Dahm, HH | 1 |
| Lutzeyer, W | 1 |
| Omoto, T | 1 |
| Kano, M | 1 |
| Ariyoshi, A | 1 |
| Momose, S | 1 |
| Masaki, Z | 1 |
| Morita, I | 1 |
| Ishisawa, N | 1 |
| Gropp, C | 1 |
| Havemann, K | 1 |
| Mishina, T | 1 |
| Watanabe, H | 2 |
| Fujiwara, T | 1 |
| Kobayashi, T | 1 |
| Maegawa, M | 1 |
| Nakao, M | 1 |
| Nakagawa, S | 2 |
| Nemoto, R | 1 |
| Kato, T | 1 |
| Mori, H | 1 |
| Chiba, R | 1 |
| Shindo, M | 1 |
| Kato, H | 1 |
| Pavlotsky, A | 2 |
| Eidelman, A | 2 |
| Barak, F | 2 |
| Walach, N | 1 |
| Horn, Y | 2 |
| Sekine, H | 4 |
| Fukui, I | 4 |
| Yamada, T | 3 |
| Kojima, S | 1 |
| Ohshima, H | 2 |
| Simonato, A | 1 |
| Zanon, M | 1 |
| Raber, M | 1 |
| Carmignani, G | 1 |
| Nishimine, K | 1 |
| Uchida, H | 1 |
| Matsuo, N | 2 |
| Sakaguchi, H | 1 |
| Hirohashi, S | 1 |
| Nishimura, Y | 1 |
| Guo, Q | 1 |
| Ohishi, H | 1 |
| Nagano, N | 1 |
| Yoshioka, T | 1 |
| Stupp, R | 1 |
| Vokes, EE | 1 |
| Zhao, LR | 1 |
| Zhao, WX | 1 |
| Shao, MH | 1 |
| Jacquet, P | 1 |
| Averbach, AM | 1 |
| Stephens, AD | 1 |
| Nakashima, K | 4 |
| Aramaki, M | 3 |
| Kawano, K | 2 |
| Yoshida, T | 3 |
| Kim, YI | 4 |
| Kitano, S | 2 |
| Kobayashi, M | 5 |
| Hanada, H | 1 |
| Umekita, N | 2 |
| Maeshiro, T | 2 |
| Miyamoto, S | 2 |
| Yamada, F | 2 |
| Awane, Y | 2 |
| Nakata, E | 1 |
| Okajima, K | 1 |
| Ishida, Y | 1 |
| Munetomo, Y | 1 |
| Gotoh, K | 1 |
| Toyohara, M | 1 |
| Miyazaki, H | 1 |
| Matsunaga, S | 1 |
| Maeura, Y | 1 |
| Fujimura, T | 1 |
| Szemes, Z | 1 |
| Kovács, R | 1 |
| Kikuchi, K | 4 |
| Smith, HO | 1 |
| Stringer, CA | 1 |
| Kavanagh, JJ | 2 |
| Gershenson, DM | 1 |
| Edwards, CL | 1 |
| Shiina, S | 1 |
| Tagawa, K | 1 |
| Niwa, Y | 1 |
| Unuma, T | 1 |
| Komatsu, Y | 1 |
| Yoshiura, K | 1 |
| Hamada, E | 1 |
| Takahashi, M | 6 |
| Shiratori, Y | 1 |
| Terano, A | 1 |
| Turk, PS | 1 |
| Belliveau, JF | 1 |
| Darnowski, JW | 1 |
| Weinberg, MC | 1 |
| Leenen, L | 1 |
| Abram, AC | 1 |
| Nabizadeh, S | 1 |
| Feldman, PS | 1 |
| Cantrell, RW | 1 |
| Levine, PA | 1 |
| Wahlen, SA | 1 |
| Slater, JD | 1 |
| Wagner, RJ | 1 |
| Wang, WA | 1 |
| Keeney, ED | 1 |
| Hocko, JM | 1 |
| King, A | 1 |
| Slater, JM | 1 |
| Kosaki, G | 3 |
| Onodera, T | 1 |
| Endo, M | 1 |
| Nakagawara, G | 1 |
| Sano, K | 1 |
| Kaibara, N | 2 |
| Kakegawa, T | 2 |
| Nakano, S | 2 |
| Kurihara, M | 2 |
| Kitamura, S | 1 |
| Ohtani, T | 1 |
| Akazawa, S | 1 |
| Takahashi, H | 1 |
| Tokunaga, K | 1 |
| Klingenberger, HJ | 2 |
| Huland, E | 3 |
| Klän, R | 1 |
| Moyano Calvo, JL | 2 |
| Herrero Torres, L | 2 |
| Melón Rey, FJ | 2 |
| Rabadán Ruiz, M | 2 |
| Pereira Sanz, I | 2 |
| Nio, Y | 1 |
| Tamura, K | 1 |
| Tsubono, M | 1 |
| Kawabata, K | 1 |
| Masai, Y | 1 |
| Hayashi, H | 1 |
| Ishigami, S | 1 |
| Araya, S | 1 |
| Imamura, M | 1 |
| Bouffioux, C | 2 |
| Kurth, KH | 3 |
| Kruger, CB | 1 |
| De Pauw, M | 2 |
| Li, JQ | 1 |
| Zhang, YQ | 1 |
| Zhang, WZ | 1 |
| Tono, T | 1 |
| Tamaki, Y | 1 |
| Yagyu, T | 1 |
| Mishima, H | 1 |
| Nakagawa, H | 2 |
| Cho, G | 1 |
| Shin, E | 1 |
| Kobayashi, K | 6 |
| Takatsuka, Y | 1 |
| Kikkawa, N | 2 |
| Nakamori, S | 1 |
| Imaoka, S | 1 |
| Nakano, H | 2 |
| Hiratsuka, M | 1 |
| Sasaki, Y | 1 |
| Kabuto, T | 1 |
| Takano, S | 1 |
| Moriguchi, M | 1 |
| Seki, N | 1 |
| Higaki, T | 1 |
| Watanabe, Y | 2 |
| Takahashi, T | 1 |
| Ito, Y | 1 |
| Oishi, H | 1 |
| Nakata, Y | 1 |
| Kono, S | 1 |
| Fujimoto, S | 4 |
| Mutou, T | 1 |
| Masaoka, H | 1 |
| Ito, M | 1 |
| Fernández Arjona, M | 1 |
| Minguez Martínez, R | 1 |
| Minervini, R | 3 |
| Felipetto, R | 3 |
| Viganò, L | 3 |
| Cecchi, M | 2 |
| Fiore, AA | 1 |
| Iorio, B | 1 |
| Vennarecci, G | 1 |
| Venditti, D | 1 |
| Cervelli, V | 1 |
| Giudiceandrea, F | 1 |
| Casciani, CU | 1 |
| Maehara, Y | 3 |
| Okuyama, T | 1 |
| Kakeji, Y | 2 |
| Baba, H | 2 |
| Furusawa, M | 2 |
| Sugimachi, K | 4 |
| Longo, WE | 1 |
| Vernava, AM | 1 |
| Wade, TP | 1 |
| Coplin, MA | 1 |
| Virgo, KS | 1 |
| Johnson, FE | 1 |
| Marchiori, L | 1 |
| Mansueto, GC | 1 |
| Nifosi, F | 1 |
| Bortolasi, L | 1 |
| Dal Dosso, I | 1 |
| Facci, E | 1 |
| Perus, G | 1 |
| Nicoli, N | 1 |
| Shimizu, K | 2 |
| Iyobe, T | 2 |
| Ii, T | 2 |
| Yagi, M | 3 |
| Nonomura, A | 1 |
| Miyazaki, I | 2 |
| Panzer, M | 1 |
| Hültenschmidt, B | 1 |
| Döker, R | 1 |
| Huber, K | 1 |
| Kuhne-Velte, HJ | 1 |
| Hutter, M | 1 |
| Rühl, U | 1 |
| Wendt, T | 1 |
| Guinda Sevillano, C | 1 |
| Arnáiz Esteban, F | 1 |
| Fernández Rosáenz, J | 1 |
| Pérez Arbej, JA | 1 |
| Martínez Pérez, E | 1 |
| Nogueras Gimeno, MA | 1 |
| Espuela Orgaz, R | 1 |
| Yamada, Y | 2 |
| Washida, H | 1 |
| Tozawa, K | 1 |
| Honma, H | 1 |
| Kang, K | 1 |
| Yasui, M | 1 |
| Nonami, T | 1 |
| Kurokawa, T | 1 |
| Nakao, A | 1 |
| Harada, A | 1 |
| Hashimoto, S | 1 |
| Kajikawa, M | 1 |
| Hiraoka, E | 1 |
| Takagi, H | 1 |
| Oi, H | 1 |
| Kim, T | 1 |
| Kishimoto, H | 1 |
| Matsushita, M | 1 |
| Tateishi, H | 1 |
| Okamura, J | 1 |
| Smith, DE | 1 |
| Shah, KH | 1 |
| Rao, AR | 1 |
| Frost, DB | 1 |
| Latino, F | 1 |
| Anderson, PJ | 1 |
| Peddada, AV | 1 |
| Kagan, AR | 1 |
| Hamazoe, R | 2 |
| Maeta, M | 2 |
| Gaboardi, F | 1 |
| Bozzola, A | 1 |
| Dotti, E | 1 |
| Galli, L | 1 |
| Pagni, G | 1 |
| Mulders, PF | 1 |
| Meyden, AP | 1 |
| Doesburg, WH | 1 |
| Oosterhof, GO | 1 |
| Debruyne, FM | 5 |
| Ohwada, F | 1 |
| Yokokawa, M | 1 |
| Llopis, M | 1 |
| Moreno, J | 1 |
| Botella, R | 1 |
| Algado, M | 1 |
| Boccardo, F | 1 |
| Cannata, D | 1 |
| Rubagotti, A | 1 |
| Guarneri, D | 1 |
| Decensi, A | 1 |
| Canobbio, L | 1 |
| Curotto, A | 1 |
| Martorana, G | 1 |
| Pegoraro, C | 1 |
| Selvaggi, F | 1 |
| Tabuchi, Y | 1 |
| Nakamura, T | 2 |
| Saitoh, Y | 1 |
| Vecchioli Scaldazza, C | 1 |
| Gall, FP | 1 |
| Regueiro López, JC | 1 |
| Alvarez-Cienfuegos, FR | 1 |
| Leva Vallejo, M | 1 |
| Prieto Castro, R | 1 |
| Merchan García, JA | 1 |
| Saceda López, JL | 1 |
| Requena Tapia, MJ | 1 |
| López-Pardo, RL | 1 |
| Gelabert-Mas, A | 1 |
| Arango Toro, O | 3 |
| Bielsa Gali, O | 3 |
| Lladó Carbonell, C | 2 |
| Suzuki, K | 4 |
| Aikawa, H | 2 |
| Endo, Y | 1 |
| Tani, T | 1 |
| Kawaguchi, A | 1 |
| Eguchi, Y | 1 |
| Sano, H | 1 |
| Kurumi, Y | 1 |
| Hanasawa, K | 1 |
| Ishibashi, H | 1 |
| Terata, N | 1 |
| Shibata, J | 1 |
| Tanum, G | 1 |
| Karlsen, KO | 1 |
| Sakai, K | 1 |
| Irie, K | 2 |
| Terasawa, T | 1 |
| Shimoyama, T | 1 |
| Iwanaga, T | 1 |
| Fukuda, I | 1 |
| Okumura, S | 1 |
| Yasutake, K | 4 |
| Brockmann, WP | 1 |
| Wiegel, T | 1 |
| Sommer, K | 1 |
| Steiner, P | 1 |
| Hübener, KH | 1 |
| Hamdy, FC | 1 |
| Hastie, KJ | 1 |
| Kerry, R | 1 |
| Williams, JL | 3 |
| Plasswilm, L | 2 |
| Yamashita, F | 1 |
| Tanaka, M | 2 |
| Satomura, S | 1 |
| Tanikawa, K | 1 |
| Macdonald, JS | 1 |
| Fleming, TR | 1 |
| Peterson, RF | 1 |
| Berenberg, JL | 1 |
| McClure, S | 1 |
| Chapman, RA | 1 |
| Eyre, HJ | 1 |
| Solanki, D | 1 |
| Cruz, AB | 1 |
| Gagliano, R | 1 |
| Lupi, G | 1 |
| Raspagliesi, F | 1 |
| Zucali, R | 1 |
| Fontanelli, R | 1 |
| Paladini, D | 1 |
| Kenda, R | 1 |
| di Re, F | 1 |
| Grigor, KM | 3 |
| Lallemand, G | 1 |
| Benyon, LL | 1 |
| Fellows, J | 1 |
| Freedman, LS | 3 |
| Hall, RR | 2 |
| Hargreave, TB | 4 |
| Munson, K | 1 |
| Newling, DW | 4 |
| Richards, B | 2 |
| Robinson, MR | 4 |
| Rose, MB | 1 |
| Smith, PH | 4 |
| Whelan, P | 3 |
| Van der Meijden, AP | 3 |
| Macaluso, MP | 1 |
| Pawinsky, A | 1 |
| Van Glabbeke, M | 1 |
| Seegenschmiedt, MH | 1 |
| Ganssauge, F | 1 |
| Nishisaki, H | 1 |
| Nakashima, T | 1 |
| Hasegawa, H | 1 |
| Horita, K | 1 |
| Yoshida, R | 1 |
| Nakanishi, Y | 1 |
| Abo, K | 1 |
| Lundholm, C | 2 |
| Norlén, BJ | 2 |
| Ekman, P | 1 |
| Lagerkvist, M | 1 |
| Lindeborg, T | 1 |
| Olsson, JL | 1 |
| Tveter, K | 1 |
| Westberg, R | 1 |
| Krege, S | 1 |
| Giani, G | 1 |
| Meyer, R | 1 |
| Otto, T | 1 |
| Pampaloni, S | 1 |
| Fiorentini, L | 1 |
| Simak, R | 1 |
| Wiener, H | 1 |
| Foeger, A | 1 |
| Susani, M | 2 |
| Zhang, ZF | 1 |
| Maier, U | 6 |
| Marberger, M | 2 |
| Tsavaris, NB | 1 |
| Tentas, K | 1 |
| Kosmidis, P | 1 |
| Mylonakis, N | 1 |
| Sakelaropoulos, N | 1 |
| Kosmas, C | 1 |
| Lisaios, B | 1 |
| Soumilas, A | 1 |
| Mandrekois, D | 1 |
| Tsetis, A | 1 |
| Klonaris, C | 1 |
| Kaneyasu, Y | 3 |
| Okawa, MK | 3 |
| Kokubo, N | 2 |
| Takemoto, M | 1 |
| Karasawa, K | 2 |
| Fukuhara, N | 2 |
| Toda, J | 2 |
| Okawa, T | 3 |
| Cummings, BJ | 2 |
| Matsui, R | 1 |
| Kashihara, K | 1 |
| Higashi, T | 1 |
| Seo, K | 1 |
| Taoka, Y | 1 |
| Yoshida, S | 2 |
| Nishitani, H | 1 |
| Takegawa, Y | 1 |
| Hukumura, Y | 1 |
| Inoue, K | 5 |
| Kasahara, K | 1 |
| Yamashita, M | 1 |
| Morioka, M | 1 |
| Fujita, Y | 2 |
| Shuin, T | 1 |
| Nohales Taurines, G | 1 |
| Cortadellas Angel, R | 1 |
| Gelabert Mas, A | 2 |
| Ojea Calvo, A | 1 |
| Domínguez Freire, F | 1 |
| Vérez Vivero, M | 1 |
| Alonso Rodrigo, A | 1 |
| Rodríguez Iglesias, B | 1 |
| Benavente Delgado, J | 1 |
| Barros Rodríguez, M | 1 |
| Nogueira March, YJ | 1 |
| Komatsu, H | 2 |
| Murakami, M | 1 |
| Yoden, E | 1 |
| Kono, K | 1 |
| Okamoto, Y | 1 |
| Maetani, Y | 1 |
| Sai, H | 1 |
| Sasaki, R | 1 |
| Kazawa, N | 1 |
| Sano, A | 1 |
| Kuroda, Y | 1 |
| Ogawa, M | 3 |
| Tomita, M | 1 |
| Cakmakli, S | 1 |
| Ersöz, S | 1 |
| Tuğ, T | 1 |
| Karaayvaz, M | 1 |
| Akgül, H | 1 |
| Tseng, SH | 1 |
| Tsai, YY | 1 |
| Chen, FK | 1 |
| Yamaguchi, Y | 1 |
| Urabe, N | 1 |
| Momiki, S | 1 |
| Obata, S | 1 |
| Ogawa, T | 2 |
| Kimura, H | 2 |
| Iop, A | 1 |
| Cartei, G | 1 |
| Vigevani, E | 1 |
| Clocchiatti, L | 1 |
| Mansutti, M | 1 |
| Sibau, AM | 1 |
| Frucht-Pery, J | 1 |
| Sugar, J | 1 |
| Baum, J | 1 |
| Pe'er, J | 1 |
| Savir, H | 1 |
| Meisler, DM | 1 |
| Foster, JA | 1 |
| Folberg, R | 1 |
| Rozenman, Y | 1 |
| Ellis, P | 1 |
| Smith, I | 1 |
| Ebbs, S | 1 |
| Baum, M | 1 |
| Sacks, N | 1 |
| McKinna, J | 1 |
| Okura, M | 1 |
| Hiranuma, T | 1 |
| Adachi, T | 1 |
| Ogura, T | 1 |
| Aikawa, T | 1 |
| Yoshioka, H | 1 |
| Hayashido, Y | 1 |
| Kogo, M | 1 |
| Matsuya, T | 1 |
| Shimizu, Y | 3 |
| Akiyama, F | 1 |
| Umezawa, S | 1 |
| Ishiya, T | 1 |
| Utsugi, K | 1 |
| Hasumi, K | 1 |
| Iwasaka, T | 1 |
| Kamura, T | 1 |
| Yokoyama, M | 1 |
| Sugimori, H | 1 |
| Ayed, M | 1 |
| Ben Hassine, L | 1 |
| Ben Slama, R | 1 |
| Chelbi, N | 1 |
| Ghozzi, S | 1 |
| Drissi, H | 1 |
| Jemni, M | 1 |
| Chebil, M | 1 |
| Chopin, DK | 1 |
| Hartmann, JT | 2 |
| Harstrick, A | 1 |
| Daikeler, T | 2 |
| Kollmannsberger, C | 2 |
| Müller, C | 1 |
| Seeber, S | 1 |
| Kanz, L | 2 |
| Solomon, LZ | 1 |
| Jennings, AM | 1 |
| Foley, SJ | 1 |
| Birch, BR | 1 |
| Cooper, AJ | 1 |
| Nabeya, Y | 1 |
| Okazaki, Y | 1 |
| Tohnosu, N | 2 |
| Yamazaki, M | 1 |
| Iizuka, H | 1 |
| Akutsu, N | 1 |
| Kono, T | 1 |
| Sato, H | 1 |
| Kubosawa, H | 1 |
| Tsukamoto, T | 1 |
| Fujioka, T | 1 |
| Yamauchi, T | 1 |
| Mori, Y | 1 |
| Nagakubo, I | 1 |
| Smith, TJ | 1 |
| Ryan, LM | 1 |
| Douglass, HO | 2 |
| Haller, DG | 1 |
| Dayal, Y | 1 |
| Kirkwood, J | 1 |
| Tormey, DC | 1 |
| Schutt, AJ | 1 |
| Hinson, J | 1 |
| Sischy, B | 1 |
| Palumbo, G | 2 |
| Cantore, M | 2 |
| Pozone, T | 1 |
| Clerico, M | 1 |
| Chaudhuri, PK | 1 |
| Smits, G | 1 |
| Schaafsma, E | 1 |
| Kiemeney, L | 1 |
| Caris, C | 1 |
| Debruyne, F | 1 |
| Akpek, EK | 1 |
| Ertoy, D | 1 |
| Kalayci, D | 1 |
| Hasiripi, H | 1 |
| Petrowsky, H | 1 |
| Heinrich, S | 1 |
| Staib-Sebler, E | 1 |
| Gog, C | 1 |
| Janshon, G | 1 |
| Lorenz, M | 1 |
| Iborra, I | 2 |
| Ricós, JV | 2 |
| Monrós, JL | 2 |
| Casanova, J | 2 |
| Dumont, R | 2 |
| Wester, K | 1 |
| Nakazato, H | 1 |
| Mauroy, B | 1 |
| Bonnal, JL | 1 |
| Prevost, B | 1 |
| Chive, M | 1 |
| Lhotellier, V | 1 |
| Sozanski, JP | 1 |
| Vanseymortier, L | 1 |
| Stefaniak, X | 1 |
| Klas, JV | 1 |
| Rothenberger, DA | 1 |
| Wong, WD | 1 |
| Madoff, RD | 1 |
| Sunamura, M | 1 |
| Egawa, S | 1 |
| Shibuya, K | 1 |
| Shimamura, H | 1 |
| Takeda, K | 1 |
| Kobari, M | 1 |
| Matsuno, S | 1 |
| Tsutsui, S | 1 |
| Murakami, S | 1 |
| Takenaka, Y | 1 |
| Ferraris, V | 2 |
| Serao, A | 1 |
| Buffa, G | 1 |
| Nakajima, Y | 1 |
| Arai, K | 1 |
| Iwasaki, Y | 1 |
| Ambiru, S | 1 |
| Miyazaki, M | 1 |
| Ito, H | 1 |
| Nakagawa, K | 1 |
| Shimizu, H | 1 |
| Nakajima, N | 1 |
| Kokufu, I | 1 |
| Taniguchi, H | 1 |
| Fukuda, K | 1 |
| Yamamoto, M | 1 |
| Yano, T | 1 |
| Yamada, K | 2 |
| Kitano, H | 1 |
| Horsell, KW | 1 |
| Merten, S | 1 |
| Clingan, P | 1 |
| King, DW | 1 |
| Cocconi, G | 1 |
| Bisagni, G | 1 |
| Ceci, G | 1 |
| Di Blasio, B | 1 |
| De Lisi, V | 1 |
| Passalacqua, R | 1 |
| Zadro, A | 1 |
| Boni, C | 1 |
| Morandi, P | 1 |
| Savoldi, L | 1 |
| Quietzsch, D | 1 |
| Mayer, F | 1 |
| Hawkins, AS | 1 |
| Yu, J | 1 |
| Hamming, NA | 1 |
| Rubenstein, JB | 1 |
| Yokomori, T | 1 |
| Iesato, H | 1 |
| Kamoshita, N | 1 |
| Nagaoka, H | 1 |
| Okabe, T | 1 |
| Kato, Y | 1 |
| Anderson, N | 1 |
| Lokich, J | 1 |
| Moore, C | 1 |
| Bern, M | 1 |
| Coco, F | 1 |
| Morganti, AG | 1 |
| De Franco, A | 1 |
| Battista Doglietto, G | 1 |
| Trodella, L | 1 |
| Ziccarelli, L | 1 |
| Kondás, J | 1 |
| Kiss, L | 1 |
| Határ, A | 1 |
| Kiss, A | 1 |
| Lukács, T | 1 |
| Szeldeli, P | 1 |
| Törzsök, F | 1 |
| Bodrogi, I | 1 |
| Huang, YH | 1 |
| Wu, JC | 1 |
| Lui, WY | 1 |
| Chau, GY | 1 |
| Tsay, SH | 1 |
| Chiang, JH | 1 |
| King, KL | 1 |
| Huo, TI | 1 |
| Chang, FY | 1 |
| Lee, SD | 1 |
| Echarti, C | 1 |
| Jurincic-Winkler, CD | 1 |
| Klippel, KF | 2 |
| Pere, AK | 1 |
| Manivit, P | 1 |
| Polo, R | 1 |
| Tabary, D | 1 |
| Nabet, M | 1 |
| Polo, M | 1 |
| Adamy, M | 1 |
| Rubini, B | 1 |
| Fromaget, JM | 1 |
| Chipponi, PN | 1 |
| Untereiner, M | 1 |
| Demirci, H | 1 |
| McCormick, SA | 1 |
| Chen, S | 1 |
| Lin, Z | 1 |
| Xu, E | 1 |
| Brady, JD | 1 |
| Assimos, DG | 1 |
| Jordan, GH | 1 |
| Zhang, ZY | 1 |
| Chen, J | 1 |
| Tang, MQ | 1 |
| Liu, Q | 1 |
| Uchida, N | 1 |
| Tsuzuki, Y | 1 |
| Ando, T | 1 |
| Mochida, Y | 1 |
| Yoshikawa, M | 1 |
| Sekihara, M | 1 |
| Ide, M | 1 |
| Ohno, Y | 1 |
| Kuwano, H | 1 |
| Focan, C | 1 |
| Bury, J | 1 |
| Beauduin, M | 1 |
| Herman, ML | 1 |
| Vindevoghel, A | 1 |
| Brohée, D | 1 |
| Lecomte, M | 1 |
| Tassinari, D | 1 |
| Arcangeli, V | 1 |
| Panzini, I | 1 |
| Sartori, S | 1 |
| Gianni, L | 1 |
| Ravaioli, A | 1 |
| Chakravarthy, A | 1 |
| Abrams, RA | 1 |
| Yeo, CJ | 1 |
| Korman, LT | 1 |
| Donehower, RC | 1 |
| Hruban, RH | 1 |
| Zahurek, ML | 1 |
| Grochow, LB | 1 |
| O'Reilly, S | 1 |
| Hurwitz, H | 1 |
| Jaffee, EM | 1 |
| Lillemoe, KD | 1 |
| Cameron, JL | 1 |
| Niinobu, T | 1 |
| Shibata, T | 1 |
| Fukushima, Y | 1 |
| Kitada, M | 1 |
| Tukahara, Y | 1 |
| Hata, S | 1 |
| Ikeda, K | 2 |
| Hayashida, H | 1 |
| Fuzita, J | 1 |
| Takahashi, Y | 1 |
| Suzuki, R | 1 |
| Shimano, T | 1 |
| Takami, M | 1 |
| Ishida, T | 2 |
| Roth, AD | 1 |
| Berney, CR | 1 |
| Rohner, S | 1 |
| Allal, AS | 1 |
| Morel, P | 1 |
| Marti, MC | 1 |
| Aapro, MS | 1 |
| Alberto, P | 1 |
| Russo, F | 1 |
| Vaglini, M | 1 |
| Neykov, K | 1 |
| Donkov, I | 1 |
| Mirchov, R | 1 |
| Witkamp, AJ | 1 |
| Kaag, MM | 1 |
| van Slooten, GW | 1 |
| van Coevorden, F | 1 |
| Zoetmulder, FA | 1 |
| Baselli, EC | 1 |
| Greenberg, RE | 1 |
| Au, JL | 1 |
| Badalament, RA | 1 |
| Wientjes, MG | 1 |
| Young, DC | 1 |
| Warner, JA | 1 |
| Venema, PL | 1 |
| Pollifrone, DL | 1 |
| Harbrecht, JD | 1 |
| Chin, JL | 1 |
| Miles, BJ | 1 |
| Paridaens, D | 1 |
| Beekhuis, H | 1 |
| van Den Bosch, W | 1 |
| Remeyer, L | 1 |
| Melles, G | 1 |
| Elias, D | 1 |
| Blot, F | 1 |
| El Otmany, A | 1 |
| Antoun, S | 1 |
| Lasser, P | 1 |
| Boige, V | 1 |
| Rougier, P | 1 |
| Ducreux, M | 1 |
| Cartsburg, O | 2 |
| Kersten, A | 1 |
| Sundmacher, R | 2 |
| Nadjari, B | 1 |
| Pomjanski, N | 2 |
| Böcking, A | 2 |
| Huncharek, M | 1 |
| Kupelnick, B | 1 |
| Ohya, K | 1 |
| Kojima, SI | 1 |
| Igarashi, K | 1 |
| Kim, JY | 1 |
| Bae, HS | 1 |
| Tan, SM | 1 |
| Willsher, PC | 1 |
| Blamey, RW | 1 |
| Ting, LL | 1 |
| Ko, JY | 1 |
| Hsu, MM | 1 |
| Sheen, TS | 1 |
| Lou, PJ | 1 |
| Wang, CC | 1 |
| Chung, NN | 1 |
| Lui, LT | 1 |
| Bono, AV | 1 |
| Mack, D | 1 |
| Hall, R | 1 |
| de Balincourt, C | 1 |
| Brausi, M | 1 |
| Zang, Z | 1 |
| Xu, H | 1 |
| Yu, L | 1 |
| Yang, D | 2 |
| Xie, S | 1 |
| Li, Z | 1 |
| Li, J | 1 |
| Li, M | 1 |
| Guo, Y | 1 |
| Gu, F | 1 |
| Dunst, J | 2 |
| Haensgen, G | 1 |
| Seitz, JF | 2 |
| Duffaud, F | 1 |
| Dahan, L | 1 |
| Ries, P | 1 |
| Ville, E | 1 |
| Laugier, R | 1 |
| Harnett, AN | 1 |
| Chatterjee, S | 1 |
| Siganos, CS | 1 |
| Kozobolis, VP | 1 |
| Christodoulakis, EV | 1 |
| Ohmura, T | 1 |
| Suzuki, H | 2 |
| Shirasawa, H | 1 |
| Manziuk, LV | 1 |
| Artamonova, EV | 1 |
| Sholokhov, VN | 1 |
| Strygina, EA | 1 |
| Li, S | 1 |
| Liu, S | 1 |
| Han, W | 1 |
| Hao, J | 1 |
| Khokhar, S | 1 |
| Soni, A | 1 |
| SinghSethi, H | 1 |
| Sony, P | 1 |
| Pangtey, MS | 1 |
| Daniell, M | 1 |
| Maini, R | 1 |
| Tole, D | 1 |
| Kallen, C | 1 |
| Hillenkamp, J | 1 |
| Hagiwara, A | 1 |
| Wang, W | 1 |
| Su, G | 1 |
| Qi, X | 1 |
| Ma, D | 1 |
| Fan, Y | 1 |
| Naseripour, M | 1 |
| Butterworth, SA | 1 |
| Panton, ON | 1 |
| Klaassen, DJ | 1 |
| Shah, AM | 1 |
| McGregor, GI | 1 |
| Morgia, G | 1 |
| Mauceri, G | 1 |
| Mazzone, G | 1 |
| Motta, M | 1 |
| Yoshida, O | 1 |
| Kakehi, Y | 1 |
| Nishio, Y | 1 |
| Tomoyoshi, T | 1 |
| Konami, T | 1 |
| Igawa, M | 1 |
| Takenaka, I | 1 |
| Fujita, K | 1 |
| Fuse, H | 1 |
| Sakai, T | 1 |
| Katayama, T | 1 |
| Wang, SH | 1 |
| Witjes, WP | 1 |
| van der Meijden, PM | 2 |
| Roos, EP | 1 |
| Steerenberg, PA | 3 |
| Doesburg, W | 2 |
| Okada, K | 1 |
| Iwao, Y | 1 |
| Kiriyama, M | 1 |
| Iwasa, K | 1 |
| Masutani, H | 1 |
| Stockler, M | 1 |
| Raghavan, D | 1 |
| McCaughan, BC | 1 |
| Grygiel, J | 1 |
| McNeil, E | 1 |
| Gianoutsos, P | 1 |
| Murata, M | 1 |
| Takagi, S | 1 |
| Seki, M | 1 |
| Tezuka, T | 1 |
| Shinohara, K | 1 |
| Miura, T | 2 |
| Kotake, T | 2 |
| Matsumura, Y | 5 |
| Isaka, S | 3 |
| Obata, K | 2 |
| Ohe, H | 2 |
| Ohi, Y | 1 |
| Kihara, K | 1 |
| Tachibana, Y | 1 |
| Kawai, T | 2 |
| Ishiwata, D | 1 |
| Oshima, H | 1 |
| Okano, T | 1 |
| Abe, K | 1 |
| Shimazaki, J | 1 |
| Uekado, Y | 1 |
| Hirano, A | 1 |
| Shinka, T | 1 |
| Ohkawa, T | 1 |
| Tsushima, T | 3 |
| Nasu, Y | 2 |
| Abeki, N | 1 |
| Noda, M | 1 |
| Saika, T | 1 |
| Ohmori, H | 3 |
| Kobashi, K | 1 |
| Ozaki, Y | 3 |
| Tanahashi, T | 1 |
| Busemann, E | 1 |
| Gerdes, J | 1 |
| Ulmer, AJ | 1 |
| Flad, HD | 1 |
| Klimberg, VS | 1 |
| Langston, JD | 1 |
| Maners, A | 1 |
| Gocio, JC | 1 |
| Hutchins, LF | 1 |
| Lang, NP | 1 |
| Westbrook, KC | 1 |
| Broadwater, JR | 1 |
| Giovannini, M | 1 |
| Sfedj, D | 1 |
| Houvenaeghel, G | 1 |
| Delpero, JR | 1 |
| Dilhuydy, JM | 2 |
| Bonichon, F | 1 |
| Höbarth, K | 2 |
| Wu, JJ | 1 |
| Yin, ZL | 1 |
| Zhu, JN | 1 |
| Okuyama, K | 1 |
| Awano, T | 1 |
| Koide, Y | 1 |
| Matsubara, H | 1 |
| Nakaichi, H | 1 |
| Funami, Y | 1 |
| Matsushita, K | 3 |
| Amano, H | 1 |
| Ochiai, T | 1 |
| Matsumine, T | 1 |
| Murayama, Y | 1 |
| Sano, M | 1 |
| Katai, H | 1 |
| Maeda, K | 1 |
| Sakai, S | 1 |
| Koh, J | 1 |
| Yamamoto, O | 1 |
| Hosoda, Y | 1 |
| Dobrowsky, W | 4 |
| Covens, A | 1 |
| O'Connell, G | 1 |
| Rusthoven, J | 1 |
| Mazurka, J | 1 |
| Ferrito, F | 1 |
| Brandão, T | 1 |
| Santos, A | 1 |
| Takeda, M | 1 |
| Mizuguchi, N | 1 |
| Ohyama, Y | 1 |
| Suzuki, S | 1 |
| Itoh, M | 1 |
| Mukojima, T | 1 |
| Kumagai, T | 1 |
| Iwasaki, H | 1 |
| Katsumata, T | 1 |
| Fukai, S | 1 |
| Utsunomiya, T | 1 |
| Tanaka, S | 1 |
| Takashima, T | 1 |
| Shizumi, Y | 2 |
| Nishigaki, H | 1 |
| Horiike, S | 1 |
| Taniwaki, M | 1 |
| Misawa, S | 1 |
| Kashima, K | 1 |
| Hironaka, T | 1 |
| Sato, Y | 1 |
| Tohma, H | 1 |
| Shikama, T | 1 |
| Ichinose, Y | 1 |
| Hara, N | 1 |
| Ohta, M | 2 |
| Motohiro, A | 1 |
| Kuda, T | 1 |
| Aso, H | 1 |
| Hoffman, MS | 1 |
| Roberts, WS | 1 |
| LaPolla, JP | 1 |
| Fiorica, JV | 1 |
| Hewitt, S | 1 |
| Cavanagh, D | 1 |
| Nakayama, K | 1 |
| Seimiya, Y | 1 |
| Yamakawa, Y | 1 |
| Koi, S | 1 |
| Yokosuka, K | 1 |
| Teshima, H | 1 |
| Chen, JT | 1 |
| Fujimoto, I | 1 |
| Yamauchi, K | 1 |
| Miyanaga, N | 1 |
| Jauhiainen, K | 4 |
| Alfthan, O | 4 |
| Hansson, E | 1 |
| Kanerva, K | 1 |
| Permi, J | 1 |
| Sotarauta, M | 1 |
| Vaalasti, T | 1 |
| Hörbarth, K | 1 |
| Gustafson, H | 1 |
| Nyman, C | 1 |
| Brolin, J | 1 |
| Borgström, E | 1 |
| Tribukait, B | 1 |
| Vesa Llanes, J | 1 |
| Corominas, J | 1 |
| Megias Garrigós, J | 1 |
| Pelluch Auladell, A | 1 |
| Romero Pérez, P | 1 |
| Fernandez García, J | 1 |
| Gassó Matoses, M | 1 |
| Sánchez Marcos, M | 1 |
| Mira Llinarés, A | 1 |
| Lev, A | 1 |
| Nakoa, N | 1 |
| Kamino, K | 1 |
| Miura, K | 2 |
| Hayashi, T | 1 |
| Ohnishi, M | 1 |
| Takayasu, Y | 1 |
| Okamoto, E | 1 |
| Dobrowsky, E | 2 |
| Strassl, H | 2 |
| Braun, O | 1 |
| Gritzmann, N | 1 |
| Scheiber, V | 1 |
| Calabuig, C | 1 |
| Nigro, ND | 1 |
| Yabusaki, N | 1 |
| Tago, K | 1 |
| Ueno, A | 1 |
| Takai, M | 2 |
| Ohno, K | 1 |
| Endoh, F | 2 |
| Masuda, Y | 4 |
| Obata, G | 2 |
| Kokubun, M | 2 |
| Moriya, Y | 3 |
| Sugihara, K | 3 |
| Hojo, K | 2 |
| Makuuchi, M | 1 |
| Tsujitani, S | 1 |
| Watanabe, A | 1 |
| Tomoda, H | 1 |
| Wong, CS | 1 |
| Keane, TJ | 1 |
| O'Sullivan, B | 1 |
| Catton, CN | 1 |
| Avril, A | 1 |
| Stricker, PD | 1 |
| Grant, AB | 1 |
| Hosken, BM | 1 |
| Taylor, JS | 1 |
| Månsson, W | 1 |
| Henrikson, H | 1 |
| Idwall, I | 1 |
| Lindholm, K | 1 |
| Mikulowski, P | 1 |
| Mårtensson, S | 1 |
| Oldbring, J | 1 |
| Niimoto, M | 1 |
| Saeki, T | 1 |
| Toi, M | 1 |
| Nishiyama, M | 1 |
| Hirai, T | 2 |
| Yanagawa, E | 1 |
| Hattori, T | 3 |
| Harder, F | 1 |
| Laffer, U | 1 |
| Berres, M | 1 |
| Jäggi, P | 1 |
| Metzger, U | 1 |
| Feddersen, I | 2 |
| Brachmann, W | 2 |
| Hubmann, H | 2 |
| Kaufmann, J | 2 |
| Knipper, W | 2 |
| Lantzius-Beninga, F | 2 |
| Yuri, Y | 1 |
| Tsukada, T | 1 |
| Andrysek, O | 1 |
| Horák, J | 1 |
| Vítek, P | 1 |
| Yasumoto, R | 1 |
| Asakawa, M | 1 |
| Yoshihara, H | 1 |
| Sakamoto, W | 1 |
| Iseki, T | 1 |
| Nakatani, T | 1 |
| Wada, S | 1 |
| Kishimoto, T | 1 |
| Maekawa, M | 1 |
| Nishio, S | 1 |
| Schneider, A | 1 |
| Arndt, R | 1 |
| Oohno, K | 1 |
| Kobayashi, N | 1 |
| Tanaka, H | 1 |
| Ota, J | 1 |
| Fujita, M | 1 |
| Sugimoto, T | 1 |
| Sakamoto, Y | 1 |
| Kawano, N | 1 |
| Houjo, K | 1 |
| O'Brien, ME | 1 |
| Bayliss, EJ | 1 |
| Stewart, ME | 1 |
| Smyth, JF | 1 |
| Rodger, A | 1 |
| Leonard, RC | 1 |
| Auther, C | 1 |
| Mori, S | 1 |
| Nishihira, T | 1 |
| Matsumoto, T | 1 |
| Kawachi, S | 1 |
| Yamaguchi, S | 1 |
| Komoriyama, H | 1 |
| Tsukikawa, S | 1 |
| Imaki, S | 1 |
| Morikubo, M | 1 |
| Asakura, T | 1 |
| Okamura, R | 1 |
| Fukuda, M | 1 |
| Kanasugi, K | 1 |
| Ruutu, M | 1 |
| Imamura, Y | 2 |
| Yoshimura, Y | 2 |
| Tokisue, M | 1 |
| Ohno, S | 1 |
| Masuda, T | 1 |
| Meanwell, CA | 1 |
| Luesley, DM | 1 |
| Blackledge, G | 1 |
| Mould, JJ | 1 |
| Chan, KK | 1 |
| Perren, TJ | 1 |
| Lawton, FG | 1 |
| Uchida, T | 1 |
| Honda, N | 1 |
| Arakawa, T | 1 |
| Omata, T | 1 |
| Endo, T | 1 |
| Ishibashi, A | 1 |
| Koshiba, K | 1 |
| Hadjissotiriou, GG | 1 |
| Green, DK | 1 |
| McIntyre, MA | 1 |
| Chisholm, GD | 1 |
| Giannone, L | 1 |
| Brenner, DE | 1 |
| Jones, HW | 1 |
| Greco, FA | 1 |
| Burnett, LS | 1 |
| Leichman, L | 1 |
| Herskovic, A | 1 |
| Leichman, CG | 1 |
| Lattin, PB | 1 |
| Tapazoglou, E | 1 |
| Rosenberg, JC | 1 |
| Arbulu, A | 1 |
| Kinzie, J | 1 |
| Stewart, DJ | 1 |
| Grahovac, Z | 1 |
| Hugenholtz, H | 1 |
| Russell, NA | 1 |
| Richard, MT | 1 |
| Benoit, BG | 1 |
| Riding, MD | 1 |
| Danjoux, C | 1 |
| Maroun, JA | 1 |
| Yokoyama, T | 1 |
| Hiura, M | 1 |
| Kaneko, H | 1 |
| Yorishima, M | 1 |
| Chiba, T | 1 |
| Lele, SB | 1 |
| Piver, MS | 1 |
| Suyama, Y | 1 |
| Kitagawa, Y | 1 |
| Horishi, M | 1 |
| Yashige, H | 1 |
| Miyoshi, M | 1 |
| Mieno, K | 1 |
| Takeda, Y | 2 |
| Satoi, Y | 1 |
| Amino, K | 1 |
| Miura, S | 1 |
| Shikata, J | 1 |
| Lahousen, M | 1 |
| Haas, H | 1 |
| Pickel, H | 1 |
| Russell, KJ | 1 |
| Koh, WJ | 1 |
| Russell, AH | 1 |
| Griffin, BR | 1 |
| Markette, KL | 1 |
| Tong, DY | 1 |
| Griffin, TW | 1 |
| Redman, C | 1 |
| Lawton, F | 1 |
| Stuart, N | 1 |
| O'Brien, M | 1 |
| Buxton, J | 1 |
| Mould, J | 1 |
| Chetiyawardana, A | 1 |
| Crawford, M | 1 |
| Patterson, M | 1 |
| Sykes, V | 1 |
| Braun, OM | 1 |
| Neumeister, B | 1 |
| Popp, W | 1 |
| Scherrer, R | 1 |
| Rausch, EM | 1 |
| Krisch, K | 1 |
| Holzner, JH | 2 |
| Baumgartner, G | 1 |
| Aoki, Y | 1 |
| Tabuse, Y | 1 |
| Tanimura, H | 1 |
| Katsumi, M | 1 |
| Asae, M | 1 |
| Ichimiya, G | 1 |
| Imai, T | 1 |
| Ooshima, K | 1 |
| Kakihara, M | 1 |
| Kashitani, M | 1 |
| Giesbers, AA | 1 |
| Van Helsdingen, PJ | 1 |
| Kramer, AE | 1 |
| Okamura, T | 1 |
| Korenaga, D | 1 |
| Saito, A | 1 |
| Inokuchi, K | 2 |
| Kondou, T | 1 |
| Abe, O | 2 |
| Tanabe, T | 1 |
| Ogawa, N | 2 |
| Alon, H | 1 |
| Kim, HH | 1 |
| Lee, C | 1 |
| Shrestha, RD | 1 |
| Kiuchi, S | 1 |
| Konno, C | 1 |
| Koike, S | 1 |
| Kitsukawa, Y | 1 |
| Hozumi, T | 1 |
| Katou, J | 1 |
| Okutani, T | 1 |
| Habr-Gama, A | 1 |
| da Silva e Sousa Júnior, AH | 1 |
| Nadalin, W | 1 |
| Gansl, R | 1 |
| da Silva, JH | 1 |
| Pinotti, HW | 1 |
| Thomas, G | 1 |
| Dembo, A | 1 |
| DePetrillo, A | 1 |
| Pringle, J | 1 |
| Ackerman, I | 1 |
| Bryson, P | 1 |
| Balogh, J | 1 |
| Osborne, R | 1 |
| Rosen, B | 1 |
| Fyles, A | 1 |
| Jordan, AM | 1 |
| Murphy, WM | 2 |
| de Jong, WH | 2 |
| Franssen, MP | 2 |
| Sawada, T | 1 |
| Senapad, S | 1 |
| Neungton, S | 1 |
| Usavajindawath, C | 1 |
| Vijatrasil, S | 1 |
| Thaithanaisawanya, V | 1 |
| Malviya, VK | 1 |
| Deppe, G | 1 |
| Schoenmaker, M | 1 |
| Komi, N | 1 |
| Uchino, J | 1 |
| Wolf, N | 1 |
| Shimizu, T | 1 |
| Fujimori, M | 2 |
| Takahashi, S | 1 |
| Komatsu, M | 1 |
| Masuda, H | 1 |
| Sugenoya, A | 1 |
| Senga, O | 2 |
| Iida, F | 2 |
| Tada, I | 1 |
| Mitarai, Y | 1 |
| Horikoshi, N | 2 |
| Mukaiyama, T | 1 |
| Kuraishi, Y | 1 |
| Sato, M | 2 |
| Terashima, M | 1 |
| Takagane, A | 1 |
| Saito, K | 1 |
| Odaka, Y | 1 |
| Oikawa, K | 1 |
| Hetherington, JW | 2 |
| Iino, Y | 1 |
| Yokoe, T | 1 |
| Ohyama, S | 1 |
| Yonemura, Y | 1 |
| Matsuki, N | 1 |
| Miyata, R | 1 |
| Noto, H | 1 |
| Sakuma, H | 1 |
| Sawa, T | 1 |
| Ogino, S | 1 |
| Miyazaka, I | 1 |
| Harima, Y | 1 |
| Shiraishi, T | 1 |
| Murata, T | 1 |
| Harima, K | 1 |
| Sawada, S | 1 |
| Eagan, RT | 1 |
| Frytak, S | 1 |
| Richardson, RL | 1 |
| Creagan, ET | 1 |
| Nichols, WC | 1 |
| Mobley, WC | 1 |
| Loening, SA | 1 |
| Narayana, AS | 1 |
| Culp, DA | 1 |
| Cant, JD | 1 |
| Flanigan, RC | 1 |
| Ellison, MF | 1 |
| Butler, KM | 1 |
| Gomella, LG | 1 |
| McRoberts, JW | 1 |
| Yokozawa, T | 1 |
| Hanamura, N | 1 |
| Terai, N | 1 |
| Kaneko, G | 1 |
| Kasuga, Y | 1 |
| Ueda, H | 1 |
| Yano, K | 1 |
| Estes, NC | 1 |
| Morphis, JG | 1 |
| Hornback, NB | 1 |
| Jewell, WR | 1 |
| Akagi, T | 1 |
| Obama, T | 1 |
| Levin, DR | 1 |
| Kikuchi, S | 1 |
| Adib, RS | 1 |
| Secco, GB | 1 |
| Sertoli, MR | 1 |
| Scarpati, D | 1 |
| Marino, G | 1 |
| Fardelli, R | 1 |
| Nobile, MT | 1 |
| Corvò, R | 1 |
| Erlichman, C | 1 |
| Rauth, AM | 1 |
| Battistella, R | 1 |
| Fine, S | 1 |
| Flechtner, H | 1 |
| Heim, ME | 1 |
| Henss, H | 1 |
| Arnold, H | 1 |
| Fritze, D | 1 |
| Fritsch, H | 1 |
| Fritz, M | 1 |
| Trux, FA | 1 |
| Ino, Y | 1 |
| Isono, T | 1 |
| Iguchi, T | 1 |
| Thomas, GM | 1 |
| Dembo, AJ | 1 |
| Black, B | 1 |
| Bean, HA | 1 |
| Beale, FA | 1 |
| Pringle, JR | 1 |
| Rawlings, G | 1 |
| Depetrillo, D | 1 |
| Sakuyama, T | 1 |
| Kimura, A | 1 |
| Yanagisawa, S | 1 |
| Soji, K | 1 |
| Hano, H | 1 |
| Takahashi, N | 1 |
| Nagao, F | 1 |
| Tanemura, H | 1 |
| Saji, S | 1 |
| Takao, H | 1 |
| Kida, H | 1 |
| Kunieda, K | 1 |
| Miya, K | 1 |
| Azuma, S | 1 |
| Furuta, T | 1 |
| Sakata, K | 1 |
| Shimokawa, K | 1 |
| Yoshimoto, J | 1 |
| Hirao, Y | 1 |
| Okajima, E | 1 |
| Ohara, S | 1 |
| Ozono, S | 1 |
| Hiramatsu, T | 1 |
| Yoshida, K | 1 |
| Aoyama, H | 1 |
| Watanabe, S | 1 |
| Maru, A | 1 |
| Smith, AY | 1 |
| Vitale, PJ | 1 |
| Lowe, BA | 1 |
| Woodside, JR | 1 |
| Alter, AJ | 1 |
| Malek, GH | 1 |
| Koga, S | 1 |
| Shimizu, N | 1 |
| Murakami, A | 1 |
| Wakatsuki, T | 1 |
| Brickner, TJ | 1 |
| Gilbertson, GF | 1 |
| Stone, WC | 1 |
| Jurincic, CD | 1 |
| Gasch, J | 1 |
| Schreinemachers, LM | 1 |
| Geboers, AD | 1 |
| van Leeuwen, MJ | 1 |
| Ruitenberg, EJ | 1 |
| Egghart, G | 1 |
| Steegmüller, O | 1 |
| Wenderoth, U | 1 |
| Hautmann, R | 1 |
| Uscinska, BM | 1 |
| Schwarzman, MI | 1 |
| Johanson, KE | 1 |
| Surya, B | 1 |
| Brown, J | 1 |
| Werner, A | 1 |
| Diedrich, K | 1 |
| Krebs, D | 1 |
| Bode, U | 1 |
| Musch, E | 1 |
| Fourcade, RO | 1 |
| Giuliano, F | 1 |
| Buzdar, AU | 1 |
| Marcus, C | 1 |
| Smith, TL | 1 |
| Blumenschein, GR | 1 |
| Tseng, MH | 1 |
| Park, HC | 1 |
| Keuppens, F | 1 |
| Hendrickx, G | 1 |
| Cooper, EH | 1 |
| Yu, H | 1 |
| Glashan, RW | 1 |
| de Wall, JG | 1 |
| van Oosterom, AT | 1 |
| de Jong, EA | 1 |
| Tjaden, UR | 1 |
| Zincke, H | 1 |
| Benson, RC | 1 |
| Hilton, JF | 1 |
| Taylor, WF | 1 |
| Somerville, JJ | 1 |
| Inagaki, J | 1 |
| Usui, N | 1 |
| Nakada, H | 1 |
| Adachi, K | 1 |
| Yamazaki, H | 1 |
| Tada, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2b, Single-Arm, Multicenter Trial to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) at Intermediate Risk of Recurrence[NCT03558503] | Phase 2 | 63 participants (Actual) | Interventional | 2018-10-15 | Completed | ||
| Neoadjuvant Short-term Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in NMIBC[NCT03348969] | Phase 4 | 120 participants (Actual) | Interventional | 2017-11-01 | Active, not recruiting | ||
| Multicenter Randomized Controlled Phase III Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy[NCT03700905] | Phase 3 | 276 participants (Anticipated) | Interventional | 2018-08-21 | Active, not recruiting | ||
| A Randomized Phase II Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer[NCT00192049] | Phase 2 | 90 participants | Interventional | 2003-12-31 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled Phase 3 Multicenter Study of Immediate Postoperative Instillation of Gemcitabine in Patients With Superficial Transitional Cell Carcinoma of the Bladder[NCT00191477] | Phase 3 | 355 participants (Actual) | Interventional | 2004-01-31 | Terminated (stopped due to The study was stopped early for futility reasons.) | ||
| A Prospective, Open-label Randomized Clinical Trial of a Single Bladder Instillation of Mitomycin C vs. Gemcitabine vs. No Additional Treatment Immediately After Transurethral Resection of Bladder Tumor (TURBT)[NCT02695771] | Phase 3 | 101 participants (Actual) | Interventional | 2016-04-19 | Completed | ||
| Effect of Intravesical B.C.G and Gemcitabine on Semen Quality and Testicular Volume in Patients With Non-muscle Invasive Bladder Cancer Patients[NCT05701332] | Phase 4 | 25 participants (Anticipated) | Interventional | 2023-04-01 | Not yet recruiting | ||
| A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions[NCT04172675] | Phase 2 | 107 participants (Actual) | Interventional | 2020-02-28 | Active, not recruiting | ||
| Observational Study on Second Line Treatment of Colorectal Liver Metastases (KRas wt) by Hepatic Intra-arterial Chemoembolization With Dc Beads 70-150 μm Microspheres Preloaded With Irinotecan 200 Mgr Plus Systemic Cetuximab[NCT01891552] | 40 participants (Actual) | Observational [Patient Registry] | 2013-05-31 | Completed | |||
| HYMN: A Randomized Controlled Phase III Trial Comparing Hyperthermia Plus Mitomycin to a Second Course of Bacillus Calmette-Guerin or Standard Therapy in Patients With Recurrence of Non-Muscle Invasive Bladder Cancer Following Induction or Maintenance Bac[NCT01094964] | Phase 3 | 242 participants (Anticipated) | Interventional | 2009-10-31 | Recruiting | ||
| A Randomized Phase II Study of the Administration of Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy for Patients With Squamous Cell Carcinoma of the Anal Canal (BISQUIT)[NCT03870607] | Phase 2 | 75 participants (Anticipated) | Interventional | 2019-03-13 | Recruiting | ||
| Study of the Association Between Tumor Microenvironment Macrophages and Treatment Response in Squamous Cell Carcinoma of the Anal Canal[NCT05019235] | 154 participants (Actual) | Observational | 2021-08-05 | Active, not recruiting | |||
| Tumor Recurrence After Abdominal-perineal Amputation in Squamous Cell Carcinoma of the Anus[NCT05201105] | 43 participants (Actual) | Observational | 2021-10-15 | Completed | |||
| Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced Anal Canal Squamous Carcinoma Patients[NCT05060471] | Phase 2 | 27 participants (Anticipated) | Interventional | 2021-09-08 | Enrolling by invitation | ||
| A Phase 3, Multicenter, Double-Blind Randomized Study of Mitomycin, 5-Fluorouracil and IMRT Combined With or Without Anti-PD-1 in Patients With Locally Advanced Anal Canal Squamous Carcinoma[NCT05374252] | Phase 3 | 102 participants (Anticipated) | Interventional | 2022-05-07 | Recruiting | ||
| Phase II Trial of Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology[NCT03092518] | Phase 2 | 27 participants (Actual) | Interventional | 2017-06-05 | Active, not recruiting | ||
| Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase 3, Multicentre, Randomised Controlled Trial (CAN)[NCT02958111] | Phase 3 | 406 participants (Actual) | Interventional | 2017-01-31 | Active, not recruiting | ||
| Randomized, Placebo-controlled, Double-blind Phase II Clinical Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Immunotherapy Combined With Concurrent Chemoradiotherapy for High-risk Nasopharyngeal Carcinoma[NCT03925090] | Phase 2 | 150 participants (Anticipated) | Interventional | 2019-12-08 | Active, not recruiting | ||
| Phase Ⅲ Trial of Concurrent Chemoradiotherapy Followed by Adjuvant Chemotherapy (GP Versus PF) in Patients With N2-3 Nasopharyngeal Carcinoma[NCT03321539] | Phase 3 | 216 participants (Anticipated) | Interventional | 2017-10-30 | Active, not recruiting | ||
| The Effects of Sequential Mitomycin and Bacillus Calmette-Guérin Treatment Versus Bacillus Calmette-Guérin Monotherapy in Patients With High Risk Non-Muscle Invasive Bladder Cancer[NCT03790384] | Phase 4 | 140 participants (Anticipated) | Interventional | 2019-01-15 | Not yet recruiting | ||
| Intravesical Instillation Therapy With Bacillus Calmette-Guérin (BCG) and Sequential BCG and Electromotive Mitomycin-C (EMDA-MCC) in Patients With High-risk Non-muscle-invasive Bladder Carcinoma[NCT03664869] | Phase 3 | 300 participants (Anticipated) | Interventional | 2018-10-26 | Recruiting | ||
| Prospective Cohort Study of Transurethral Resection of Bladder Tumor (TURBT) Combined With Adjuvant Intravenous GC Chemotherapy to Prevent Moderate-high Recurrence and Progression Risks of Muscle-invasive Bladder Cancer[NCT02716961] | 208 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | |||
| An Adaptive, Randomized Phase II Trial to Determine Pathologic Complete Response With the Addition of Carboplatin With and Without Veliparib to Standard Chemotherapy in the Neoadjuvant Treatment of Triple-Negative Breast Cancer[NCT01818063] | Phase 2 | 9 participants (Actual) | Interventional | 2013-04-25 | Completed | ||
| A Randomized Phase II Trial of Sequential Chemo-Immunotherapy Versus Immunotherapy Alone in Carcinoma in Situ of the Urinary Bladder[NCT00023842] | Phase 2 | 97 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| Intravesically Heated Thermo-chemotherapy With Mitomycin-C Prior to TURBT- Prospective Controlled Study[NCT02471547] | 300 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | |||
| Single Preoperative Intravesical Instillation of Electromotive Mitomycin-c for Primary Non-muscle Invasive Bladder Cancer: a Prospective Randomized Trial.[NCT01149174] | Phase 3 | 352 participants (Actual) | Interventional | 1994-01-31 | Completed | ||
| Intravesical Electromotive Mitomycin for High Risk Urothelial Non-muscle Invasive Bladder Cancer After Intravesical Bacillus Calmette-Guérin Failure[NCT04311580] | Phase 2 | 52 participants (Actual) | Interventional | 2000-01-01 | Completed | ||
| Comparative Study on the Efficacy of Mitomycin and Lobaplatin in the Treatment of Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy[NCT04845490] | Phase 2 | 201 participants (Anticipated) | Interventional | 2022-09-01 | Not yet recruiting | ||
| Prospective Observational Study on Isolated Limb Perfusion of Melphalan in Treating Patients With Metastasis or Recidivism of Limb Melanoma or Sarcoma That Are Not Operable[NCT01920516] | 40 participants (Anticipated) | Observational | 2013-07-31 | Recruiting | |||
| Intravesical Mitomycin-C With Bladder Wall Hyperthermia in Intermediate and High Risk Non-muscle Invasive Bladder Cancer[NCT03694535] | 44 participants (Actual) | Interventional | 2012-01-01 | Completed | |||
| The Clinical Randomized Trial of Adjuvant Transarterial Chemo Embolization (TACE) to Reduce the Recurrence in Hepatocellular Carcinoma (HCC) Patients at High Risk After Resection[NCT02788526] | Phase 3 | 180 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| D2 Radical Resection After Neoadjuvant Chemotherapy Combined With HIPEC for Advanced Gastric Cancer: a Prospective Randomized Controlled Trial[NCT02960061] | Phase 3 | 640 participants (Anticipated) | Interventional | 2016-11-30 | Not yet recruiting | ||
| A Prospective, Multicentral, Open-label, Randomized, Controlled Clinical Trial to Investigation the Value of Extensive Intraoperative Peritoneal Lavage After Curative Gastrectomy for Locally Advanced Gastric Cancer[NCT02745509] | 508 participants (Actual) | Interventional | 2016-03-31 | Completed | |||
| Comparative Study on the Efficacy of Lobaplatin and Paclitaxel in the Treatment of Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy[NCT04808466] | Phase 2 | 231 participants (Anticipated) | Interventional | 2021-09-18 | Recruiting | ||
| Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer[NCT02343614] | Phase 2 | 58 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| A Multicenter Observational and Feasibility Study of Excision of Superficially Invasive Squamous Cell Carcinoma (SISCCA) of the Anal Canal and Perianus in HIV-Infected Persons[NCT02437851] | Phase 2 | 16 participants (Actual) | Interventional | 2015-04-30 | Active, not recruiting | ||
| A Randomised Phase-III Study Comparing Cytoreductive Surgery Plus Intraperitoneal Chemotherapy Versus Modern Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis.[NCT01524094] | Phase 3 | 49 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To evaluate the tumor ablative effect of UGN-102 in patients with LG NMIBC. CR rate was defined as the percentage of patients with no detectable disease (NDD) as determined by cystoscopy, for cause biopsy, and urine cytology. (NCT03558503)
Timeframe: 3 months after the first instillation of UGN-102
| Intervention | percentage of patients (Number) |
|---|---|
| UGN-102 | 65.1 |
Mitomycin AUC was assessed in a subset of 6 patients treated with UGN-102 (NCT03558503)
Timeframe: 0 (pre-instillation) to 6 hours after the first instillation of UGN-102
| Intervention | ng*h/mL (Mean) |
|---|---|
| UGN-102 | 5.69 |
Mitomycin Cmax was assessed in a subset of 6 patients treated with UGN-102 (NCT03558503)
Timeframe: 0 (pre-instillation), 0.5, 1, 2, 3, 4, 5, and 6 hours after the first instillation of UGN-102
| Intervention | ng/mL (Mean) |
|---|---|
| UGN-102 | 2.27 |
The number of patients with abnormal, CS physical examination findings post-baseline will be summarized (NCT03558503)
Timeframe: Up to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| UGN-102 | 0 |
The number of patients with abnormal, CS urology-oriented physical examination findings post-baseline will be summarized (NCT03558503)
Timeframe: Up to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| UGN-102 | 2 |
The number of patients who met PCS criteria for vital signs parameters post-baseline will be summarized (NCT03558503)
Timeframe: Up to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| UGN-102 | 8 |
To evaluate the durability of response in patients with LG NMIBC who achieve CR. DCR rate was defined as the percentage of patients who maintained CR at the respective time point. (NCT03558503)
Timeframe: 6, 9, and 12 months after the first instillation of UGN-102
| Intervention | percentage of patients (Number) | ||
|---|---|---|---|
| 6 months (3 months after CR at the 3-month Visit) | 9 months (6 months after CR at the 3-month Visit) | 12 months (9 months after CR at the 3-month Visit) | |
| UGN-102 | 95.1 | 73.2 | 61.0 |
Mitomycin plasma concentrations were assessed in a subset of 6 patients treated with UGN-102 (NCT03558503)
Timeframe: 0 (pre-instillation), 0.5, 1, 2, 3, 4, 5, and 6 hours after the first instillation of UGN-102
| Intervention | ng/mL (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Pre-instillation | 0.5 hours post-instillation | 1 hour post-instillation | 2 hours post-instillation | 3 hours post-instillation | 4 hours post-instillation | 5 hours post-instillation | 6 hours post-instillation | |
| UGN-102 | 0 | 0.75 | 0.60 | 0.34 | 1.88 | 1.93 | 0.57 | 0.32 |
The number of patients who met PCS criteria for chemistry or hematology parameters post-baseline will be summarized (NCT03558503)
Timeframe: Up to 12 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Any PCS chemistry value | Any PCS hematology value | |
| UGN-102 | 8 | 4 |
The number of patients with each type of event will be summarized. Adverse event severity was graded according to Common Terminology Criteria for Adverse Events version 5.0 as follows: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe or medically significant), Grade 4 (life-threatening), Grade 5 (fatal). (NCT03558503)
Timeframe: Up to 12 months
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Any TEAEs | Any study drug or procedure related TEAEs | Maximum severity Grade 1 | Maximum severity Grade 2 | Maximum severity Grade 3 | Maximum severity Grade 4 | Maximum severity Grade 5 | Any TEAEs leading to treatment discontinuation | Any serious TEAEs | |
| UGN-102 | 57 | 40 | 26 | 24 | 5 | 1 | 1 | 6 | 5 |
Defined as the time from study enrollment to the date of the first procedure confirming histopathological recurrence or disease progression or death from any cause. Recurrence-free survival (RFS) was censored at the date of the last follow-up visit for participants who were still alive and who had no recurrence/progression. (NCT00191477)
Timeframe: Surgery to recurrence or death (Follow-up assessments were performed at 3 and 6 months after the first TUR-BT, and every 6 months thereafter, until recurrence/progression of disease, or until the end of study, up to 24 months)
| Intervention | Months (Median) |
|---|---|
| Gemcitabine | 37.2 |
| Placebo | 40.2 |
RFS rate was estimated using Kaplan-Meier method. RFS was analyzed in different subgroups based on risk, disease status, and concomitant Bacillus Calmette-Guerin (BCG) instillations. Risk: Grading (G1,G2,G3) was performed according to American Joint Committee on Cancer Staging Criteria for Bladder Cancer. Newly diagnosed disease: Initial diagnosis at study entry. Recurrent disease: history of at least one superficial bladder tumor that was surgically treated and relapsed prior to study entry. With BCG: received at least one instillation of BCG during study. Without BCG: didn't receive BCG. (NCT00191477)
Timeframe: Surgery to recurrence or death (Follow-up assessments were performed at 3 and 6 months after the first TUR-BT, and every 6 months thereafter, until recurrence/progression of disease, or until the end of study, up to 24 months)
| Intervention | percentage of participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Low Risk (G1/G2) - 12 Months (N=106, N=109) | Low Risk (G1/G2) - 24 Months (N=106, N=109) | High Risk (G3) - 12 Months (N=13, N=14) | High Risk (G3) - 24 Months (N=13, N=14) | Newly Diagnosed Disease - 12 Months (N=94, N=98) | Newly Diagnosed Disease - 24 Months (N=94, N=98) | Recurrent Disease - 12 Months (N=30, N=26) | Recurrent Disease - 24 Months (N=30, N=26) | With BCG - 12 Months (N=13, N=21) | With BCG - 24 Months (N=13, N=21) | Without BCG - 12 Months (N=111, N=103) | Without BCG - 24 Months (N=111, N=103) | |
| Gemcitabine | 78.5 | 63.9 | 66.7 | 57.1 | 79.3 | 65.4 | 72.2 | 59.5 | 61.5 | 49.2 | 79.9 | 65.8 |
| Placebo | 78.4 | 64.3 | 42.4 | 31.8 | 79.8 | 63.6 | 58.9 | 50.5 | 79.4 | 63.5 | 74.5 | 60.1 |
Because median time to recurrence was not reached, percentage of participants without event was estimated using Kaplan-Meier method. Time to recurrence was censored on date of death for patients who died, and on date of last visit for patients who were alive, without recurrence. (NCT00191477)
Timeframe: Surgery to recurrence (Follow-up assessments were performed at 3 and 6 months after the first TUR-BT, and every 6 months thereafter, until recurrence/progression of disease, or until the end of study, up to 24 months)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Recurrence-Free at 12 Months | Recurrence-Free at 24 Months | |
| Gemcitabine | 78.4 | 66.3 |
| Placebo | 76.9 | 63.7 |
Tumor recurrence type (superficial, stage pTA or pT1; or muscle-invasive, stage≥pT2) was classified according to American Joint Committee on Cancer Staging Criteria for Bladder Cancer (AJCC Cancer Staging Manual, 6th edition). (NCT00191477)
Timeframe: Surgery to recurrence (Follow-up assessments were performed at 3 and 6 months after the first TUR-BT, and every 6 months thereafter, until recurrence/progression of disease, or until the end of study, up to 24 months)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| No Tumor Recurrence | Superficial Tumor - Stage pTa or pT1 | Muscle-Invasive Tumor - Any Stage ≥pT2 | pTx - Tumor Cannot be Assessed | |
| Gemcitabine | 76 | 44 | 3 | 1 |
| Placebo | 78 | 45 | 1 | 0 |
The secondary endpoint for this study will be the number of subjects who did not experience dystrophic calcification or bladder calculi measured by the number of patients with Grade 3 through Grade 5 Adverse Events that are related to study arm, graded according to NCI CTCAE Version 4.03.Version 4.03 (NCT02695771)
Timeframe: Two years
| Intervention | Participants (Count of Participants) |
|---|---|
| Mitomycin C | 24 |
| Gemcitabine | 23 |
| No Intervention | 25 |
The NCI CTCAE Version 4.03 grades adverse events as follows: grade 3 include severe but non-life-threatening consequences that result in hospitalization and/or interventions, including elective radiologic or operative interventions; grade 4 events include life-threatening consequences, such as those requiring urgent reoperation; and grade 5 events result in treatment-related death. (NCT02695771)
Timeframe: Two years
| Intervention | Participants (Count of Participants) |
|---|---|
| Mitomycin C | 15 |
| Gemcitabine | 14 |
| No Intervention | 20 |
PCR is defined as the absence of any residual invasive cancer on hematoxylin and eosin (H&E) evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes. (NCT01818063)
Timeframe: 36 months following surgery
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm 1 (Paclitaxel, Carboplatin) | 3 |
| Arm 2 (Veliparib, Paclitaxel, Carboplatin) | 3 |
68 reviews available for mitomycin and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage.
Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Female; Humans; Male; Mitomycin; | 2022 |
Drug instillation in the management of urinary tract urothelial carcinoma.
Topics: Carcinoma, Transitional Cell; Humans; Instillation, Drug; Kidney; Mitomycin; Neoplasm Recurrence, Lo | 2022 |
Comparison Between Intravesical Chemotherapy Epirubicin and Mitomycin-C after TURB vs TURB Alone With Recurrence Rate of Non-Muscle Invasive Bladder Cancer: Meta-Analysis.
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Epirubicin; Female; Humans; Male; Mitomy | 2022 |
A systematic review of the efficacy of intravesical electromotive drug administration therapy for non-muscle invasive bladder cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Humans; Mitomycin; Neoplasm | 2023 |
Mitomycin Gel (UGN-101) as a Kidney-sparing Treatment for Upper Tract Urothelial Carcinoma in Patients with Imperative Indications and High-grade Disease.
Topics: Carcinoma, Transitional Cell; Humans; Kidney; Kidney Neoplasms; Mitomycin; Multicenter Studies as To | 2023 |
Cancer stem cell fate determination: mito-nuclear communication.
Topics: Cell Differentiation; Humans; Mitochondria; Mitomycin; Neoplasm Recurrence, Local; Neoplastic Stem C | 2023 |
Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC).
Topics: Anus Neoplasms; Chemoradiotherapy; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as | 2019 |
Treatment options and results of adjuvant treatment in nonmuscle-invasive bladder cancer (NMIBC) during the Bacillus Calmette-Guérin shortage.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Chemotherapy, Adjuvant; Huma | 2020 |
[Diagnosis and Therapy of Benign and Malignant Tumors of the Conjunctiva].
Topics: Adult; Child; Conjunctiva; Conjunctival Neoplasms; Humans; Melanoma; Mitomycin; Neoplasm Recurrence, | 2020 |
An evaluation of UGN-101, a sustained-release hydrogel polymer-based formulation containing mitomycin-C, for the treatment of upper urothelial carcinomas.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Clinical Trials as Topic; Delayed-Action | 2020 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical electromotive drug administration for non-muscle invasive bladder cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma in Situ; Carcinoma | 2017 |
[Current Therapies in Superficial Malignant Tumors].
Topics: Conjunctival Neoplasms; Humans; Mitomycin; Neoplasm Recurrence, Local; Skin Neoplasms; Treatment Out | 2018 |
[Thermochemotherapy with Mitomycin C: an update on alternative treatment strategies in non-muscleinvasive bladder cancer].
Topics: Antibiotics, Antineoplastic; BCG Vaccine; Disease Progression; Humans; Hyperthermia, Induced; Mitomy | 2018 |
Emerging intravesical drugs for the treatment of non muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Animals; Antineoplastic Agents; BCG Vaccine; Disease Progression; Drug | 2018 |
A mitochondrial based oncology platform for targeting cancer stem cells (CSCs): MITO-ONC-RX.
Topics: Animals; Breast Neoplasms; Cell Proliferation; Humans; Mitochondria; Mitomycin; Neoplasm Recurrence, | 2018 |
Anal cancer treatment: current status and future perspectives.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; C | 2015 |
Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma
Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitiona | 2016 |
[Peritoneal tumor pathology: case n(o) 2: a "sticky" peritoneal tumor].
Topics: Abdominal Pain; Adult; Antineoplastic Agents, Alkylating; Appendectomy; Appendiceal Neoplasms; Combi | 2015 |
Ocular Surface Squamous Neoplasia in a Living-Related Conjunctival Limbal Allograft.
Topics: Aged; Allografts; Antibiotics, Antineoplastic; Carcinoma in Situ; Combined Modality Therapy; Conjunc | 2016 |
Recurrent verrucous carcinoma of the urinary bladder after transurethral resection followed by intravesical mitomycin, and a review of the literature.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma, Verrucous; Humans; Male; | 2016 |
Evaluating the efficacy and safety of intravesical chemotherapies for non-muscle invasive bladder cancer: a network meta-analysis.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocol | 2016 |
[Bacillus of Calmette-Guérin immunotherapy: which protocol?].
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Clin | 2008 |
Therapeutic options in the management of intermediate-risk nonmuscle-invasive bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Disease Progres | 2009 |
Treatment of ocular surface squamous neoplasia with Mitomycin C.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma in Situ; Chemotherapy, Adjuva | 2010 |
Conjunctival melanoma: pitfalls and dilemmas in management.
Topics: Antibiotics, Antineoplastic; Conjunctival Neoplasms; Cryotherapy; Humans; Lymphatic Metastasis; Mela | 2010 |
Mitomycin C for the treatment of bladder cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Clinical Trials as Topic; Drug Eruptions; | 2010 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2012 |
Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review.
Topics: Antibiotics, Antineoplastic; BCG Vaccine; Biopsy; Carcinoma, Transitional Cell; Chemotherapy, Adjuva | 2012 |
Adjuvant methods to improve results of local bladder irrigations by chemotherapy for NMIBC.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Combined Mo | 2013 |
Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Cyst | 2003 |
Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2004 |
Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma | 2004 |
[Irinotecan hydrochloride (CPT-11) for advanced cervical cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Car | 2004 |
[BOMP (BLM, VCR, MMC, and CDDP) therapy for advanced cervical cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Clinical Trials as Topic; Comb | 2004 |
Bladder cancer: current optimal intravesical treatment.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Cystectomy | 2005 |
Postoperative chemotherapy for gastric cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2006 |
A review of adjuvant therapy for resected primary gastric cancer with an update on Taegu's phase III trial with intraperitoneal chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clini | 2006 |
Repeat transurethral resection lowers recurrence rates in T1 bladder tumors, even after intravesical mitomycin C.
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Humans; Male; Mitomycin; Neoplasm Recurr | 2006 |
Intravesical chemotherapy of superficial bladder cancer.
Topics: Absorption; Animals; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Doxorubicin; Endoscopy; | 1983 |
The biology and treatment of superficial bladder cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; BCG Vaccine; Carcinoma, Squamous Cell; Carcinoma, Trans | 1984 |
Synchronous chemotherapy and radiotherapy for carcinoma of the anal canal--an alternative to abdominoperineal resection.
Topics: Abdomen; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous C | 1984 |
Therapeutic use of mitomycin C in bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Mitomycin; Mitomyc | 1984 |
Intravesical chemotherapy.
Topics: Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Clinical Trials as Topic; Combined | 1984 |
Intravesical and systemic chemotherapy in the management of superficial bladder cancer.
Topics: Administration, Topical; Aged; Antineoplastic Agents; Biopsy; Carcinoma, Transitional Cell; Cisplati | 1984 |
[Advances in the treatment of head and neck tumors. 2. Radiochemotherapy].
Topics: Cisplatin; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasms; Humans; Mitomycin; Neop | 1995 |
BCG in perspective: advances in the treatment of superficial bladder cancer.
Topics: Administration, Intravesical; BCG Vaccine; Doxorubicin; Humans; Mitomycin; Neoplasm Recurrence, Loca | 1995 |
[Our experience with mitomycin C in the prophylaxis of superficial bladder tumors; retrospective study].
Topics: Female; Follow-Up Studies; Humans; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Retrosp | 1994 |
Papillary-like bladder calcifications following intravescical mitomycin C. A case report.
Topics: Administration, Intravesical; Calcinosis; Carcinoma, Transitional Cell; Combined Modality Therapy; H | 1993 |
Anal canal cancer: current treatment and results.
Topics: Anal Canal; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Ant | 1996 |
[Combined hormone/chemotherapy for advanced prostatic cancer].
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Cyclophosphamide; Diethylstilbestro | 1997 |
[Adjuvant chemotherapy of lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cispl | 1987 |
[Clinical evaluation of chemoradiotherapy for advanced cervical cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Drug | 1997 |
[Intravesical instillation in the treatment of superficial tumors of the bladder].
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma; Carcinoma, Transi | 1998 |
Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer: individual patient data meta-analysis of randomized trials.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 1999 |
Malignant tumors of the anal canal: the spectrum of disease, treatment, and outcomes.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus | 1999 |
[Therapeutic strategy for the recurrence of pancreatic cancer following pancreatectomy].
Topics: Infusions, Intra-Arterial; Liver Neoplasms; Mitomycin; Neoplasm Recurrence, Local; Pancreatectomy; P | 1999 |
Chemotherapy of advanced or recurrent cervical carcinoma with a consecutive low-dose cisplatin combined with bleomycin, vincristine, and mitomycin-C (consecutive low-dose BOMP).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleo | 2000 |
Maintenance therapy for superficial bladder cancer.
Topics: Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Combined Modality Therapy; H | 2001 |
Chemotherapeutic prophylaxis of superficial bladder tumors.
Topics: Antineoplastic Agents; Doxorubicin; Humans; Mitomycin; Neoplasm Recurrence, Local; Urinary Bladder N | 2001 |
Simultaneous radiochemotherapy in cervical cancer: recommendations for chemotherapy.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop | 2001 |
Acute erythroleukemia with t(3;5) accompanied by hepatocellular carcinoma.
Topics: Aclarubicin; Adolescent; Adult; Aged; Anemia, Refractory, with Excess of Blasts; Carcinoma, Hepatoce | 1991 |
[Calcified bladder lesions secondary to the instillation of mitomycin C].
Topics: Administration, Intravesical; Calcinosis; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Comb | 1991 |
Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Carcinoma, Tran | 1989 |
Management of peritoneal carcinomatosis.
Topics: Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Fluorouracil; Humans; Injections, Intra | 1989 |
[5-Fluorouracil, adriamycin, and mitomycin C (FAM) combination chemotherapy in adenocarcinoma of the parotid gland].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Doxorubicin; | 1989 |
Intravesical therapy for bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Cystoscopy; Doxorubicin; Female; H | 1988 |
Mitomycin C therapy in superficial bladder cancer.
Topics: Drug Evaluation; Humans; Mitomycin; Mitomycins; Neoplasm Recurrence, Local; Urinary Bladder Neoplasm | 1985 |
238 trials available for mitomycin and Local Neoplasm Recurrence
| Article | Year |
|---|---|
The benefit of a neoadjuvant instillation of chemotherapy in non-muscle invasive bladder cancer: Interim analysis of the PRECAVE randomized clinical trial.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Cystectomy; Humans; Mitomycin; Neoadjuvan | 2021 |
Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; BCG Vaccine; Humans; Hyperthermia, Induc | 2022 |
Minimal Patient-Reported Side Effects for a Chemoablative Gel (UGN-102) Used as Frontline Treatment in Adults with Nonmuscle-Invasive Bladder Cancer.
Topics: Administration, Intravesical; Adult; Antibiotics, Antineoplastic; Female; Flatulence; Humans; Male; | 2022 |
DaBlaCa-13 Study: Oncological Outcome of Short-Term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Humans; Mitomycin; Neoplasm Invasiveness; | 2023 |
Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients With Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study. Letter.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Humans; Mitomycin; Neoadjuvant Therapy; N | 2023 |
Re: Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients with Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Humans; Mitomycin; Neoadjuvant Therapy; N | 2023 |
Guidance of adjuvant instillation in intermediate-risk non-muscle invasive bladder cancer by drug screens in patient derived organoids: a single center, open-label, phase II trial.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Humans; Mitomycin; Neoplasm Invasiveness; Neop | 2023 |
Re: DaBlaCa-13 Study: Oncological Outcome of Short-term, Intensive Chemoresection with Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Humans; Mitomycin; Neoplasm Invasiveness; | 2023 |
Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS).
Topics: Administration, Intravesical; Female; Humans; Male; Mitomycin; Neoplasm Invasiveness; Neoplasm Recur | 2023 |
Chemoablation with Intensive Intravesical Mitomycin C Treatment: A New Approach for Non-muscle-invasive Bladder Cancer.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Chemother | 2019 |
Development of a high-precision bladder hyperthermic intracavitary chemotherapy device for bladder cancer and pharmacokinetic study.
Topics: Adult; Aged; Analysis of Variance; Animals; Antibiotics, Antineoplastic; Cystoscopy; Disease-Free Su | 2019 |
Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Ad | 2020 |
The value of a comprehensive primary outcome - results of a negative randomized control trial in the non-muscle invasive bladder cancer population.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Humans; Mitomycin; Neoplasm Recurrence, L | 2021 |
Bladder intracavitary hyperthermic perfusion chemotherapy for the prevention of recurrence of non-muscle invasive bladder cancer after transurethral resection.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Combined Modality Therapy; Female; Humans; Hyperthermia, I | 2017 |
Mitomycin C hypoxic pelvic perfusion for unresectable recurrent rectal cancer: pharmacokinetic comparison of surgical and percutaneous techniques.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma, Squamous Cel | 2017 |
The effect of timing of an immediate instillation of mitomycin C after transurethral resection in 941 patients with non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Cystectomy; Female; Humans; Male; Middle | 2018 |
Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Th
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Agents; BCG Vaccine; Carcinoma | 2019 |
BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004).
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherap | 2019 |
Adjuvant chemotherapy for gastric cancer: a randomised phase 3 trial of mitomycin-C plus either short-term doxifluridine or long-term doxifluridine plus cisplatin after curative D2 gastrectomy (AMC0201).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Floxurid | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2013 |
Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squ | 2013 |
Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasi
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Antibiotics, Anti | 2013 |
Enhanced efficacy of postoperative adjuvant chemotherapy in advanced gastric cancer: results from a phase 3 randomized trial (AMC0101).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Fema | 2014 |
Intravesical thermo-chemotherapy based on conductive heat: a first pharmacokinetic study with mitomycin C in superficial transitional cell carcinoma patients.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Combi | 2014 |
Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial.
Topics: Anal Canal; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Colost | 2014 |
Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomiz
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Chem | 2015 |
Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomiz
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Chem | 2015 |
Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomiz
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Chem | 2015 |
Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomiz
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Chem | 2015 |
Routine second-look after surgical treatment of colonic peritoneal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemo | 2015 |
Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy P | 2015 |
Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cape | 2016 |
Quality of transurethral resection of bladder tumor procedure influenced a phase III trial comparing the effect of KLH and mitomycin C.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Immunological; Chemotherapy, Adjuvant; Cl | 2017 |
Clinical efficacy of modified preoperative neoadjuvant chemotherapy in the treatment of locally advanced (stage IB2 to IIB) cervical cancer: randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Fema | 2008 |
[Therapeutic effect of mitomycin C in the immediate postoperatory in patients with low-risk non-muscle-invasive bladder tumours].
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Female; Humans; Male; Middle Aged; Mito | 2008 |
Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term follow-up.
Topics: Administration, Intravesical; Antimetabolites, Antineoplastic; Carcinoma, Papillary; Carcinoma, Tran | 2007 |
[Therapeutic effect of mitomycin C in the immediate postoperative period in patients with intermediate-risk non-muscle-invasive bladder tumors].
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Female; Humans; | 2008 |
A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, A | 2008 |
[Combination of irinotecan and Mitomycin C as second-line chemotherapy for patients with unresectable advanced or recurrent gastric cancer in clinical practice].
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2009 |
Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; De | 2010 |
The role of chemo-radiotherapy in the management of locally advanced carcinoma of the vulva: single institutional experience and review of literature.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2011 |
Treatment of ocular surface squamous neoplasia with Mitomycin C.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma in Situ; Chemotherapy, Adjuva | 2010 |
Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vacci | 2011 |
Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vacci | 2011 |
Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vacci | 2011 |
Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vacci | 2011 |
Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemotherapy, Adjuvant | 2011 |
A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Resistanc | 2011 |
Long-term experience with early single mitomycin C instillations in patients with low-risk non-muscle-invasive bladder cancer: prospective, single-centre randomised trial.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Combined Modality Therapy; Female; | 2011 |
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; | 2011 |
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; | 2011 |
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; | 2011 |
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; | 2011 |
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; | 2011 |
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; | 2011 |
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; | 2011 |
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; | 2011 |
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; | 2011 |
[Evaluation of the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure in the treatment of non-muscle-invasive bladder cancer].
Topics: Administration, Intravesical; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplas | 2011 |
Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Cell Prol | 2012 |
Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette-Guérin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective FinnBladder 2 study with a 17-
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, A | 2012 |
Secondary cytoreductive surgery and peri-operative intraperitoneal chemotherapy for peritoneal recurrence of colorectal and appendiceal peritoneal carcinomatosis following prior primary cytoreduction.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Appendiceal Neoplasms; Chemotherapy, Adjuvant; Chemoth | 2013 |
Single early instillation of mitomycin C and urinary alkalinization in low-risk non-muscle-invasive bladder cancer: a preliminary study.
Topics: Administration, Intravesical; Adult; Aged; Antibiotics, Antineoplastic; Cystoscopy; Disease-Free Sur | 2013 |
High-dose 5-fluorouracil / folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer. A phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Do | 2002 |
Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma.
Topics: Adjuvants, Immunologic; Aged; Antibiotics, Antineoplastic; BCG Vaccine; Drug Administration Schedule | 2002 |
Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2002 |
Hypoxic pelvic and limb perfusion with melphalan and mitomycin C for recurrent limb melanoma: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusio | 2003 |
[Transarterial chemoperfusion of inoperable pancreas carcinoma and local recurrence].
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2003 |
Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antibiotics, Antineoplastic; BCG Vaccine | 2003 |
Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2003 |
[Prevention of postoperative recurrence of human bladder carcinoma by intravesical instillation of immunotoxin, a clinical study].
Topics: Administration, Intravesical; Aged; BCG Vaccine; Carcinoma, Transitional Cell; Female; Humans; Immun | 2003 |
Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2003 |
[Prospective randomized trial of prophylaxis of postoperative peritoneal carcinomatosis of advanced gastric cancer: intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Charcoal; Chemotherapy, Cancer, Regional Perfusi | 2003 |
[Prevention and treatment of bladder tumors recurrence with furtulon].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2000 |
[Epidermoid carcinomas of the anal canal treated with definitive radiation therapy in a series of 305 patients].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brac | 2003 |
[Oral tegafur plus mitomycin versus intravesical mitomycin alone in the prevention of recurrence in stage Ta bladder tumors].
Topics: Administration, Intravesical; Administration, Oral; Antibiotics, Antineoplastic; Antineoplastic Agen | 2003 |
[Management of conjunctival malignant melanoma associated with primary acquired melanosis (PAM) using 0.02% mitomycin C eyedrops].
Topics: Administration, Topical; Antibiotics, Antineoplastic; Conjunctival Neoplasms; Female; Humans; Male; | 2003 |
[Significance of thermo-chemotherapy as tumor dormancy therapy for recurrent rectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 2003 |
Preoperative mitomycin, ifosfamide, and cisplatin followed by esophagectomy in squamous cell carcinoma of the esophagus: pathologic complete response induced by chemotherapy leads to long-term survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2003 |
Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma.
Topics: Administration, Intravesical; Aged; Antibiotic Prophylaxis; Antibiotics, Antineoplastic; Carcinoma, | 2003 |
Mitomycin C as an adjunct in the treatment of localised ocular surface squamous neoplasia.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Squamous Cell; C | 2004 |
Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Carcinoma | 2004 |
[Rationale and progress of the phase III trial: intensification of the treatment of locally advanced squamous cell carcinoma of the anal canal].
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplasti | 2003 |
Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Combined Modalit | 2004 |
Stop-flow technique for loco-regional delivery of high dose chemotherapy in the treatment of advanced pelvic cancers.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Chemotherapy, Cancer, Regional | 2004 |
[Transcatheter hepatic arterial chemoembolization and thymosin alpha1 in postoperative treatment of hepatocellular carcinoma].
Topics: Adjuvants, Immunologic; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Carboplatin | 2004 |
Phase II study of irinotecan combined with mitomycin-C for advanced or recurrent squamous cell carcinoma of the uterine cervix: the JGOG study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; | 2004 |
Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Humans; Leucovo | 2005 |
Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Duodenal Neoplas | 2005 |
Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy coo
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined | 2005 |
Thermo-chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Male; Midd | 2005 |
A phase-1 study of sequential mitomycin C and 5-aminolaevulinic acid-mediated photodynamic therapy in recurrent superficial bladder carcinoma.
Topics: Aged; Aminolevulinic Acid; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional C | 2005 |
Postoperative adjuvant chemotherapy for stage I non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, | 2005 |
Photodynamic therapy for bladder cancer.
Topics: Aminolevulinic Acid; Antineoplastic Combined Chemotherapy Protocols; Humans; Mitomycin; Neoplasm Rec | 2005 |
Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2006 |
Intravesical adjuvant therapy using mitomycin C.
Topics: Administration, Intravesical; Adult; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell | 2006 |
[Clinical trial of chemotherapy identified according to chemosensitivity assay for oral cancer patients with unresectable recurrent lesions].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administration Schedu | 2006 |
The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma | 2006 |
Significance of histologic type of primary lesion and metastatic lymph nodes as a prognostic factor in stage III colon cancer.
Topics: Adenocarcinoma; Alkylating Agents; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic | 2006 |
Hepatic arterial infusion alternating with systemic chemotherapy in patients with non-resectable hepatic metastases from colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; He | 2006 |
Phase II study of bleomycin, vindesine, mitomycin C and cisplatin (BEMP) in recurrent or disseminated squamous cell carcinoma of the uterine cervix.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 2007 |
Combining cisplatin and mitomycin with radiotherapy in anal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2007 |
Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineopl | 2007 |
Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; BCG Vaccine; Ca | 2007 |
Neoadjuvant chemotherapy in locally advanced primary breast cancers: the Nottingham experience.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Me | 2007 |
The influence of thermo-chemotherapy on bladder tumours: an immunohistochemical analysis.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Cell | 2007 |
Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplati | 2007 |
[Comparison of the effectiveness between long-term instillation of mitomycin C and short-term prophylaxis with MMC or bacille Calmette-Guérin. Study of patients with non-muscle-invasive urothelial cancer of the urinary bladder].
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vacci | 2008 |
Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2008 |
concomitant chemoradiotherapy with mitomycin C and cisplatin in advanced unresectable carcinoma of the head and neck: phase I-II clinical study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2008 |
EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus | 2008 |
Bleomycin and mitomycin-C (BLM-M) in recurrent squamous uterine cervical carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carci | 1982 |
Mitomycin C as an adjuvant in resected gastric cancer.
Topics: Actuarial Analysis; Adult; Aged; Clinical Trials as Topic; Female; Follow-Up Studies; Gastrectomy; H | 1983 |
Bladder cancer chemotherapy studies supported by the National Bladder Cancer Project.
Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Carcinoma in Situ; Carcinoma, Papillary; Ci | 1983 |
Randomized clinical trial on chemoprophylaxis of recurrence in cases of superficial bladder cancer.
Topics: Clinical Trials as Topic; Cystitis; Doxorubicin; Humans; Japan; Mitomycin; Mitomycins; Neoplasm Recu | 1983 |
Treatment of advanced breast cancer with two doxorubicin-containing regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Doxorubi | 1984 |
[Cooperative studies on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Female; Fluorouraci | 1984 |
Drug combinations in the treatment of gastric adenocarcinoma: a randomized Southwest Oncology Group study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Sch | 1984 |
Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: influence on recurrence, progression and survival.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Combined Modality Therapy; Female; | 1984 |
Therapeutic use of mitomycin C in bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Mitomycin; Mitomyc | 1984 |
Intravesical chemotherapy.
Topics: Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Clinical Trials as Topic; Combined | 1984 |
Resume of selected studies of the National Bladder Cancer Collaborative Group A and new protocols.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Cisplatin; Clini | 1984 |
[Postoperative adjuvant arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuv | 1995 |
[Study of hepatic arterial infusion chemotherapy for prophylaxis of liver metastases of colorectal cancer after hepatic resection].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 1995 |
[Combination therapy of high dose 5'-DFUR+MMC for advanced or recurrent gastric cancer. 5'-DFUR Joint Research Group in the Osaka District for Gastric Cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Administration Schedule; | 1995 |
Local mitomycin-C therapy in relapse-prevention of superficial bladder neoplasms treated by means of laser.
Topics: Adult; Aged; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Female; Humans; Injections, Intra | 1994 |
[Cooperative study of surgical adjuvant chemotherapy for colorectal cancer. Cooperative Study Group of Surgical Adjuvant Chemotherapy for Colorectal Cancer in Japan].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Admi | 1995 |
Treatment of advanced or recurrent squamous cell carcinoma of the uterine cervix with mitomycin-C, bleomycin, and cisplatin chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1993 |
[A controlled study of AO-90, a methionine-free intravenous amino acid solution, in combination with 5-fluorouracil and mitomycin C in advanced gastric cancer patients (surgery group evaluation)].
Topics: Adolescent; Adult; Aged; Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Drug Administr | 1995 |
[A controlled study of AO-90, a methionine-free intravenous amino acid solution, in combination with 5-fluorouracil and mitomycin C in advanced gastric cancer patients (internal medicine group evaluation)].
Topics: Adolescent; Adult; Aged; Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Drug Administr | 1995 |
[Long-term results of intravesical prevention of recurrence with mitomycin C and adriamycin in patients with superficial bladder cancer].
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy P | 1994 |
Long-term monitoring of 486P 3/12 antigen pattern (quantitative immunocytology) before, during, and after mitomycin C prophylaxis in patients with superficial bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antigens, Neoplasm; Biomarkers, Tumor; Carci | 1995 |
Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Chemotherapy, A | 1995 |
[Evaluation of prophylactic intra-hepatic-arterial infusion chemotherapy after resection of hepatic metastases from colorectal primaries].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Do | 1994 |
[Adjuvant chemo-endocrine chemotherapy with gastrin antagonist after resection of liver metastasis in colorectal cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 1994 |
[The significance of portal infusion chemotherapy for prevention of recurrence in residual liver after hepatectomy for metastases from colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; He | 1994 |
[Pelvic hyperthermochemotherapy combined with surgery for rectal cancer].
Topics: Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Intraoperative Care; Lymphatic Met | 1994 |
[Prospective and randomized study comparing mitomycin C and interferon alpha 2b in the prevention of superficial tumors of the bladder].
Topics: Adolescent; Adult; Aged; Carcinoma, Transitional Cell; Female; Humans; Interferon alpha-2; Interfero | 1994 |
Postoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion.
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modali | 1994 |
[The treatment of hepatocellular carcinoma by chemoembolization].
Topics: Acetamides; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoe | 1994 |
Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, | 1994 |
Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study.
Topics: Aged; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; | 1994 |
Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study.
Topics: Aged; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; | 1994 |
Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study.
Topics: Aged; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; | 1994 |
Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study.
Topics: Aged; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; | 1994 |
Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study.
Topics: Aged; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; | 1994 |
Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study.
Topics: Aged; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; | 1994 |
Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study.
Topics: Aged; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; | 1994 |
Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study.
Topics: Aged; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; | 1994 |
Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study.
Topics: Aged; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; | 1994 |
Prognostic factors in pTa-pT1 superficial bladder tumours treated with intravesical instillations. The Dutch South-Eastern Urological Collaborative Group.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; BCG Vaccine; Carcinoma in Situ; Carcin | 1994 |
Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Carcinoma in Situ; Carcinoma, Papillar | 1994 |
[Prophylaxis of transitional cell carcinoma of the bladder G1-G2; pTa-pT1 with mitomycin C or interferon alpha-2a. Preliminary data].
Topics: Carcinoma, Transitional Cell; Combined Modality Therapy; Follow-Up Studies; Humans; Interferon alpha | 1993 |
[Response of superficial bladder carcinoma to prophylacit treatment with mitomycin-C versus interferon. Preliminary study].
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Female; Humans; Interferon-alpha; Male | 1993 |
[A prospective and randomized study of the complete response, index of recurrences and progression in superficial bladder carcinoma treated with mitomycin C alone versus mitomycin C and BCG alternatively].
Topics: BCG Vaccine; Carcinoma, Transitional Cell; Chi-Square Distribution; Drug Therapy, Combination; Femal | 1993 |
[The chemoradiotherapy of advanced colorectal carcinoma--the results and toxicity in a pilot study with 44 patients].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 1993 |
[Simultaneous radiochemotherapy in recurrent and metastatic breast neoplasm. Clinical experience].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Ant | 1995 |
Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherap | 1995 |
Combined preoperative chemoradiotherapy followed by radical surgery in locally advanced vulvar carcinoma. A pilot study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1996 |
The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma | 1996 |
Marker tumour responses to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 3089
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineop | 1996 |
Simultaneous radiochemotherapy for recurrent and metastatic breast carcinoma: evaluation of two treatment concepts.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Ant | 1996 |
A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, A | 1996 |
A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antibiotics, Antineoplastic; BCG Vaccine | 1996 |
Recurrences and progression of superficial bladder cancer following long-term intravesical prophylactic therapy with mitomycin C: 48-month follow-up.
Topics: Administration, Intravesical; Analysis of Variance; Antibiotic Prophylaxis; Antibiotics, Antineoplas | 1996 |
5-Fluorouracil, epirubicin, and mitomycin C versus 5-fluorouracil, epirubicin, mitomycin C, and leucovorin in advanced gastric carcinoma. A randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Epirubicin; Female; Fluorour | 1996 |
[Clinical evaluation of intra-arterial infusion chemotherapy for advanced or recurrent pelvic tumors with or without radiotherapy].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplati | 1996 |
[Results of a prospective study of chemoprophylaxis with alternating mitomycin-C and BCG: complete response and recurrence and progression index].
Topics: Adjuvants, Immunologic; Antibiotics, Antineoplastic; BCG Vaccine; Combined Modality Therapy; Disease | 1996 |
[Prevention of superficial bladder cancer with mitomycin C or interferon: final results of a prospective study].
Topics: Adult; Aged; Aged, 80 and over; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Mitomycin | 1996 |
Long-term follow-up of cytostatic intravesical instillation in patients with superficial bladder carcinoma. Is short-term, intensive instillation better than maintenance therapy?
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma | 1997 |
[Experience in treatment of patients with locally advanced or recurrent breast cancer: intraarterial infusion chemotherapy combined with radiotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ci | 1997 |
Dose intensity of uracil and tegafur in postoperative chemotherapy for patients with poorly differentiated gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Diseas | 1997 |
Postoperative adjuvant chemotherapy with mitomycin C and UFT for rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Combinatio | 1997 |
[Clinical evaluation of intra-arterial infusion chemotherapy for advanced or recurrent cervical cancer with or without radiotherapy].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 1997 |
Mitomycin C treatment for conjunctival-corneal intraepithelial neoplasia: a multicenter experience.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma in S | 1997 |
Induction chemotherapy is associated with an increase in the incidence of locoregional recurrence in patients with carcinoma of the oral cavity: results from a single institution.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 1998 |
Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer.
Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Colorectal Neoplasms; Diarrhea; Disease Progressio | 1998 |
Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus: a study of the Eastern Cooperative Oncology Group.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Comb | 1998 |
Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression.
Topics: Adjuvants, Immunologic; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Dise | 1998 |
Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Female; Follow-Up Studies; Humans; Male; | 1999 |
5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group.
Topics: Adjuvants, Immunologic; Antibiotics, Antineoplastic; BCG Vaccine; Disease Progression; Follow-Up Stu | 1999 |
Three new active cisplatin-containing combinations in the neoadjuvant treatment of locally advanced and locally recurrent breast carcinoma: a randomized phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Epirubicin | 1999 |
Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Infusion Pumps | 1999 |
[Effect of combination chemotherapy with multiple drugs (FLMP therapy) based on the circadian rhythms of the human body in advanced recurrent gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Circadian Rhythm; Cisplatin; Drug Administrati | 1999 |
A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dis | 1999 |
The effect of intravesical mitomycin C on the recurrence of superficial (Ta-T1) bladder cancer. A Hungarian Multicenter Study.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Humans; Hun | 1999 |
Prospective case-controlled trial of adjuvant chemotherapy after resection of hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Case-Control Studies; Che | 2000 |
Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or alternating monthly interferon-alpha2B and bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Antineoplas | 2000 |
Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: clinical experience with histopathologic observations.
Topics: Administration, Topical; Adult; Aged; Antibiotics, Antineoplastic; Atrophy; Chemotherapy, Adjuvant; | 2000 |
[Long-term results of intravesical N-CWS instillation to prevent recurrence after surgery for bladder cancer].
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Antibiotics, Antineoplastic; Carc | 1997 |
Adjuvant intraportal chemotherapy for Dukes B2 and C colorectal cancer also receiving systemic treatment: results of a multicenter randomized trial. Groupe Régional d'Etude du Cancer Colo-Rectal (Belgium).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2000 |
Can mitomycin C represent a valid partner for 5-fluorouracil in second-line chemotherapy of colorectal cancer?
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2000 |
Intra-arterial chemotherapy in locally advanced or recurrent carcinomas of the penis and anal canal: an active treatment modality with curative potential.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Anus Neoplasms; Arteries; Bleo | 2000 |
Hypoxic pelvic perfusion with mitomycin C using a simplified balloon-occlusion technique in the treatment of patients with unresectable locally recurrent rectal cancer.
Topics: Antibiotics, Antineoplastic; Catheterization; Chemotherapy, Cancer, Regional Perfusion; Female; Huma | 2001 |
Regional plus systemic chemotherapy: an effective treatment in recurrent non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoth | 2001 |
Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma | 2001 |
Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Colorectal Ne | 2001 |
Combined results from three phase II trials of neoadjuvant chemotherapy in operable adenocarcinoma of the oesophagus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2001 |
Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder.
Topics: Adjuvants, Immunologic; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma | 2001 |
A controlled clinical study of serosa-invasive gastric carcinoma patients who underwent surgery plus intraperitoneal hyperthermo-chemo-perfusion (IHCP).
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Combined Modality | 2001 |
Locally advanced primary breast cancer: medium-term results of a randomised trial of multimodal therapy versus initial hormone therapy.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2001 |
Induction chemotherapy with mitomycin, epirubicin, cisplatin, fluorouracil, and leucovorin followed by radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Sur | 2001 |
[Prevention of postoperative recurrence of bladder cancer: a clinical study].
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; BCG | 1999 |
Use of mitomycin C in the treatment of corneal conjunctival intraepithelial neoplasia.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma in S | 2002 |
A randomized comparative dose-ranging study of interferon-alpha and mitomycin-C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Dose-Response Relationship, Drug; | 2002 |
Local injection of M-CH combined with i.p. hyperthermic hypo-osmolar infusion is an effective therapy in advanced gastric cancer.
Topics: Adenocarcinoma; Charcoal; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Injectio | 2002 |
Topical mitomycin C for extensive, recurrent conjunctival-corneal squamous cell carcinoma.
Topics: Administration, Topical; Adult; Aged; Antibiotics, Antineoplastic; Carcinoma, Squamous Cell; Conjunc | 2002 |
[Prophylactic effect of UFT in combination with intravesical chemotherapy on the recurrence of superficial bladder tumor].
Topics: Administration, Intravesical; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic C | 1992 |
BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale, design, and interim analysis of the trial of the South-East Cooperative Urological Group, The Netherlands.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Humans; | 1992 |
Long-term results of intravesical chemoprophylaxis of superficial bladder cancer: experience of the Japanese Urological Cancer Research Group for Adriamycin.
Topics: Actuarial Analysis; Administration, Intravesical; Aged; Combined Modality Therapy; Doxorubicin; Drug | 1992 |
Intravesical combination chemotherapy with mitomycin C and doxorubicin for superficial bladder cancer: a randomized trial of maintenance versus no maintenance following a complete response.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocol | 1992 |
Sequential instillation therapy with mitomycin C and adriamycin for superficial bladder cancer.
Topics: Administration, Intravesical; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cystitis; | 1992 |
Results of adjuvant chemotherapy for invasive uroepithelial cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cis | 1992 |
[Prophylactic intravesical instillation therapy in patients with superficial bladder cancer--results of a randomized prospective study].
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Doxorubicin; Drug Administration Schedul | 1992 |
Randomized trial of adjuvant chemotherapy for operable breast cancer comparing i.v. CMF to an epirubicin-containing regimen [see comment].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1992 |
4'-epidoxorubicin versus mitomycin C intravesical chemoprophylaxis of superficial bladder cancer.
Topics: Administration, Intravesical; Aged; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Epirubicin | 1992 |
[Chemotherapy for advanced and recurrent cancer patients--the effect of combination chemotherapy using cisplatin, peplomycin, mitomycin C, adriamycin, and 5-fluorouracil].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Colorectal Neopla | 1990 |
Postoperative adjuvant chemotherapy in non-small cell lung cancer: prognostic value of DNA ploidy and post-recurrent survival.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Non-Small-Cell Lung; Car | 1991 |
[Treatment of advanced or recurrent cervical cancer by a new BOMP regimen consisting of bleomycin, vincristine, mitomycin-C, and low-dose consecutive cisplatin].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1991 |
Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guérin) in superficial bladder cancer.
Topics: Administration, Intravesical; Aged; BCG Vaccine; Carcinoma, Transitional Cell; Female; Humans; Immun | 1991 |
Prophylactic instillation therapy of superficial bladder cancer. A randomized study comparing mitomycin C and adriamycin with special reference to DNA ploidy.
Topics: Administration, Intravesical; Combined Modality Therapy; DNA, Neoplasm; Doxorubicin; Female; Humans; | 1991 |
Recurrence of superficial bladder tumors in prostatic urethra.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma in Si | 1991 |
[Intravesical instillation of bacillus Calmette-Guerin for superficial bladder carcinoma: study on significance of additional maintenance instillations of bacillus Calmette-Guerin].
Topics: Administration, Intravesical; Adult; Aged; BCG Vaccine; Carcinoma, Transitional Cell; Drug Administr | 1991 |
Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Pro | 1991 |
Prospective randomized controlled study on bestatin in resectable gastric cancer--third report.
Topics: Adjuvants, Immunologic; Aminopeptidases; Antibiotics, Antineoplastic; Antineoplastic Combined Chemot | 1990 |
[Following curative resection of colorectal cancer, portal chemotherapy especially benefits non-transfused patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Colorectal Neoplasms; Combined Mo | 1990 |
Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients.
Topics: Administration, Intravesical; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modalit | 1990 |
[Intravesical instillation chemotherapy of anticancer agents including cylocide: studies of prophylactic effects on the recurrence].
Topics: Actuarial Analysis; Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; Ch | 1990 |
Immunocytology as a possible marker to identify patients who require prophylaxis.
Topics: Administration, Intravesical; Aged; Antibodies, Monoclonal; Antigens, Neoplasm; Biomarkers, Tumor; C | 1990 |
[Cooperative study on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer (II). Cooperative study group on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer supp
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; F | 1990 |
[Early phase II study of the combined use of AO-90 methionine-free amino acid solution and anticancer agents (5-FU and MMC) in patients with advanced and recurrent gastrointestinal cancer. AO-90 Study group].
Topics: Adult; Aged; Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1990 |
Evaluation of principles in intravesical chemo- and immunotherapy for superficial bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Carcinoma, Papi | 1990 |
Metaphylactic effect of mitomycin C with and without hyaluronidase after transurethral resection of bladder cancer: randomized trial.
Topics: Adult; Aged; Carcinoma, Transitional Cell; Clinical Trials as Topic; Combined Modality Therapy; Doub | 1989 |
[Clinical effect of combined chemotherapy with UFT, MMC and OK-432 in recurring or advanced cancer of the digestive organs].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Digestive System Neo | 1989 |
Recurrence of superficial bladder carcinoma after intravesical instillation of mitomycin-C. Comparison of exposure times.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Carcinoma in Situ; Carcinoma, Transiti | 1989 |
[Multi-institutional cooperative study of adjuvant immunochemotherapy in gastric cancer--five-year survival rate].
Topics: Adjuvants, Immunologic; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Top | 1989 |
Efficacy of intravesical mitomycin C in the treatment of superficial transitional cell carcinoma of the urinary bladder.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Clinical | 1989 |
Intravesical mitomycin C instillation as a prophylactic treatment of superficial bladder tumor.
Topics: Administration, Intravesical; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mitomycin; Mitom | 1989 |
Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party).
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Cystoscopy; Follow-Up Studies; Humans; M | 1989 |
Mitomycin-C and BCG in intravesical chemotherapy and immunotherapy of superficial bladder cancer. Finnbladder Research Group.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Drug Administration Schedule; Follow-U | 1989 |
BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale and design of the trial of the Southeast Co-operative Urological Group, The Netherlands.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Papillary; Cystitis; Humans | 1989 |
BCG-(RIVM) versus mitomycin intravesical therapy in patients with superficial bladder cancer. EORTC GU Group and the Dutch South-East Collaborative Group.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma, Papillary; Carcinoma, Transitional Cell; Clini | 1989 |
[Cooperative study of surgical adjuvant chemotherapy of colorectal carcinoma (second study): a preliminary report. Cooperative Study Group of Surgical Adjuvant Chemotherapy of Colorectal Cancer in Japan].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Drug A | 1989 |
A trial of prophylactic thiotepa or mitomycin C intravesical therapy in patients with recurrent or multiple superficial bladder cancers.
Topics: Carcinoma, Transitional Cell; Clinical Trials as Topic; Humans; Mitomycin; Mitomycins; Neoplasm Recu | 1986 |
[Prophylactic intravesical instillation therapy with adriamycin (ADM) and mitomycin C (MMC) in patients with superficial bladder cancer].
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Combined Mod | 1986 |
Prophylactic intravesical instillation therapy with adriamycin and mitomycin C in patients with superficial bladder cancer.
Topics: Administration, Intravesical; Carcinoma, Papillary; Clinical Trials as Topic; Combined Modality Ther | 1987 |
Prophylactic treatment for superficial bladder cancer following transurethral resection.
Topics: Administration, Intravesical; Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Combined Mo | 1987 |
Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of superficial bladder cancer. Prospective, randomized, controlled studies of the Japanese Urological Cancer Research Group.
Topics: Administration, Intravesical; Aged; Clinical Trials as Topic; Combined Modality Therapy; Doxorubicin | 1987 |
Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C.
Topics: Adult; Chemotherapy, Cancer, Regional Perfusion; Drug Evaluation; Female; Humans; Hyperthermia, Indu | 1988 |
Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized study.
Topics: Administration, Intravesical; Antigens; Clinical Trials as Topic; Female; Follow-Up Studies; Hemocya | 1988 |
Cytostatic intravesical instillation in patients with superficial bladder carcinoma for the prevention of recurrent tumors.
Topics: Administration, Intravesical; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clini | 1988 |
BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer.
Topics: Administration, Intravesical; Animals; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; | 1988 |
Is there an optimal treatment scheme for adjuvant intravesical therapy? Preliminary analysis of an EORTC protocol comparing early and delayed instillation with and without maintenance of either adriamycin or mitomycin-C in patients with superficial transi
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Clinical Trials as Topic; Combined Modal | 1988 |
[Can topical chemoprevention modify the rate of recurrence and progression of superficial bladder cancer?].
Topics: Administration, Intravesical; Clinical Trials as Topic; Combined Modality Therapy; Doxorubicin; Foll | 1988 |
Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party).
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Clinical | 1988 |
Proteinuria after intravesical chemotherapy.
Topics: Carcinoembryonic Antigen; Carcinoma in Situ; Clinical Trials as Topic; Doxorubicin; Humans; Mitomyci | 1985 |
Gastric cancer: overview of current therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 1985 |
Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Transitional Cell; Clinical | 1985 |
[Significance of urothelial dysplasia in macroscopically normal mucosa in patients with bladder tumors. Results of a randomized study with and without intravesical mitomycin C in the prevention of recurrence].
Topics: Aged; Biopsy; Clinical Trials as Topic; Female; Humans; Hyperplasia; Male; Middle Aged; Mitomycin; M | 1985 |
438 other studies available for mitomycin and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Urine DNA for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: a pilot study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cetuximab; Chemoradiotherapy; Cli | 2022 |
Comparison of intravesical adjuvant therapy in bladder cancer with two different maintenance regimens of mitomycin and BCG.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Humans; Mitomycin; Neoplasm | 2022 |
Loco-regional deep hyperthermia combined with intravesical Mitomycin instillation reduces the recurrence of non-muscle invasive papillary bladder cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Humans; Hyperthermia, Induced; Mitomycin; | 2021 |
Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Humans; Immunotherapy; Mitomycin; | 2023 |
In vitro assessment of intra-operative and post-operative environment in reducing bladder cancer recurrence.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Humans; Hyperthermia, Induced | 2022 |
Chidamide and mitomycin C exert synergistic cytotoxic effects against bladder cancer cells in vitro and suppress tumor growth in a rat bladder cancer model.
Topics: Administration, Intravesical; Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; BCG Vaccine | 2022 |
Visualizing Ocular Surface Squamous Neoplasia.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Therapy; Conjunctival | 2022 |
Continuous Saline Bladder Irrigation in Reducing Recurrence and Progression When Compared to Immediate Mitomycin- C Instillation Post- Resection of Bladder Tumor: A Short Communication.
Topics: Administration, Intravesical; Cystectomy; Female; Humans; Male; Middle Aged; Mitomycin; Neoplasm Rec | 2022 |
Outcomes of Vesicourethral Anastomotic Stenosis and Bladder Neck Contracture With Direct Visual Internal Urethrotomy With Mitomycin-C After Prostate Cancer Treatment.
Topics: Constriction, Pathologic; Contracture; Humans; Male; Mitomycin; Neoplasm Recurrence, Local; Prostate | 2022 |
Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradio | 2022 |
Impact of Urinary pH on the Efficacy of a Postoperative Single Instillation of Mitomycin-C.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Humans; Hydrogen-Ion Concentration; Mitom | 2022 |
Real-life data of adjuvant IFN-α2b and MMC in conjunctival melanocytic lesions.
Topics: Adjuvants, Immunologic; Conjunctival Neoplasms; Humans; Interferon-alpha; Melanosis; Mitomycin; Neop | 2023 |
Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma | 2023 |
Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma | 2023 |
Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma | 2023 |
Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma | 2023 |
Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma | 2023 |
Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma | 2023 |
Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma | 2023 |
Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma | 2023 |
Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma | 2023 |
Definitive chemoradiation in nonmetastatic squamous cell carcinoma anal canal: A single-institution experience.
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell | 2022 |
Definitive chemoradiation in nonmetastatic squamous cell carcinoma anal canal: A single-institution experience.
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell | 2022 |
Definitive chemoradiation in nonmetastatic squamous cell carcinoma anal canal: A single-institution experience.
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell | 2022 |
Definitive chemoradiation in nonmetastatic squamous cell carcinoma anal canal: A single-institution experience.
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell | 2022 |
Evaluation of thermal dose effect in radiofrequency-induced hyperthermia with intravesical chemotherapy for nonmuscle invasive bladder cancer.
Topics: Combined Modality Therapy; Epirubicin; Humans; Hyperthermia, Induced; Mitomycin; Neoplasm Invasivene | 2023 |
Immunological effects of heated intraperitoneal chemotherapy can be augmented by thymosin α1.
Topics: Animals; Colorectal Neoplasms; Combined Modality Therapy; Hyperthermia, Induced; Mice; Mitomycin; Ne | 2023 |
A 6-month maintenance schedule of mitomycin C after radical nephroureterectomy for upper tract urothelial carcinoma for the prevention of intravesical recurrence: a retrospective, single center study.
Topics: Carcinoma, Transitional Cell; Humans; Mitomycin; Neoplasm Recurrence, Local; Nephroureterectomy; Ret | 2023 |
Long-term prevention of bladder cancer progression by alpha1-oleate alone or in combination with chemotherapy.
Topics: Animals; Antibiotics, Antineoplastic; Epirubicin; Mice; Mitomycin; Neoplasm Recurrence, Local; Oleic | 2023 |
Complete Remission of BCG-Refractory High-grade Bladder CIS with Pharmacologic Ascorbate and Mistletoe.
Topics: Adult; Aged; Antineoplastic Agents; BCG Vaccine; Carcinogens; Carcinoma in Situ; Female; Humans; Mal | 2023 |
Adjuvant intravesical treatment in patients with intermediate and high-risk non-muscle-invasive bladder cancer with BCG versus MMC applied with COMBAT or EMDA. Results of a prospective study.
Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Humans; Mitomycin; Neoplasm Invas | 2023 |
Conservative treatment for high-risk NMIBC failing BCG treatment: who benefits from adding electromotive drug administration (EMDA) of mitomycin C (MMC) to a second BCG induction cycle?
Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Combined Modality Therapy; Conser | 2023 |
Variation in Statewide Intravesical Treatment Rates for Non-Muscle Invasive Bladder Cancer During the Bacillus Calmette-Guerin Drug Shortage.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; BCG Vaccine; Humans; Medicare; Mitomycin | 2023 |
Sequential Treatment With Bacillus Calmette-Güerin (BCG) and Mitomycin C Administered With Electromotive Drug Administration (EMDA) in Patients With High-Risk Nonmuscle Invasive Bladder Cancer After BCG Failure.
Topics: Administration, Intravesical; Aged; BCG Vaccine; Humans; Immunotherapy; Mitomycin; Neoplasm Invasive | 2023 |
Single-Dose Post-Office Fulguration Mitomycin C Instillation Appears to Improve Recurrence-Free Survival in Patients With Low-Grade Noninvasive Bladder Cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Female; Hum | 2023 |
The efficacy of hyperthermic intravesical chemotherapy in high-risk non-muscle-invasive bladder cancer patients with BCG intolerance.
Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Carcinoma, Transitional Cell; Hum | 2023 |
Demographics, pathological characteristics and survival in urothelial bladder cancer in a cohort of Sri Lankan patients.
Topics: Aged; Carcinoma, Transitional Cell; Demography; Female; Humans; Male; Mitomycin; Neoplasm Recurrence | 2022 |
Single-dose perioperative mitomycin-C versus thiotepa for low-grade noninvasive bladder cancer.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic A | 2019 |
Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS).
Topics: Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Chemotherapy, Adjuvant; Chemot | 2020 |
Intraoperative mitomycin C and cryotherapy as adjunct therapy for recurrent lobular capillary haemangioma of conjunctiva.
Topics: Adult; Antibiotics, Antineoplastic; Combined Modality Therapy; Conjunctival Neoplasms; Cryotherapy; | 2020 |
Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Combined M | 2021 |
Intraoperative prophylactic intravesical chemotherapy to reduce bladder recurrence following radical nephroureterectomy.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Femal | 2020 |
Radiation with concurrent radiosensitizing capecitabine tablets and single-dose mitomycin-C for muscle-invasive bladder cancer: A convenient alternative to 5-fluorouracil.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Mitomycin; | 2020 |
Haematotoxicity in IMRT/VMAT curatively treated anal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, | 2020 |
[Treatment of Ta and T1 intermediate or high risk bladder cancer with intravesical Bacillus Calmette-Guérin or mitomycin C].
Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Humans; Mitomycin; Neoplasm Recur | 2021 |
Outcomes of multicystic peritoneal mesothelioma treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Cytoreduction Surgical Procedures; Doxorubicin; Femal | 2021 |
Prognostic Implications of Treatment Delays for Patients with Non-muscle-invasive Bladder Cancer.
Topics: BCG Vaccine; Humans; Mitomycin; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Prognosis; Retros | 2022 |
Sarcopenia and dosimetric parameters in relation to treatment-related leukopenia and survival in anal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chem | 2021 |
Effectivity of intravescical thermo-chemotherapy prophylaxis for patients with high recurrence and progression risk for non-muscle invasive bladder cancer.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Combined | 2017 |
Excision and topical 0.04% mitomycin C for extensive and recurrent conjunctival squamous cell carcinoma in an AIDS patient. A case report.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antibiotics, Antineoplastic; Carcinoma, Squamous Cell; Co | 2017 |
Mitomycin C or interferon as adjuvant therapy to surgery for ocular surface squamous neoplasia: comparative study.
Topics: Administration, Ophthalmic; Adult; Aged; Aged, 80 and over; Alkylating Agents; Carcinoma in Situ; Ca | 2018 |
Fewer Recurrences with Immediate versus Delayed Intravesical Mitomycin C: A Prospective Randomized European Trial.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell | 2018 |
Update on the role of endovesical chemotherapy in nonmuscle-invasive bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitiona | 2018 |
Impact of age on outcomes of patients with non-muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C.
Topics: Administration, Intravesical; Age Factors; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitiona | 2018 |
Re: Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Humans; Mitomycin; Neoplasm Recurrence, L | 2018 |
Carotid artery infusion via implantable catheters for squamous cell carcinoma of the tonsils.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carotid Arteries; Ca | 2018 |
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Humans; Kidney Function Tests; Kidney Ne | 2018 |
Palliation with a multimodality treatment including hypoxic pelvic perfusion for unresectable recurrent rectal cancer: outcomes based on a retrospective study.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Immunological; Cetuximab; Chemotherapy, Ca | 2018 |
Postoperative intravesical chemotherapy has an important role in reducing subsequent bladder tumours - why is it not routine?
Topics: Administration, Intravesical; Humans; Mitomycin; Neoplasm Recurrence, Local; Postoperative Period; U | 2018 |
Clinicopathologic correlation of ocular surface squamous neoplasia from a university hospital in North Taiwan 1994 to 2014.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Conjunctival Neopla | 2019 |
Comparison of Different Treatment Schedules of Mitomycin C Intravesical Instillation in High-Risk Superficial Bladder Cancer Patients.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Cohort Studies | 2019 |
Continuous saline bladder irrigation for two hours following transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer does not prevent recurrence or progression compared with intravesical Mitomycin-C.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Combined Modalit | 2018 |
Management of Invasive Squamous Cell Carcinomas of the Conjunctiva.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Therapy; Conjunctival | 2019 |
Intravesical treatment of chemotherapeutic agents sensitizes bacillus Calmette‑Guerin by the modulation of the tumor immune environment.
Topics: Administration, Intravesical; Animals; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; | 2019 |
A Comparison of Different Prophylactic Intravesical Chemotherapy Regimens for Bladder Cancer Recurrence After Nephroureterectomy for Primary Upper Tract Urothelial Carcinomas: A Retrospective 2-center Study.
Topics: Administration, Intravesical; Aged; Combined Modality Therapy; Cystoscopy; Disease-Free Survival; Do | 2019 |
Hypoxic pelvic perfusion with cisplatin and mitomycin C in multidisciplinary palliative treatment of patients with unresectable recurrent rectal cancer: a retrospective study.
Topics: Aged; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Female; Humans; Ma | 2019 |
Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal metastases.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combi | 2013 |
Transarterial chemoembolization for treatment of hepatocellular carcinoma: A single center experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, | 2013 |
The effect of surgical wide excision and amniotic membrane transplantation with adjuvant topical mitomycin C treatment in recurrent conjunctival--corneal intraepithelial neoplasia.
Topics: Aged; Alkylating Agents; Amnion; Carcinoma in Situ; Combined Modality Therapy; Conjunctival Neoplasm | 2014 |
Clinical and pathological characteristics of ocular surface squamous neoplasia in an Asian population.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma in Situ; Carcinoma, S | 2013 |
ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carb | 2013 |
Risk factors for ocular surface squamous neoplasia recurrence after treatment with topical mitomycin C and interferon alpha-2b.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoc | 2014 |
Would the benefits of hexaminolevulinate fluorescence cystoscopy be eliminated if every patient received postoperative installation of intravesical chemotherapy?
Topics: Aminolevulinic Acid; Antibiotics, Antineoplastic; Cystoscopy; Female; Humans; Male; Mitomycin; Neopl | 2013 |
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Blood Transfusio | 2014 |
Intravesical mitomycin C combined with local microwave hyperthermia in non-muscle-invasive bladder cancer with increased European Organization for Research and Treatment of Cancer (EORTC) score risk of recurrence and progression.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Disease P | 2014 |
Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cetuximab; | 2015 |
Immediate radical therapy or conservative treatments when meeting the Milan criteria for advanced HCC patients after successful TACE.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheter Ablation; | 2014 |
Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Combined Modality Therapy; Disease-Free | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Prognostic Significance of Nodal Ratio in Patients Undergoing Adjuvant Chemoradiotherapy After Curative Resection for Ampullary Cancer.
Topics: Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Ad | 2016 |
Inguinal lymph node recurrence in the untreated groin of patients with anal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Anus Neoplasms; Combined Modality Therapy; Fe | 2014 |
Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus | 2014 |
Predicting factors for recurrence in low-grade Ta primary bladder tumours.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma, Transitional Ce | 2014 |
Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Appendiceal Neoplas | 2015 |
Is thermochemotherapy with the Synergo system a viable treatment option in patients with recurrent non-muscle-invasive bladder cancer?
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Biopsy; F | 2015 |
Poor outcomes after liver transplantation in patients with incidental cholangiocarcinoma irrespective of tumor localization.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic | 2014 |
Iterative procedures combining cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for isolated peritoneal recurrence.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; C | 2014 |
Commentary on "economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases." Lee CT, Barocas D, Globe DR, Oefelein MG, Colayco DC, Bruno A, O׳Day K, Bramley T, Department of Urology, University
Topics: Antibiotics, Antineoplastic; Cost of Illness; Humans; Mitomycin; Neoplasm Recurrence, Local; Urinary | 2014 |
Anal carcinoma - Survival and recurrence in a large cohort of patients treated according to Nordic guidelines.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Cisplatin; | 2014 |
Transcatheter arterial chemoembolization combined with interferon-α is safe and effective for patients with hepatocellular carcinoma after curative resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoemboliz | 2015 |
[Intravesical instillation for bladder tumors].
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Drug | 2014 |
Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocol | 2016 |
Reducing recurrence in non-muscle-invasive bladder cancer using photodynamic diagnosis and immediate post-transurethral resection of the bladder chemoprophylaxis.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Chemoprevention; Cystoscopy; Female; Fo | 2015 |
[Management of locally advanced anal canal carcinoma with modulated arctherapy and concurrent chemotherapy].
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell | 2015 |
Ablative Intravesical Chemotherapy for Small Recurrent Non-Muscle-Invasive Bladder Cancer: A Prospective Study.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic A | 2016 |
Long-term outcomes of the FinnBladder-4 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Female; Humans; Interferon-alpha; Male; | 2015 |
Reply from authors re: Robert S. Svatek. Long-term outcomes of the FinnBladder-4 study. Eur Urol 2015;68:618-9: which type of maintenance matters?
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Female; Humans; Interferon-alpha; Male; | 2015 |
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Chemotherap | 2015 |
Evaluation of a 36 Gy elective node irradiation dose in anal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2015 |
Curcumin Improves the Tumoricidal Effect of Mitomycin C by Suppressing ABCG2 Expression in Stem Cell-Like Breast Cancer Cells.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast N | 2015 |
Evaluation of Su Fu'ning Lotion's Inhibitory Effects on Bladder Cancer Cells In Vitro and In Vivo by Intravesical Instillation.
Topics: Administration, Intravesical; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; | 2016 |
Reply to Yan Shibing and Wei Qiang's Letter to the Editor re: Morgan Rouprêt, Marko Babjuk, Eva Compérat, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. Eur Urol 2015;68:868-79.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Neop | 2016 |
Re: Morgan Rouprêt, Marko Babjuk, Eva Compérat, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. Eur Urol 2015;68:868-79.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Neop | 2016 |
The Expanded Use of Percutaneous Resection for Upper Tract Urothelial Carcinoma: A 30-Year Comprehensive Experience.
Topics: Adjuvants, Immunologic; Adult; Age Factors; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BC | 2016 |
Candidates for Intensive Local Treatment in cIIIA-N2 Non-Small Cell Lung Cancer: Deciphering the Heterogeneity.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Car | 2016 |
[Stage IB2, IIA and IIB cervical carcinoma without lymph node extension treated with neoadjuvant chemoradiotherapy].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 2016 |
Sequential bacillus Calmette-Guérin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Alkylating Agents; Cystoscopy; Drug Ther | 2016 |
Metabolic tumour volume of anal carcinoma on (18)FDG PET/CT before combined radiochemotherapy is the only independant determinant of recurrence free survival.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2016 |
Editorial comments on: Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder, by E. Kaasinen et al. (in this i
Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Follow-Up Stud | 2016 |
Successful Delivery in a 39-Year-Old Patient with Anal Cancer after Fertility-Preserving Surgery Followed by Primary Chemoradiation and Low Anti-Mullerian Hormone Level.
Topics: Adult; Anti-Mullerian Hormone; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carci | 2016 |
Intravesical chemotherapy use after radical nephroureterectomy: A national survey of urologic oncologists.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Chem | 2017 |
Re: Long-Term Outcome of Patients with Frequently Recurrent Non-Muscle-Invasive Bladder Carcinoma Treated with One Perioperative plus Four Weekly Instillations of Mitomycin C followed by Monthly bacillus Calmette-Guérin (BCG) or Alternating BCG and Interf
Topics: BCG Vaccine; Humans; Interferon alpha-2; Interferon-alpha; Mitomycin; Neoplasm Recurrence, Local; Pr | 2017 |
Successful topical treatment with mitomycin-C in a female with post-brachytherapy vaginal stricture.
Topics: Adolescent; Brachytherapy; Constriction, Pathologic; Female; Humans; Magnetic Resonance Imaging; Mit | 2008 |
An audit of conjunctival melanoma treatment in Liverpool.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Brachytherapy; | 2009 |
Platinum-based chemotherapy in triple-negative breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, | 2008 |
Increasing patient comfort by optimized postoperative administration of intravesical mitomycin C.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Chemother | 2008 |
Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Combined Mo | 2009 |
A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy P | 2009 |
Long-term follow-up of neoadjuvant intraarterial chemotherapy using an original four-lumen double-balloon (4L-DB) catheter for locally advanced uterine cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Catheterizati | 2009 |
Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2009 |
Recurrent laryngeal metastasis of a malignant melanoma: surgical therapy with the first application of mitomycin C.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Agents; Combined Modality Therapy; Dysphonia; Female; Human | 2009 |
Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, A | 2009 |
The MRC superficial bladder cancer trial of intravesical mytomicin-c after complete surgical resection. Sequential statistical methods applied to survival data from a randomised clinical trial.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Cystectomy; Data Interpretation, Statisti | 2009 |
HIV and anal cancer outcomes: a single institution's experience.
Topics: Antineoplastic Agents; Anus Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Chemotherapy, Adjuvan | 2009 |
Preoperative radiochemotherapy in the treatment of advanced oral cancer: outcome of 276 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cohort Studie | 2009 |
[Postoperative and adjuvant intravesical therapy of superficial bladder tumours. Clinical practice and applied therapeutic agents].
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Chem | 2009 |
Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, A | 2009 |
Editorial comment.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Comb | 2009 |
Topical mitomycin following cryotherapy for treatment of recurrent ocular surface melanoma.
Topics: Administration, Topical; Aged, 80 and over; Antibiotics, Antineoplastic; Combined Modality Therapy; | 2009 |
Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy?
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma | 2010 |
Editorial comment.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Combined Mo | 2010 |
Re-challenge chemotherapy for relapsed non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Child; | 2010 |
[Therapeutic effects of vinorelbine-based chemotherapy--retrospective study of 65 patients with metastatic or relapsed breast cancer].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2010 |
Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2010 |
Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Chemotherapy, | 2010 |
High-grade acute organ toxicity as a positive prognostic factor in primary radiochemotherapy for anal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2011 |
Effects of intraperitoneal chemotherapy with mitomycin C on the prevention of peritoneal recurrence in colorectal cancer patients with positive peritoneal lavage cytology findings.
Topics: Antibiotics, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Female; Follow-Up Stud | 2011 |
Treatment of ocular surface squamous cell intraepithelial neoplasia with and without mitomycin C.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Biopsy; Carcinoma in Situ; Chemotherapy | 2011 |
Squamous cell carcinoma of the anal margin: the university of Florida experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brac | 2011 |
Bacillus Calmette-Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class I-deficient tumor cells.
Topics: Adjuvants, Immunologic; Adult; Aged; Antibiotics, Antineoplastic; BCG Vaccine; Histocompatibility An | 2011 |
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of recurrent endometrial carcinoma confined to the peritoneal cavity.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Endometrial Neopl | 2010 |
Hepatobiliary procedures in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Diseases; Chemotherapy, Cancer, Regional P | 2011 |
Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Female; H | 2011 |
Adjuvant chemoradiotherapy after curative resection for extrahepatic bile duct cancer: a long-term single center experience.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; B | 2012 |
Superficial bladder tumours: recurrence and progression.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Biopsy; Carcinoma, Transitional Cell; C | 2011 |
Continuous saline bladder irrigation after transurethral resection is a prophylactic treatment choice for non-muscle invasive bladder tumor.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Femal | 2011 |
Adjuvant chemolipiodolization reduces early recurrence derived from intrahepatic metastasis of hepatocellular carcinoma after hepatectomy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Case-Control Studie | 2011 |
Outcomes in 15 patients with conjunctival melanoma treated with adjuvant topical mitomycin C: complications and recurrences.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Conjunctival N | 2011 |
Conjunctival squamous cell carcinoma arising in immunosuppressed patients (organ transplant, human immunodeficiency virus infection).
Topics: Adult; Aged; Carcinoma, Squamous Cell; Conjunctival Neoplasms; Female; Graft Rejection; HIV Infectio | 2011 |
Early recurrence of pseudomyxoma peritonei following treatment failure of cytoreductive surgery and perioperative intraperitoneal chemotherapy is indicative of a poor survival outcome.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Blood | 2012 |
Re: Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor. T. Maeda, E. Kikuchi, K. Matsumoto, A. Miyajima and M. Oya. J Urol 2011; 185: 802-806.
Topics: Antibiotics, Antineoplastic; Female; Humans; Male; Mitomycin; Neoplasm Recurrence, Local; Urinary Bl | 2011 |
Chemotherapy: Electromotive mitomycin in superficial bladder cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Electrochem | 2011 |
[Intraabdominal chemotherapy of prevailing forms of colon cancer].
Topics: Abdominal Cavity; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic Neoplasms; Fluo | 2011 |
Therapeutic isolated limb perfusion (ILP) in the management of patients with advanced or recurrent limb melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Humans; Lo | 2012 |
Comparison of local control effects of superselective transcatheter arterial chemoembolization using epirubicin plus mitomycin C and miriplatin for hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carci | 2012 |
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for patients with peritoneal carcinomatosis secondary to urachal adenocarcinoma.
Topics: Adenocarcinoma; Adolescent; Adult; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Chemotherapy | 2012 |
Aggressive management of peritoneal carcinomatosis from mucinous appendiceal neoplasms.
Topics: Adenocarcinoma, Mucinous; Antibiotics, Antineoplastic; Appendiceal Neoplasms; Disease-Free Survival; | 2012 |
Prognostic significance of intraoperative chemotherapy and extensive lymphadenectomy in patients with node-negative gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2012 |
[Combined management of colon cancer local recurrences with using intraabdominal chemotherapy].
Topics: Abdominal Cavity; Antibiotics, Antineoplastic; Colonic Neoplasms; Disease Management; Humans; Mitomy | 2011 |
Cost-effectiveness of fluorescent cystoscopy for noninvasive papillary tumors: pro.
Topics: Antibiotics, Antineoplastic; Carcinoma, Papillary; Cost-Benefit Analysis; Cystoscopy; Humans; Mitomy | 2012 |
Chemoradiotherapy of anal carcinoma: survival and recurrence in an unselected national cohort.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Ne | 2012 |
Adjuvant intravesical instillation for primary T1G3 bladder cancer: BCG versus MMC in Korea.
Topics: Antibiotics, Antineoplastic; BCG Vaccine; Mitomycin; Neoplasm Recurrence, Local; Republic of Korea; | 2012 |
Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovari | 2012 |
Transcatheter arterial infusion chemotherapy prior to radiofrequency thermal ablation for single hepatocellular carcinoma reduces the risk of intrahepatic distant recurrence.
Topics: Aged; Carcinoma, Hepatocellular; Catheter Ablation; Chemotherapy, Adjuvant; Epirubicin; Ethiodized O | 2012 |
Predictors of ocular surface squamous neoplasia recurrence after excisional surgery.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma in Situ; Carcinoma, Squamous Cell; Conjunctival Neoplasms; | 2012 |
Optimising existing therapeutic strategies for the treatment of non-muscle-invasive bladder cancer: the role of intensive neoadjuvant intravesical mitomycin C.
Topics: Antibiotics, Antineoplastic; Female; Humans; Male; Mitomycin; Neoadjuvant Therapy; Neoplasm Recurren | 2012 |
Histological changes due to intravesical instillation of mitomycin C.
Topics: Administration, Intravesical; Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Chemotherap | 2012 |
HIPEC in T4a colon cancer: a defendable treatment to improve oncologic outcome?
Topics: Adult; Aged; Aged, 80 and over; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Chemotherapy, C | 2012 |
Survival of patients with pathologic T0N+ oral and oropharyngeal cancer after neoadjuvant therapy and surgery: the minority report.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined C | 2013 |
Re: Renzo Colombo, Lorenzo Rocchini, Nazareno Suardi, et al. Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised ph
Topics: Antibiotics, Antineoplastic; Female; Humans; Male; Mitomycin; Neoadjuvant Therapy; Neoplasm Recurren | 2013 |
Economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Cost of Illness; Humans; Mitomycin; Neopl | 2012 |
Reply to Manish Garg, Apul Goel and Jai Prakash's letter to the editor re: Renzo Colombo, Lorenzo Rocchini, Nazareno Suardi, et al. Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non
Topics: Antibiotics, Antineoplastic; Female; Humans; Male; Mitomycin; Neoadjuvant Therapy; Neoplasm Recurren | 2013 |
Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cape | 2012 |
Improved outcomes for rectal cancer in the era of preoperative chemoradiation and tailored mesorectal excision: a series of 338 consecutive cases.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antine | 2013 |
Aggressive locoregional management of recurrent peritoneal sarcomatosis.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Chemo | 2013 |
Prognostic value of multidrug resistance 1, glutathione-S-transferase-pi and p53 in advanced nasopharyngeal carcinoma treated with systemic chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa | 2002 |
The use of postoperative topical mitomycin C in the treatment of recurrent conjunctival papilloma.
Topics: Adult; Antibiotics, Antineoplastic; Conjunctiva; Conjunctival Neoplasms; Humans; Male; Mitomycin; Ne | 2002 |
Comment on intraoperative use of mitomycin C in excision of ocular surface neoplasia with or without limbal autograft transplantation.
Topics: Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Squamous Cell; Conjunctival Neoplasms; Co | 2002 |
Gastrostomy-site tumor recurrence is not always fatal.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brachytherapy; Carcinoma, Squamous Cell; Flu | 2003 |
Neo-adjuvant chemotherapy in early stages of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuva | 2002 |
[Topical treatment with mitomycin C in considerably raised conjunctival intraepithelial neoplasia].
Topics: Administration, Topical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma in Situ; Co | 2002 |
[A case report of hepatocellular carcinoma with portal thrombus responding to hepatic arterial infusion chemo-lipiodolization].
Topics: Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Epirubicin; Humans; Iodized Oil; Li | 2002 |
Clinical outcome of conservative therapy for stage T1, grade 3 transitional cell carcinoma of the bladder.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, A | 2003 |
Impact of adjuvant chemotherapy in the long-term outcome of patients with resected gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antine | 2003 |
Third look surgery and beyond for appendiceal malignancy with peritoneal dissemination.
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplas | 2003 |
Treatment of a patient with advanced esophageal cancer with a combination of mitomycin C and capecitabine: activation of the thymidine phosphorylase as active principle?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxy | 2003 |
Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineop | 2003 |
Conjunctival intraepithelial neoplasia.
Topics: Administration, Topical; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Carcinoma in | 2003 |
Clinical benefit of chemosensitivity test for patients with regional lymph node-positive esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 2003 |
Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colore | 2003 |
[PREVENTION OF THE RECURRENCE OF CANCER].
Topics: Animals; Biomedical Research; Genetic Diseases, X-Linked; Hormones; Leukemia, Hairy Cell; Lymphatic | 1964 |
[SUPPLEMENTARY THERAPEUTIC MEASURES TO PREVENT THE RECURRENCE OF BREAST CANCER USED IN ASSOCIATION WITH RADICAL SURGERY].
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Humans; Mastectomy; Mechlorethamine; Mito | 1964 |
Intravesical therapy for superficial bladder cancer: slow but steady progress.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Combined Mo | 2003 |
Multimodality management of hepatocellular carcinoma larger than 10 cm.
Topics: Acetic Acid; Age Factors; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 2003 |
T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic | 2004 |
Application of molecular diagnosis for detection of peritoneal micrometastasis and evaluation of preoperative chemotherapy in advanced gastric carcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; C | 2004 |
Clinically aggressive pseudomyxoma peritonei: a variant of a histologically indolent process.
Topics: Adult; Antigens, Neoplasm; Antineoplastic Agents; Female; Fluorouracil; Humans; Male; Middle Aged; M | 2004 |
Cytoreductive surgery plus intraperitoneal hyperthermic perfusion is an effective treatment for metastasized malignant mixed mesodermal tumours (MMMT)--report of six cases.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 2004 |
A pilot study of neoadjuvant chemotherapy with mitomycin C, etoposide, cisplatin, and epirubicin for adenocarcinoma of the cervix.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Comb | 2004 |
Percutaneous nephroscopic management of upper urinary tract transitional cell carcinoma: recurrence and long-term followup.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Endo | 2004 |
[Multidisciplinary treatment of recurrent epithelial ovarian carcinoma and prognostic analysis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Comb | 2004 |
[The value of Roferon-A combined with hepatic artery chemoembolization and portal vein chemotherapy after radical resection in hepatocellular carcinoma for preventing recurrence].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combi | 2004 |
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant mixed mesodermal tumours with peritoneal dissemination.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy | 2005 |
Preoperative radiochemotherapy and radical resection for stages II-IV oral and oropharyngeal cancer: outcome of 222 patients.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2005 |
Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2005 |
Re: A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Antineoplastic Agents; Humans; Mitomycin; | 2005 |
Elevated tumour markers prior to complete tumour removal in patients with pseudomyxoma peritonei predict early recurrence.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Biomarkers, Tumor; CA-125 Antigen; CA-19-9 Antigen; Carcin | 2005 |
Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years' experience.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Conjunctival N | 2005 |
Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2005 |
Radiation therapy and simultaneous chemotherapy for recurrent cervical carcinoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 2005 |
[Transcatheter hepatic arterial chemoembolization on recurrent hepatocellular carcinoma after resection].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2005 |
Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival?
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Combined Moda | 2005 |
Conservative treatment of high grade superficial bladder tumours.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Antineoplas | 2005 |
Long-term results after neoadjuvant radiochemotherapy for locally advanced resectable extraperitoneal rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil | 2006 |
Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Feasibility Studies; Humans; Male; Mitomy | 2006 |
Chemo-prevention in superficial bladder cancer using mitomycin C: a survey of the practice patterns of British urologists.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Combined Modality Therapy; Humans; Mitomy | 2006 |
Reducing recurrence and costs in superficial bladder cancer: preclinical evaluation of osmotic cytolysis by distilled water vs. mitomycin.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Cell Proliferation; Cell Survival; Cost S | 2006 |
[5 years intravesical instillation with mitomycin-C and pirarubicin as a prophylactic treatment for superficial bladder cancer].
Topics: Administration, Intravesical; Adult; Aged; Antibiotic Prophylaxis; Doxorubicin; Drug Administration | 2006 |
Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Combined Modality Therapy; Feasibility St | 2006 |
Neoplastic mesorectal microfoci (MMF) following neoadjuvant chemoradiotherapy: clinical and prognostic implications.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; F | 2006 |
Oral cimetidine adjuvant therapy for recalcitrant, diffuse conjunctival papillomatosis.
Topics: Administration, Oral; Alkylating Agents; Child; Cimetidine; Combined Modality Therapy; Conjunctival | 2006 |
Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Fem | 2007 |
Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2007 |
Low-risk and high-risk histologic features in conjunctival primary acquired melanosis with atypia: Clinicopathologic analysis of 29 cases.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Cell Nucleolus; Cell Nucleus; Chemother | 2007 |
Interview with Dr Richard Sylvester: transition cell carcinoma of the bladder. Interview by Christine McKillop.
Topics: Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Humans; Mitomycin; Neoplasm Recurr | 2007 |
Editorial comment on: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder c
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Huma | 2007 |
Anus-preservation treatment for anal cancer: retrospective analysis at a single institution.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2007 |
Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma; Chemothe | 2007 |
Critical analysis of treatment failure after complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from appendiceal mucinous neoplasms.
Topics: Adenocarcinoma, Mucinous; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Appen | 2007 |
Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2007 |
[Transarterial chemoperfusion of the pelvis--results in symptomatic locally recurrent tumors and lymph node metastases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arteries; Drug Resistance, Neoplasm; Female; | 2007 |
Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; BCG Vaccine; Carcinoma, Transitio | 2007 |
Incidence of postoperative pancreatic fistula and hyperamylasemia after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2007 |
Holmium laser treatment for low grade, low stage, noninvasive bladder cancer with local anesthesia and early instillation of mitomycin C.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Anesthesia, Local; Carcinoma, Transitional Ce | 2007 |
[Transarterial chemoperfusion with gemcitabine and mitomycin C in pancreatic carcinoma: results in locally recurrent tumors and advanced tumor stages].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Sche | 2007 |
Isolated chemotherapeutic perfusion of pelvis as neoadjuvant or palliative therapy for advanced cancer of the rectum.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusio | 2008 |
Orbital invasion despite topical anti-metabolite therapy for conjunctival carcinoma.
Topics: Administration, Topical; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Con | 2008 |
[Bilateral ocular surface squamous neoplasia and neurodermatitis. Two cases with different courses].
Topics: Adult; Antibiotics, Antineoplastic; Biological Dressings; Carcinoma, Squamous Cell; Chemotherapy, Ad | 2008 |
[Bleomycin combined with mitomycin C in recurrent cervix cancer].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Bleomycin; Drug Therapy, Combination; Female; Humans; Midd | 1982 |
[Problems in the treatment of cervical carcinoma].
Topics: Aged; Bleomycin; Female; Humans; Mitomycin; Mitomycins; Neoplasm Recurrence, Local; Uterine Cervical | 1983 |
[Intra-arterial infusion of oncostatics in recurrent cervical carcinoma].
Topics: Antineoplastic Agents; Bleomycin; Cisplatin; Doxorubicin; Drug Therapy, Combination; Female; Humans; | 1983 |
Non-platinum-containing combination chemotherapy for stage III-IV head and neck squamous carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamid | 1983 |
Adenoid cystic carcinoma of the salivary gland. Sustained complete response to chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenoid Cystic; Doxorubicin; Drug | 1983 |
Preoperative chemotherapy and radiation therapy in the management of anal epidermoid carcinoma.
Topics: Adult; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Drug Therapy, Combination; Female; Fluorourac | 1983 |
Combined modality therapy for esophageal squamous cell carcinoma.
Topics: Abdomen; Adult; Aged; Carcinoma, Squamous Cell; Drug Therapy, Combination; Esophageal Neoplasms; Eso | 1983 |
Definitive nonsurgical therapy of epithelial malignancies of the anal canal. A report of 12 cases.
Topics: Adult; Aged; Antineoplastic Agents; Anus Neoplasms; Brachytherapy; Carcinoma, Squamous Cell; Drug Th | 1983 |
Prostatic recurrences in the management of superficial bladder tumors.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Humans; Male; Middle Aged; M | 1983 |
[Combination chemotherapy with mitomycin C, methotrexate, and vincristine (MMV) for metastatic breast cancer refractory to adriamycin].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Doxorubicin; Drug Resistance; Drug Thera | 1983 |
Intravesical instillation of mitomycin C in the prophylactic treatment of recurring superficial transitional cell carcinoma of the bladder.
Topics: Aged; Carcinoma, Transitional Cell; Female; Humans; Male; Middle Aged; Mitomycin; Mitomycins; Neopla | 1983 |
[Treatment of recurrent gastrointestinal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Humans; Infusions, I | 1983 |
[Stage P-1 primary neoplasia of the bladder. Critical evaluation of results obtained with the use of adriamycin and mitomycin C in the prevention of recurrences].
Topics: Administration, Topical; Antibiotics, Antineoplastic; Doxorubicin; Follow-Up Studies; Humans; Mitomy | 1984 |
[Combination chemotherapy of mitomycin C and cytosine arabinoside in the intravesical treatment for superficial bladder tumors: report 2. Evaluation of prophylactic intravesical infusion therapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedul | 1984 |
[Experimental and clinical studies on intravesical instillation therapy for bladder cancer].
Topics: Adolescent; Adult; Aged; Carbazilquinone; Carcinoma, Transitional Cell; Cytodiagnosis; Doxorubicin; | 1983 |
Intra-arterial infusion chemotherapy in rectal cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Female; Fluoroura | 1984 |
[Local mitomycin-C therapy of infiltrating bladder cancer].
Topics: Administration, Topical; Combined Modality Therapy; Cystitis; Humans; Mitomycin; Mitomycins; Neoplas | 1984 |
Intravesical chemotherapy for carcinoma in situ of the urinary bladder: 5 years later.
Topics: Adult; Aged; Carcinoma in Situ; Doxorubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; M | 1984 |
[Anti-tumor effect of intravesical instillation of mitomycin C combined with cytosine arabinoside].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine | 1984 |
Effectiveness of postoperative adjuvant therapy with cytotoxic chemotherapy (cytosine arabinoside, mitomycin C, 5-fluorouracil) or immunotherapy (neuraminidase-modified allogeneic cells) in the prevention of recurrence of Duke's B and C colon cancer.
Topics: Aged; Colonic Neoplasms; Cytarabine; Female; Fluorouracil; Humans; Immunotherapy; Male; Middle Aged; | 1981 |
[Chemotherapy associating mitomycin C, thiotepa and vindesine in advanced breast cancers. Study of 100 cases (author's transl)].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Drug Therapy, Combination; Dru | 1981 |
[Intravesical chemical prevention of recurrence of superficial urothelial bladder cancer. Progress report of the Urology Clinic of Mainz University 1975-1981].
Topics: Administration, Topical; Doxorubicin; Humans; Mitomycin; Mitomycins; Neoplasm Recurrence, Local; Uri | 1982 |
[Recurrence rate in adjuvant local chemotherapy of bladder cancer with mitomycin C].
Topics: Administration, Topical; Carcinoma in Situ; Carcinoma, Transitional Cell; Humans; Mitomycin; Mitomyc | 1982 |
[Intravesical chemical prevention of recurrence. A randomized animal experimental study].
Topics: Administration, Topical; Animals; Cisplatin; Doxorubicin; Epithelium; Female; Mitomycin; Mitomycins; | 1982 |
Postoperative prophylactic intravesical instillation of cytosine arabinoside and mitomycin C in superficial bladder tumor. A follow-up study.
Topics: Adult; Aged; Cystoscopy; Cytarabine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; M | 1982 |
[Chemotherapy of stomach cancer].
Topics: Adenocarcinoma; Antineoplastic Agents; Carmustine; Cisplatin; Doxorubicin; Drug Administration Sched | 1982 |
[Periodic prophylactic bladder instillation (PPI) of mitomycin C].
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Female; Humans; Intraoperative Care; Male; Mid | 1982 |
[Arterial infusion of microencapsulated mitomycin C for the treatment of locally recurrent carcinoma of the pelvic cavity].
Topics: Aged; Capsules; Female; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Mitomycin; Mitomycins; | 1982 |
Long-term follow-up of patients with superficial transitional cell carcinoma of the urinary bladder treated by intravesical mitomycin C.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Cystosco | 1995 |
Histological grading of carcinoma in situ of the bladder: its clinical significance in patients who underwent intravesical mitomycin C and doxorubicin sequential therapy.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherap | 1996 |
Up-front intravesical chemotherapy for low stage, low grade recurrent bladder cancer.
Topics: Administration, Intravesical; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Trans | 1996 |
Segmental transarterial chemoembolization with Lipiodol mixed with anticancer drugs for nonresectable hepatocellular carcinoma: follow-up CT and therapeutic results.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Antineoplastic Combined C | 1994 |
[Treatment of advanced and recurrent gynecologic cancer with chemotherapy by cannula perfusion into both internal iliac arteries].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1994 |
Cancer recurrence following laparoscopic colectomy. Report of two patients treated with heated intraperitoneal chemotherapy.
Topics: Adenocarcinoma; Colectomy; Colonic Neoplasms; Fluorouracil; Humans; Infusions, Parenteral; Laparosco | 1995 |
Percutaneous ethanol injection therapy for hepatocellular carcinoma: results in 146 patients.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Ethanol; Femal | 1993 |
Isolated pelvic perfusion for unresectable cancer using a balloon occlusion technique.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcino | 1993 |
Fine needle aspiration (FNA) in diagnosing recurrent squamous cell carcinoma of the head and neck: truth or consequences?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cell; Cobalt Rad | 1993 |
Concurrent radiation therapy and chemotherapy in the treatment of primary squamous cell carcinoma of the vulva.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carci | 1995 |
Anticancer chemosensitivity changes between the original and recurrent tumors after successful chemotherapy selected according to the sensitivity assay.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; DNA, Neoplasm; Dox | 1995 |
[Evaluation of chemoembolization as an adjuvant therapy for primary liver carcinoma after surgical resection].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoemboliz | 1994 |
Treatment of bladder carcinoma in situ with mitomycin C: long-term follow-up.
Topics: Administration, Intravesical; Carcinoma in Situ; Carcinoma, Transitional Cell; Female; Follow-Up Stu | 1994 |
Recurrent squamous cell carcinoma of the anal canal. Predictors of initial treatment failure and results of salvage therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Comb | 1994 |
[The prognostic factors following the simultaneous radiochemotherapy of anal canal carcinoma in a multicenter series of 139 patients].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1994 |
[Fibrino-necrotic ulcers in endovesical chemoprophylaxis in superficial bladder carcinoma: our case histories].
Topics: Administration, Intravesical; Aged; Carcinoma; Combined Modality Therapy; Female; Fibrosis; Follow-U | 1994 |
[Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer].
Topics: Administration, Intravesical; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; | 1994 |
Effects of hepatic arterial infusion chemotherapy on unresectable or recurrent hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin; | 1994 |
Effective cases of transcatheter arterioportal chemoembolization with high-dose iodized oil for hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, | 1994 |
Cancer of the anal canal: treatment with chemotherapy and low-dose radiation therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Carcinoma, | 1994 |
Conservative treatment of upper urinary tract tumors with Nd:YAG laser.
Topics: Adult; Combined Modality Therapy; Endoscopy; Hematuria; Humans; Laser Therapy; Male; Mitomycin; Neop | 1994 |
Intravesical mitomycin C for the treatment of carcinoma in situ of the bladder: 36 months follow-up.
Topics: Administration, Intravesical; Aged; Carcinoma in Situ; Cystectomy; Female; Humans; Male; Middle Aged | 1994 |
Intravesical mitomycin C and doxorubicin sequential therapy for carcinoma in situ of the bladder: a longer followup result.
Topics: Administration, Intravesical; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Car | 1994 |
Incrusted cystitis after intravesical mitomycin C treatment.
Topics: Administration, Intravesical; Calcinosis; Carcinoma, Transitional Cell; Combined Modality Therapy; C | 1993 |
[Prophylactic effects of mitomycin C (MMC) on the liver recurrence in a rabbit gastric VX2 cancer model with high frequency of the recurrence].
Topics: Animals; Disease Models, Animal; Female; Injections, Intravenous; Liver Neoplasms; Mitomycin; Neopla | 1993 |
Intraperitoneal chemotherapy for treatment and prevention of peritoneal carcinomatosis and sarcomatosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Doxoru | 1994 |
Epidermoid carcinoma of the anal canal: treatment by combined radiation and chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neo | 1993 |
[Clinical evaluation of postoperative adjuvant arterial infusion chemotherapy in resected hepatoma patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C | 1993 |
[Prevention of postoperative recurrence after hepatic resection for metastatic colorectal cancer by adjuvant locoregional chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Chemotherapy, | 1993 |
Chemoradiotherapy of anal carcinoma: tumour response and acute toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1993 |
[Combination therapy of high dose doxifluridine (5'-DFUR)+mitomycin C (MMC) for advanced or recurrent colorectal cancer. Joint Research Group in the Osaka Area for Combination Therapy of 5'-DFUR with Other Drugs].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms | 1993 |
Mitomycin-C in superficial bladder cancer. Is long-term maintenance therapy worthwhile after initial treatment?
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Drug Administration Schedule; Female; | 1993 |
Monitoring of lectin-reactive alpha-fetoproteins in patients with hepatocellular carcinoma treated using transcatheter arterial embolization.
Topics: Aged; alpha-Fetoproteins; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Case-Control Studi | 1995 |
[Combined chemotherapy with MMC, ADM, CDDP, etoposide (VP-16) and 5'-DFUR, (MACVD therapy) as a second-line chemotherapy for metastatic gastric cancer: three cases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Etoposide; Female; Floxuridi | 1996 |
Cytophotometry in the monitoring of bladder cancer under intravesical chemotherapy.
Topics: Administration, Intravesical; Aged; Aneuploidy; Antibiotics, Antineoplastic; Carcinoma, Transitional | 1996 |
[A case of recurrent squamous cell carcinoma of cervix successfully treated with BOMP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Fema | 1996 |
[The efficacy of ATP sensitivity assay on intravesical prophylactic instillation for superficial bladder cancer].
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineopl | 1996 |
Intra-arterial infusion chemotherapy in the treatment of locally advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antine | 1997 |
Successful treatment of recurrent corneal intraepithelial neoplasia with topical mitomycin C.
Topics: Administration, Topical; Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Corneal Diseases; Eye | 1997 |
Mitomycin C, cisplatin, and 5-fluorouracil for advanced and/or recurrent head and neck squamous cell carcinomas.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 1997 |
Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Ne | 1998 |
Combination of consecutive low-dose cisplatin with bleomycin, vincristine, and mitomycin for recurrent cervical carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin | 1998 |
Adjuvant chemotherapy after radical hysterectomy for cervical carcinoma: a comparison with effects of adjuvant radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; | 1998 |
[Results of BCG in the treatment of pTa and pT1 bladder tumors. Evaluation of a long protocol using 75 mg of Pasteur strain BCG].
Topics: Actuarial Analysis; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antin | 1998 |
Bladder cancer recurrence by implantation of exfoliated cells: is gamma-linolenic acid an effective tumoricidal agent?
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Cell Adhesion; Drug Resistance, Neoplasm; | 1998 |
Metastatic malignant meningioma of the liver with hypoglycemia: report of a case.
Topics: Aged; Chemoembolization, Therapeutic; Fatal Outcome; Hepatectomy; Humans; Hypoglycemia; Liver; Liver | 1998 |
[The results of a long-term follow-up for patients with stage Ta bladder cancer, especially regarding those with multiple recurrences].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 1998 |
Pharmacokinetics of mitomycin C in pelvic stopflow infusion and hypoxic pelvic perfusion with and without hemofiltration: a pilot study of patients with recurrent unresectable rectal cancer.
Topics: Algorithms; Antibiotics, Antineoplastic; Aorta, Abdominal; Area Under Curve; Chemotherapy, Cancer, R | 1998 |
Postoperative topical mitomycin C in conjunctival squamous cell neoplasia.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Conjunctival Ne | 1999 |
[Isolated hypoxic perfusion with mitomycin C confers no benefit for patients with advanced pancreatic carcinoma].
Topics: Adenocarcinoma; Aged; Antibiotics, Antineoplastic; Cell Hypoxia; Disease Progression; Female; Humans | 1998 |
[Study of the synergy of microwave hyperthermia/intravesical chemotherapy in the prevention of recurrences of superficial tumors of the bladder].
Topics: Administration, Intravesical; Animals; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Co | 1999 |
Prognostic impact of second cancer on the survival of early breast cancer patients.
Topics: Adult; Androstanols; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, | 1999 |
[Long-term effects on recurrence and mortality in superficial urothelioma of the bladder treated with endovesical chemotherapy].
Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitiona | 1999 |
[A case of liver metastases from gastric cancer responding to induced hypertensive chemotherapy with angiotensin II].
Topics: Aged; Angiotensin II; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic C | 1999 |
Adjuvant regional chemotherapy after hepatic resection for colorectal metastases.
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Co | 1999 |
[A case of adriamycin and methotrexate-resistant recurrent breast cancer treated with doxifluridine and mitomycin C].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 1999 |
Peritonectomy and intraperitoneal chemotherapy in appendiceal and colorectal cancer.
Topics: Abscess; Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; | 1999 |
Treatment of recurrent conjunctival papillomatosis with mitomycin C.
Topics: Antibiotics, Antineoplastic; Child, Preschool; Conjunctival Neoplasms; Female; Humans; Mitomycin; Ne | 1999 |
Chemoradiation with or without intraoperative radiation therapy in patients with locally recurrent rectal carcinoma: prognostic factors and long term outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Combi | 1999 |
Efficacy of prophylactic Immucothel in patients pretreated with conventional drugs to prevent recurrence of superficial bladder carcinoma.
Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vaccine; Female; H | 2000 |
[Initial locoregional chemotherapy in recurrent and locoregional advanced or inoperable stages of pelvic uterine and anorectal cancers].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bleomycin; Cisplatin; D | 1995 |
Urethral slough: a rare and previously unreported complication of intravesical mitomycin.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Humans; Male; Middle Aged; Mitomycin; Nec | 2000 |
Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; | 2000 |
Malignant proliferating trichilemmal tumor in the skin over the breast: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma, Squamous | 2000 |
Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2000 |
[Transcatheter arterial chemo-embolization using degradable starch microspheres (DSM) markedly effective for post-hepatectomy intra-hepatic recurrence in a patient with cholangioma].
Topics: Aged; Antibiotics, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatoc | 2000 |
[Intravesical chemotherapy with mitomycin C after TUR for superficial bladder carcinoma].
Topics: Administration, Intravesical; Aged; Carcinoma; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Hu | 1999 |
Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemothera | 2001 |
Amniotic membrane transplantation in the management of conjunctival malignant melanoma and primary acquired melanosis with atypia.
Topics: Administration, Topical; Aged; Amnion; Conjunctival Neoplasms; Corneal Transplantation; Female; Huma | 2001 |
[Treatment of 9 squamous epithelial carcinoma in situ lesions of the conjunctiva (CIN) with mitomycin C eyedrops in cytological and DNA image cytometric control].
Topics: Adult; Aged; Carcinoma in Situ; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality | 2001 |
Frequency of positive biopsies after visual disappearance of superficial bladder cancer marker lesions.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Biopsy; Carcinoma, Transitio | 2001 |
Intravesical immunotoxin as adjuvant therapy to prevent the recurrence of bladder cancer.
Topics: Administration, Intravesical; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Ca | 2000 |
[Adenocarcinomas of the distal esophagus and gastric cardia: what chemotherapy or chemoradiotherapy for recurrent or metastatic disease?].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cardia; Cisplatin; Combined Modality | 2001 |
Preoperative topical and intraoperative local mitomycin C adjuvant therapy in the management of ocular surface neoplasias.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma; Che | 2002 |
The intraoperative use of mitomycin-C in excision of ocular surface neoplasia with or without limbal autograft transplantation.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Squamous Cell; C | 2002 |
Successful treatment with 5-fluorouracil of conjunctival intraepithelial neoplasia refractive to mitomycin-C.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Carcinoma in Situ; Conjunctival Neopla | 2002 |
[Combination therapy including mutamycin (mitomycin C) in the treatment of advanced colorectal and gastric cancer].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 2001 |
Combined surgery, cryotherapy, and mitomycin-C for recurrent ocular surface squamous neoplasia.
Topics: Adult; Antibiotics, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Therapy; Conjunctiva | 2002 |
Topical mitomycin C and radiation induce conjunctival DNA-polyploidy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Biopsy; Carcinoma, Squamous Cell; Combined Modality Therap | 2001 |
Morbidity and mortality associated with intraperitoneal chemotherapy for Pseudomyxoma peritonei.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Digestive System S | 2002 |
[Retrospective survey of pharmacologic tolerance in the prevention of neoplastic recurrence of superficial urothelioma].
Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Humans; In | 1992 |
Recurrence of superficial bladder tumours after transurethral resection.
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Doxorubicin; Fem | 1992 |
[Intravesical BCG, mitomycin-C and thiotepa in the prevention of bladder tumor recurrence after operation].
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Chem | 1992 |
[Prophylactic chemotherapy by regional arterial infusion in resected hepatoma patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Doxorubicin; F | 1992 |
[Prevention of postoperative recurrence of hepatocellular carcinoma by adjuvant locoregional chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap | 1992 |
Combination chemotherapy with cisplatin, vindesine and mitomycin-C for advanced, inoperable non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1992 |
[A case of complete response of locally advanced breast cancer to arterial infusion chemotherapy: cannulation through the right femoral artery and combined use of G-CSF].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Catheters, I | 1992 |
Long-term immunobiological effects of intravesical bacillus Calmette-Guérin against bladder carcinoma recurrences.
Topics: Administration, Intravesical; BCG Vaccine; Biomarkers, Tumor; Carcinoma, Transitional Cell; Chemothe | 1992 |
Advantages of the Papillon protocol in the preoperative treatment of rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Protocols; Com | 1992 |
[Transanorectal ultrasonography in the evaluation of extension and the monitoring of epidermoid cancers of the anus treated by radiation or chemotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1992 |
Topical chemoprophylaxis of superficial bladder cancer with mitomycin C and adjuvant hyaluronidase.
Topics: Administration, Intravesical; Aged; Carcinoma, Transitional Cell; Combined Modality Therapy; Female; | 1992 |
Endovesical instillation of mitomycin-C in preventing recurrence of superficial bladder carcinoma.
Topics: Administration, Intravesical; Adult; Aged; Carcinoma, Transitional Cell; Female; Humans; Male; Middl | 1992 |
[Signification of liver metastases of colorectal cancer with special reference to recurrence in the residual liver after hepatic resection].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Doxorubi | 1992 |
[A pharmacokinetic study of intra-arterial chemotherapy for prophylactic treatment of liver metastasis after hepatectomy for liver cancer].
Topics: Chemotherapy, Adjuvant; Doxorubicin; Epirubicin; Hepatectomy; Hepatic Artery; Humans; Infusions, Int | 1992 |
[Intra-arterial chemotherapy of local recurrence and non-curative case of colorectal cancer].
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Doxorubicin; Humans; Infusions, Intra-Arterial; Mitomycin | 1992 |
Mitomycin C, 5-fluorouracil and radiation in advanced, locally recurrent rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 1992 |
Phase II study of mitomycin C and 5 fluorouracil in platinum resistant ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Drug Resistance | 1992 |
[A case of recurrent hepatocellular carcinoma after hepatic resection surviving over five years by hepatic arterial infusion of lipiodol-anticancer drug suspension].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Doxorubicin; D | 1991 |
[Effectiveness and timing of one shot transarterial infusion and/or transcatheter arterial embolization therapy for recurrence of postoperative hepatocellular carcinoma].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Doxorubicin; Embolization, Therapeuti | 1991 |
A phase II evaluation of cisplatin, bleomycin, and mitomycin-C in patients with recurrent squamous cell carcinoma of the cervix.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplati | 1991 |
[Superficial bladder cancer: prophylaxis of recurrence and progression].
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Bleomycin; Cisplatin; Doxorubicin; | 1991 |
Value of bladder wash cytology in the follow-up of patients with bladder carcinoma receiving intravesical chemoprophylaxis with mitomycin C.
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Humans; Mitomycin; Neoplasm Recurrence, | 1991 |
[Eosinophilic cystitis as a special form of response to mitomycin C. Analysis and comments on our cases].
Topics: Administration, Intravesical; Antigen-Antibody Complex; Carcinoma; Combined Modality Therapy; Cystit | 1991 |
Combined intravesical chemotherapy with mitomycin C and local bladder microwave-induced hyperthermia as a preoperative therapy for superficial bladder tumors. A preliminary clinical study.
Topics: Administration, Intravesical; Aged; Carcinoma, Transitional Cell; Cystectomy; Female; Humans; Hypert | 1991 |
Recurrent hepatocellular carcinoma after partial hepatectomy: value of treatment with transcatheter arterial chemoembolization.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Doxorubicin; Embolization, Therapeutic; Female; Ge | 1991 |
Combined modality treatment of advanced cancers of the oral cavity and oropharynx.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 1991 |
Long-term observation after intravesical metaphylaxis with mitomycin C in patients with superficial bladder tumors.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Ther | 1991 |
The force of change in the management of squamous-cell cancer of the anal canal.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1991 |
[Clinical evaluation of intra-operative pelvic hyperthermochemotherapy combined with operation for rectal cancer].
Topics: Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Intraoperative Period; Male; Middl | 1991 |
Mechanisms of relapse for colorectal cancer: implications for intraperitoneal chemotherapy.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Infusi | 1991 |
Adjuvant hepatic intra-arterial chemotherapy after potentially curative hepatectomy for liver metastases from colorectal cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 1991 |
Hepatic recurrence not prevented with low-dosage long-term intraportal 5-FU infusion after resection of colorectal liver metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 1991 |
Combined radiation therapy, mitomycin C, and 5-fluorouracil for locally recurrent rectal carcinoma: results of a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 1991 |
Topical mitomycin C therapy for carcinoma in situ of the bladder: a followup.
Topics: Administration, Intravesical; Carcinoma in Situ; Cystectomy; Humans; Mitomycin; Mitomycins; Neoplasm | 1990 |
Intravesical mitomycin C for carcinoma in situ of the urinary bladder.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Carcinoma in Situ; Carcinoma, Papillary; Comb | 1990 |
[Effect of etoposide orally administered every other day for the prevention of recurrence of bladder tumor].
Topics: Administration, Intravesical; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined | 1990 |
[Intra-arterial chemotherapy in inoperable and recurrent rectal tumors].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Injections, Intr | 1990 |
Follow up of patients receiving treatment for superficial bladder cancer with mitomycin C and BCG.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma, Transitional Cell; Combined Modality Therapy; | 1990 |
[Intra-operative pelvic hyperthermochemotherapy combined with surgery in rectal cancer].
Topics: Adult; Aged; Colostomy; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Intraopera | 1990 |
[Evaluation of subselective intraarterial infusion chemotherapy in advanced gastric cancer and recurrence case-evaluated on factors other than direct effects].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu | 1990 |
[Results of prophylactic intra-arterial infusion chemotherapy after hepatic resection in colorectal metastases].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorour | 1990 |
A phase II trial of mitomycin C and 5-fluorouracil as second-line therapy in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Evaluation; Fluo | 1990 |
[UFT-MT therapy in advanced or recurrent breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middl | 1990 |
[A study of combined chemotherapy with MMC, ADM, CDDP, etoposide (VP-16), 5'DFUR (MAC-VD therapy) in advanced cancer and local relapse of the stomach].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxoru | 1990 |
Assessment of bleomycin, adriamycin and mitomycin-C in the treatment of recurrent cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Do | 1985 |
[Prophylaxis of recurrence of superficial bladder tumor by diluted postoperative continuous intravesical instillation of anti-tumor solutions].
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Transitional Cell; Doxorubicin; Female; Hu | 1985 |
DNA/RNA ratio in bladder cancer: a factor indicating the recurrence rate?
Topics: Antibiotics, Antineoplastic; DNA; Female; Flow Cytometry; Follow-Up Studies; Humans; Male; Mitomycin | 1985 |
Combination chemotherapy for patients with advanced carcinoma of the cervix: trial of mitomycin-C, vincristine, bleomycin, and cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Female; Follow-Up | 1987 |
Nonoperative therapy for squamous-cell cancer of the esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin | 1987 |
Intraarterial mitomycin-C for recurrent brain metastases.
Topics: Adolescent; Adult; Animals; Brain Neoplasms; Carotid Artery, Internal; Humans; Infusions, Intra-Arte | 1987 |
[Clinical effect of combination chemotherapy with peplomycin and mitomycin C (PM therapy) in recurrent uterine cervical cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Female; Humans; Infusions, Intraven | 1988 |
Weekly cisplatin induction chemotherapy in the treatment of recurrent cervical carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleo | 1989 |
[The clinical course of nodular type hepatocellular carcinomas after transcatheter arterial embolization (TAE) therapy].
Topics: Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 1989 |
[Effects of intra-arterial infusion chemotherapy in local recurrence of anal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bleomycin; Carcinoma, Squamous Cell; | 1989 |
[Adjuvant chemotherapy in radical surgery of cervix cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Fem | 1989 |
Combined intracavitary and external beam irradiation for superficial transitional cell carcinoma of the bladder: an alternative to cystectomy for patients with recurrence after intravesical chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Transitional Cell; C | 1989 |
Phase II study of combination 4'-epidoxorubicin and mitomycin C in recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Epirubicin; Female; Hu | 1989 |
Histologic tumor regression grades in squamous cell carcinoma of the head and neck after preoperative radiochemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 1989 |
Postoperative adjuvant chemotherapy inhibits early recurrence of early gastric carcinoma.
Topics: Carcinoma; Combined Modality Therapy; Drug Evaluation; Gastrectomy; Humans; Lymphatic Metastasis; Mi | 1989 |
Clinical trial with surgery and intraperitoneal hyperthermic perfusion for peritoneal recurrence of gastrointestinal cancer.
Topics: Adult; Blood Proteins; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Female; | 1989 |
[Vincristine, adriamycin, mitomycin-C and UFT (VAM-UFT) therapy in progressive or recurrent breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Adm | 1989 |
Epidermoid carcinoma of the anal canal. Results of treatment by combined chemotherapy and radiation therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1989 |
Concurrent radiation and chemotherapy in vulvar carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone | 1989 |
[Results of intra-arterial infusion chemotherapy of colorectal cancer in patients with metastatic liver cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Catheterization; Colorectal Neoplasms; Combined Moda | 1989 |
Cis-platinum and mitomycin-C in treatment of recurrent, metastatic, or residual uterine cervical cancer post radiation.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 1989 |
Treatment of recurrent cervical cancer with cis-platinum and mitomycin C: a phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Female; Humans; Middle A | 1989 |
[Anal canal carcinoma: diagnosis--therapy--prognosis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Combined Modality Therapy; Female; F | 1989 |
Re: Recurrence of superficial bladder carcinoma after intravesical instillation of Mitomycin-C.
Topics: Administration, Intravesical; Data Interpretation, Statistical; Humans; Mitomycin; Mitomycins; Neopl | 1989 |
[Intra-arterial infusion chemotherapy of locally advanced and recurrent breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Intraducta | 1989 |
[A case of recurrent hepatocellular carcinoma successfully treated by arterial chemoembolization in combination with local hyperthermia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality | 1989 |
[Clinical effectiveness of arterial infusion chemotherapy in advanced and recurrent gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; | 1989 |
Persistent ulcers after bladder instillation of mitomycin C.
Topics: Chronic Disease; Humans; Mitomycin; Mitomycins; Neoplasm Recurrence, Local; Neoplasms, Multiple Prim | 1986 |
[An analysis of treatments of recurrent breast cancer in relation to the lesion].
Topics: Breast Neoplasms; Combined Modality Therapy; Doxorubicin; Female; Humans; Lymphatic Metastasis; Medr | 1985 |
[PMU therapy of recurrent gastric cancer. A case report].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; | 1986 |
[Transcatheter arterial embolization therapy of recurrent pelvic cancer].
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Catheterization | 1986 |
Phase II study of the three-drug combination of mitomycin C, CCNU, and methotrexate (MCM) in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Humans; Lomust | 1986 |
Use of intravesical cisplatin and mitomycin-C for recurrent transitional cell carcinoma of bladder refractory to thiotepa.
Topics: Biopsy; Carcinoma in Situ; Carcinoma, Transitional Cell; Cisplatin; Cystoscopy; Drug Evaluation; Dru | 1986 |
Prognostic significance of urine cytology on initial follow-up after intravesical mitomycin C for superficial bladder cancer.
Topics: Aged; Carcinoma, Transitional Cell; Cytodiagnosis; Follow-Up Studies; Humans; Middle Aged; Mitomycin | 1986 |
[RI angiography with 99mTc and 201T1-chloride scintigraphy in determining the effectiveness of intra-arterial infusion in chemotherapy of locally advanced and recurrent breast cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Doxorubicin; Female | 1986 |
Intraarterial chemotherapy and hyperthermia for pain control in patients with recurrent rectal cancer.
Topics: Aged; Female; Fluorouracil; Humans; Hyperthermia, Induced; Infusions, Intra-Arterial; Male; Middle A | 1986 |
Distilled water versus chemotherapeutic agents for transitional bladder carcinoma.
Topics: Carcinoma, Transitional Cell; Cell Survival; Humans; In Vitro Techniques; Mitomycin; Mitomycins; Neo | 1986 |
[The problems of postoperative adjuvant chemotherapy in gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Gastrectomy; Humans; Lymphatic Metastasis; Mitomycin | 1987 |
Intravesical mitomycin C for the treatment of recurrent superficial bladder tumours.
Topics: Administration, Intravesical; Humans; Mitomycin; Mitomycins; Neoplasm Recurrence, Local; Neoplasm St | 1987 |
Preoperative chemotherapy and radiotherapy in the management of epidermoid carcinoma of the anal canal.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, | 1987 |
Mitomycin C pharmacokinetics in patients with recurrent or metastatic colorectal carcinoma.
Topics: Aged; Chromatography, High Pressure Liquid; Colonic Neoplasms; Half-Life; Humans; Kidney; Kinetics; | 1987 |
5-Fluorouracil, 4-epidoxorubicin, and mitomycin C (FEM) combination chemotherapy for advanced gastric carcinoma. A phase-II trial by the "chemotherapiegruppe gastrointestinaler tumoren (CGT)".
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; Drug E | 1987 |
[Side effects and anti-cancer effects following intraperitoneal (ip) administration of mitomycin C (MMC)].
Topics: Female; Humans; Mitomycin; Mitomycins; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneum; Ut | 1987 |
Instillation of mitomycin C and doxorubicin in the prevention of recurrent superficial (Ta-T1) bladder cancer.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Carcinoma, Papillary; Doxorubicin; Fem | 1987 |
Concurrent radiation and chemotherapy for carcinoma of the cervix recurrent after radical surgery.
Topics: Combined Modality Therapy; Female; Fluorouracil; Humans; Infusions, Intravenous; Mitomycin; Mitomyci | 1987 |
[Clinical results of CDDP, MMC and 5-FU combination chemotherapy in advanced or recurrent gastrointestinal cancers].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule | 1987 |
[Experience with CDDP therapy in advanced and recurrent gastric cancer cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Doxorubic | 1987 |
Treatment of superficial papillary transitional cell carcinoma of the ureter by vesicoureteral reflux of mitomycin C.
Topics: Administration, Intravesical; Aged; Carcinoma in Situ; Carcinoma, Transitional Cell; Humans; Male; M | 1987 |
Bladder wall calcification after topical mitomycin C.
Topics: Administration, Intravesical; Aged; Calcinosis; Carcinoma, Transitional Cell; Combined Modality Ther | 1987 |
Concurrent combined chemotherapy and radiation therapy in gastrointestinal cancers.
Topics: Carcinoma, Squamous Cell; Combined Modality Therapy; Fluorouracil; Gastrointestinal Neoplasms; Human | 1987 |
Doxorubicin plus mitomycin C regimen in the prophylactic treatment of superficial bladder tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary | 1988 |
Study of intravesical mitomycin C in patients with multiple prior occurrences of superficial bladder cancer.
Topics: Administration, Intravesical; Aged; Humans; Middle Aged; Mitomycin; Mitomycins; Neoplasm Recurrence, | 1988 |
[Tolerance of intraoperative, intraperitoneal chemotherapy in advanced gynecologic malignancies].
Topics: Adolescent; Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Female | 1988 |
[Intravesical mitomycin for superficial tumors of the bladder: difficulties of cystoscopic monitoring].
Topics: Administration, Intravesical; Catheterization; Cystoscopy; Follow-Up Studies; Humans; Mitomycin; Mit | 1988 |
Early and delayed clinical cardiotoxicity of doxorubicin.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cyclo | 1985 |
Pelvic intra-arterial mitomycin C infusion in previously treated patients with metastatic, unresectable, pelvic colorectal cancer and angiographic determination of tumor vascularity.
Topics: Adult; Aged; Angiography; Cellulitis; Colonic Neoplasms; Female; Humans; Infusions, Intra-Arterial; | 1985 |
Plasma levels during intravesical instillation of mitomycin-C.
Topics: Carcinoma, Transitional Cell; Humans; Mitomycin; Mitomycins; Neoplasm Recurrence, Local; Urinary Bla | 1985 |
Mitomycin C in superficial bladder cancer: 24-month follow-up.
Topics: Antibiotics, Antineoplastic; Carcinoma in Situ; Follow-Up Studies; Humans; Mitomycin; Mitomycins; Ne | 1985 |
[A combination chemotherapy using mitomycin C, vincristine and cisplatin (MVP) for advanced cervical cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug | 1985 |